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Abstract
Parkinson's  disease  (PD)  is  a  sporadic  and  progressive  neurodegenerative  disease
characterized by dopaminergic neuronal cell death in the substantia nigra pars compacta and
by the presence of characteristic Lewy bodies (LB) and Lewy neuritic (LN) inclusions. These
inclusions are mainly constituted of the alpha-synuclein (a-syn) protein, suggesting a role of
a-syn in the neuropathophysiology of PD. Synphilin-1 (sph1) is described as an interacting
partner of a-syn, present in LBs and sharing the same intracellular compartments as a-syn.
Sph1 was shown to induce the formation of a-syn positive inclusions in vivo and in vitro as well
as  to  promote  clearance  of  protein  inclusions  by  autophagy.  But  the  impact  of  sph1  in
a-syn-mediated toxicity is inconsistent, presumably due to the variety of models used to model
synucleinopathy,  the  variety  of  toxicity  markers  analyzed  and  the  poor  description  of
aggregates found in these studies. Furthermore, the normal function of sph1 needs still to be
explored.
The overall aim of this study is to characterize the effects of sph1 on a-syn aggregation and on
the development of synucleinopathy in vivo. Therefore, we cross-bred mice overexpressing the
human  sph1  under  the  mouse  PrP  promoter  with  a  synucleinopathy  mouse  model
overexpressing the human A30P mutated a-syn under the Thy-1 promoter.
Using different fractionation protocols of brain lysates, we did not observe in mice coexpressing
sph1 an increased amount of soluble a-syn nor detergent-insoluble a-syn. At the histological
level, we observed that the coexpression of sph1 drastically decreased levels of proteinase K
resistant  a-syn  inclusions  as  well  as  thioflavin S  positive  structures.  These  changes  were
accompanied  by  the  formation  of  aggresome-like  structures  positive  for  a-syn,  K63
polyubiquitinated proteins and gamma-tubulin in double transgenic animals. We also observed
in  double  transgenic  mice  a  reduced  neuropathology  reflected  by  a  decreased
neuroinflammation and suggesting a protective role of sph1 in synucleinopathy.
Accordingly, we demonstrated that sph1 reduces the accumulation of soluble full -length and
truncated species of a-syn with aging. Similarly, we also shown that sph1 decreases levels of
fibrillar forms of a-syn. Moreover, we also reported increased levels of ubiquitinated proteins in
double transgenic mice without measuring an impairment of the ubiquitin-proteasome system
activity.  Interestingly,  we observed an increased autophagic flux in double transgenic mice,
suggesting  a  possible  role  of  the  autophagy-lysosome  pathway  in  the  reduction  of  a-syn
species.
We  tracked  the  evolution  of  neuropathology  and  associated  behavioral  alterations  over
18 months. We found that sph1 coexpression in transgenic mice overexpressing the human
mutated A30P alpha-synuclein led to a delayed motor phenotype in rotarod when compared to
single transgenic mice overexpressing A30P a-syn. A motor phenotype was also observed in
single  transgenic  sph1  mice  when  using  challenging  beam walk.  Interestingly,  mouse  gait
analysis suggested a different origin in motor impairment in sph1 and A30P single transgenic
mice.
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Introduction
1)  Parkinson´s disease
Parkinson's  disease  (PD)  was  described  possibly  for  the  first  time  under  the  name  of
Kampavata in the ancient Indian medical text (5000 B.C.) (Stern 1989). PD was also reported
in the first Chinese medical text (Nei Jing Chinese medicine 500 B.C.) (Zheng 2009). During
the ancient Rome, the Greek physician Galen (129-200) also described symptoms related to
PD [tremors of the hand at rest, exhibited tremor and decline in control motion of limbs with
aging]  (Stern  1989).  Nevertheless,  the  first  description  of  all  four  cardinal  signs  [tremor,
bradykinesia, rigor, and postural instability] was made by the Hungarian doctor Ferenc Pápai
Páriz in 1690 in his medical text Pax Corporis (Bereczki 2010).
During modern time, James Parkinson reported a medical condition termed “shaking palsy”
observed in  six patients presenting most  of  the typical  clinical  features of  PD  (Parkinson
1817). This description was completed later in the nineteenth century by the French physician
Jean-Martin  Charcot  which  fully  detailed  the  PD  symptoms  (Charcot  1877) [Historical
description of PD reviewed in (Pearce 1989; Goetz 2011)].
2)  Epidemiology
Despite  numerous epidemiological  studies,  a  high variation exists  on the prevalence and
incidence of PD (Muangpaisan et al. 2011) probably due to difficulties of diagnostic criteria,
methodology or population studied. 
It is commonly accepted that the incidence and prevalence of PD is increasing with aging,
affecting approximately 1% of the population older than 60 years and 0.3% of the general
population  [reviewed in  (de  Lau  &  Breteler  2006;  Hirtz  et  al.  2007;  Driver  et  al.  2009) ].
Although PD is not a primary or direct cause of death  (Phillips et al. 1999), life expectancy
(Driver et al. 2008; Forsaa et al. 2010) and quality of life are decreased in PD [reviewed in
(Welsh 2004)].
2.1  Clinical features
Clinical  symptoms  of  PD  are  dominated  by  four  cardinal  motor  signs:  1) tremor  at  rest,
2) rigidity (permanently increased muscle tone), 3) bradykinesia (slowness of movement), and
4) postural instability. However, these manifestations of the disease are also accompanied by
the presence of  non-motor  symptoms which  can be present  before  diagnosis  and which
emerge with disease progression. Treatment side effects could also be observed in some
patients.  These  symptoms  (Table 1-01)  could  be  categorized  under  four  main  classes:
neuropsychiatric,  autonomic,  sensory,  and  sleep  disorders  [reviewed in  (Chaudhuri  et  al.
2006; Chaudhuri & Odin 2010; Lyons & Pahwa 2011)].
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Lack of diagnostic tests, and especially of reliable biomarkers, is making diagnosis of PD
relying on clinical observation. In this context, the clinical diagnosis of PD is based on the
combination  of  motor  signs  including  bradykinesia,  rigidity,  tremor,  or  postural  instability
[reviewed in  (Jankovic 2008; Reichmann 2010)].  Dopamine replacement therapy,  which is
well known to improve motor symptoms, may be used to confirm PD diagnosis (D’Costa et al.
1995).  Most  recent  advancement  in  neuroimaging,  and  especially  in  diffusion-weighted
magnetic resonance imaging, ultrasonography and radiotracer-based imaging, could also be
used to confirm and to follow the degeneration of the nigrostriatal and basal ganglia systems
[reviewed in (Piccini & Brooks 2006)].
Table 1-01: Symptoms of Parkinson's disease
Table adapted from (Chaudhuri et al. 2006)
Neuropsychiatric disorders Autonomic disorders
Depression, apathy, anhedonia Urinary dysfunction
Anxiety Constipation, fecal incontinence
Impulse behavior Dysphagia, drooling
Cognitive impairment Orthostatic hypotension
Attention deficit Nausea, vomiting
Dementia, delirium, confusion Sexual dysfunction
Sleep disorders Sensory disorders
Insomnia Pain / paresthesia
Fragmented sleep Olfactory deficit
Excessive daytime sleepiness Taste deficit
Vivid dreaming
2.2  Etiology
PD is a neurodegenerative disorder with no identifiable cause. The definition of PD does not
include parkinsonism, a nomenclature used for syndromes where the etiology is known. This
includes parkinsonian signs due to  stroke,  infection,  neuroleptic  drugs,  and toxic  agents.
Parkinsonism also includes signs from other neurodegenerative disorders, such as multiple
system atrophy, progressive supranuclear palsy, and nigrostriatal degeneration.
Numerous etiologic studies pointed out possible genetic and environmental components on
the risk to developing PD [reviewed in  (Wirdefeldt et al. 2011; Noyce et al. 2012)]. Aging,
gender, and family history are the strongest risk factors associated with PD diagnosis. Further
risk  factors  correlated  with  PD  and  putative  premotor  symptoms  are  summarized  in
table 1-02.
|17|
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Table 1-02: Risk factors of Parkinson's disease
Table adapted from (Noyce et al. 2012)
Positive correlation Negative correlation
Age Coffee drinking, smoking, alcohol
Gender Anti-inflammatory drugs
Family history of Parkinson's disease Exercise
Head injury Cholesterol, use of statins
Rural living, pesticide exposure Hormonal therapy, oral contraceptive
Metal/solvent exposure Calcium channel blockers
Depression, constipation, anxiety Hypertension
Beta-blockers Gastric ulcers
Acetaminophen/paracetamol
2.3  Neuropathology
2.3.1  Loss of dopaminergic neurons and related lesion pattern
PD is characterize at the histological level by a severe loss of A9 dopaminergic pigmented
neurons in the substantia nigra, leading to a pale appearance of this region when compared
with healthy controls could be observed. The loss of pigmented neurons in the substantia
nigra was already reported in the 1920s in brains of patients affected with PD [reviewed in
(Goetz 2011)]. It was estimated that at the onset of symptoms 60% of the nigral dopaminergic
neurons were lost  (Pakkenberg et al.  1991) and can increase up to 94% in latest stages
(Damier et al. 1999).
The  substantia  nigra  is  a  layer  of  large  pigmented  nerve  cells  located  in  the  midbrain
(mesencephalon) and playing a critical role on the motor system control of the basal ganglia
(Hodge & Butcher 1980) [represented in Fig. 1-01 and reviewed in (Bergman & Deuschl 2002;
Groenewegen 2003;  Santens et  al.  2003)].  Loss of  these neurons leads to an increased
inhibition of the thalamocortical  projection and impairs balancing between direct excitation
and  indirect  inhibition pathways of  cortex inducing an abnormal activation of upper motor
neurons in the motor cortex and subsequently reducing excitation of cortical motor areas.
Dopaminergic neuronal cell loss in the substantia nigra is reported to be the central pathology
in PD. In addition to the loss of the nigrostriatal  dopaminergic neurons, a variety of other
neuronal  systems  (such  as  a  mild  degeneration  of  the  cholinergic,  noradrenergic,  and
serotonergic  systems)  are  also  known  to  be  affected  in  several  brain  regions  including
brainstem,  olfactory bulb,  cerebral  cortex,  spinal  cord,  or  peripheral  autonomic  system of
patients (Jellinger 1991; Forno 1996; Braak et al. 2003). Degeneration of these centers may
lead  to  diverse  clinical  symptoms  of  PD  including  depression,  constipation,  rapid  eye
movement behavior sleep disorder, cognitive, and affective changes.
|18|
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Figure 1-01: Architecture of the basal ganglia
Figure copied from (Leisman & Melillo 2013)
The motor system control of the basal ganglia is extensively
interconnected to subcortical structures such as the striatum
[composed  of  the  putamen  and  the  caudate  nucleus],  the
globus  pallidus  [composed  of  the  internal  and  external
segment], the subthalamic nucleus and the substantia nigra
[composed  of  the  pars  compacta  and  the  pars  reticulata].
Main  inputs  of  the  basal  ganglia  are  the  glutamatergic
projection of the cerebral cortex neurons [including sensory,
motor, association, and limbic areas] to the striatum and the
dopaminergic  projection  of  the  substantia  nigra  pars
compacta  (SNc).  Striatum projects  then  direct  and  indirect
inhibitory  GABAergic  output  signals  to  the  globus  pallidus
internal, to the substantia nigra reticulata complex (GPi/SNr)
and to the globus pallidus external (GPe). The direct pathway
involves  the  inhibition  of  the  GPi/SNr  GABAergic  neuron
projection onto the thalamus and reducing the inhibition of the
thalamus.  This  disinhibition  of  the  thalamus  promotes
excitatory outputs to the cortex, to the brain stem and to the
muscle  fibers  via  projection  of  glutamatergic  neurons.  The
indirect pathway involves the inhibition of the GPe GABAergic
neurons  projection  to  the  subthalamic  nucleus  (STN)  and
reduces the inhibition of the STN. The disinhibition of the STN
promotes the inhibitory outputs of the GPi/SNr complex to the
thalamus  via  GABAergic  neurons.  This  inhibition  of  the
thalamus decreases the excitatory outputs to the cortex, to
the brainstem results in a reduced muscle activity.  ACh, acetylcholine; DA, dopamine; Glu, glutamate;  Enk,
enkaphalin; SP, substance P.; SNc, substantia nigra pars compacta; GPe, globus pallidus pars externa; VL,
ventrallateral nucleus; VA, ventral anterior nucleus.
2.3.2  Lewy bodies and Lewy neurites
Lewy bodies (LBs) were first described by Friedrich Heinrich Lewy a century ago in brains of
PD patients (Lewy 1913; Lewy 1921) in which atrophic cells with fibrillar changes and cellular
loss were  described mainly in  the nucleus basalis  [discovery of  LB reviewed in  (Holdorff
2002)]. Lewy neurites can also be detected in axons of affected neurons. A large variety of
neurons  are  vulnerable  to  LBs  as  monoaminergic  neurons  (in  the  substantia  nigra  pars
compacta and the locus coeruleus)  or  cholinergic  neurons (in  the basal  forebrain,  dorsal
raphe,  and  subpeduncular  nuclei  of  the  pons).  LBs  are  also  common  in  hypothalamus
(posterior and lateral), brainstem reticular formation, olfactory bulb, and spinal cord (neurons
of the intermediolateral  cell).  Interestingly,  some regions do not  develop LBs such as the
basal ganglia, thalamus, pontine basis, or cerebellar cortex [reviewed in (Braak et al. 2004)].
LBs  are  circular  intracytoplasmic  inclusions,  8–30 nm  in  diameter,  observable  using
hematoxylin  and eosin staining.  Two major  components can be distinguished:  a  granular
dense core of protein and a clearer peripheral halo of large filaments radially oriented (Duffy &
Tennyson 1965). At the ultrastructural level, LBs as composed of a 7–20 nm large central core
containing  densely  packed  filaments  and  of  dense  granular  material  at  the  periphery
surrounded by 10 nm filaments radially arranged (Roy & Wolman 1969).
|19|
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Lewy  neurites  (LNs)  are  elongated  neuronal  processes  presenting  various  structures
commonly regrouped  under  a  thick  and  rounded form or  under  an  elongated  thread-like
structures (Braak et al. 1999; Kanazawa et al. 2008). In the earlier forms of the disease, LNs
could be observed before LBs in the medulla oblongata and in the olfactory bulb, suggesting
an early aberrant neuritic pathology preceding the formation of LBs (Braak et al. 2003).
LBs are constituted of a mixture of lipids, neurofilaments and proteins [(Goldman et al. 1983),
reviewed in  (Licker et  al.  2009)].  In the large variety of  proteins present in LBs, ubiquitin
(Kuzuhara et al. 1988; Lennox et al. 1989) and alpha-synuclein (a-syn) (Spillantini et al. 1998)
are constituting the major protein components. Other protein subgroups can be distinguished
such  as  structural  elements,  a-syn  binding  partners,  ubiquitin-proteasome  system
components,  cellular  response proteins,  phosphorylation and signal  transduction proteins,
cytoskeletal proteins, cell cycle proteins and cytosolic proteins that passively diffuse into LBs.
The exact link between a-syn and these complex inclusions is unclear, but based on a-syn
immunohistochemistry, a model of LB formation involving five successive stages of complex
aggregation (Fig. 1-02) was proposed (Wakabayashi et al. 2007).
Figure 1-02: Lewy bodies formation
Figure copied from (Wakabayashi et al. 2007)
Immunohistology of LBs at different maturation stages in the substantia nigra using a-syn antibody. A) No a-syn
could  be  normally  observed  under  normal  conditions  in  neuronal  cytoplasm.  B) Stage 1:  diffuse,  pale
cytoplasmic staining. C) Stage 2: irregularly shaped and uneven staining of moderate intensity. D) Stage 3: pale
body, displaying peripheral condensation.  E) Stage 4: one or more small LBs occasionally located within the
periphery  of  pale  bodies  and  developing  into  typical  LBs.  F) Stage 5:  LB,  composed  of  ring- like  staining
presenting a central core and a surrounding halo; scale-bar=10 μm.
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In  this  classification,  healthy neurons do not present  cytoplasmic a-syn staining.  Neurons
containing  pale  a-syn  cytoplasmic  staining,  considered  to  start  protein  accumulation,  are
regrouped under the first stage of LB formation. Neurons presenting both a moderate a-syn
staining intensity and showing an irregular shape are grouped on the stage 2 of LB formation.
In the stage 3, peripheral condensations can be observed in neurons and are termed pale
bodies. Neurons displaying both pale bodies and containing at their periphery one or several
small LBs are considered as stage 4. During the final stage, pale bodies disappear and leave
a donuts-shaped structure.
The biological significance of these cytoplasmic inclusions and especially the toxicity of LBs is
still actively debated. They have been considered to be toxic, protective or even innocuous
[reviewed in (Hartmann 2004; Shults 2006)]. LBs are usually found in brain regions with high
neuronal  cell  loss suggesting their  involvement  in  neuronal  cell  loss  (Braak et  al.  2004).
Supporting these results,  it  was shown that  LBs retain  iron and promote oxidative stress
(Castellani et al. 2000). It is also likely that LBs, via space-occupying lesions, are interfering
on  the  long  term with  metabolic  activity  or  cellular  transport  within  the  neuron  (Goedert
2001) and can reflect a proteolytic degradation dysfunction.
Observation that most of aggregated a-syn in PD is forming small deposits located at the
presynapses, and of synaptic pathology with almost complete loss of dendritic spines at the
postsynaptic area (Kramer & Schulz-Schaeffer 2007) suggests a neurotransmitter deprivation
and  raised  the  notion  that  not  cell  death  but  rather  a-syn aggregate-related  synaptic
dysfunction causes the neurodegeneration [reviewed in (Schulz-Schaeffer 2010)].
On the other hand, LBs are also found in patients without any clinical signs of parkinsonism
(Hughes et al. 1992). Interestingly, LBs do not disturb nerve cell metabolism or predispose
them to undergo apoptosis  (Gertz et al.  1994; Tompkins & Hill  1997), suggesting that the
dendritic abnormalities seen in PD are not LB dependent (Patt et al. 1991). Finally, LBs have
also been proposed to represent a survival effort of neurons by sequestering the toxic soluble
proteins in an insoluble form (McNaught, Shashidharan, et al. 2002; Olanow et al. 2004).
2.3.3  Evolution of the disease
Because only few and very well defined neurons are containing LBs and are damaged during
PD, a model of PD development was created based on the distribution and evolution of a-syn
lesions in different stages of PD observed in a large bank of brain samples. A six-stage model
has been proposed by (Braak et al. 2003) as displayed in Fig. 1-03,  and was confirmed by
other large studies (Braak et al. 2004; Dickson et al. 2010).
In this model, stages 1 and 2 are characterized by the presence of pathological events in
neurons of the dorsal vagal nucleus, olfactory bulb, and lower brainstem (including reticular
and  raphe  nuclei),  corresponding  well  to  the  early  and  frequent  pre-motor  symptoms
(depression, impaired smell and autonomous function). In these early stages, the presence of
LNs in the brainstem and the few LBs and cell  death observed in these brain regions is
suggesting that LNs are the first impaired structures which precede intraneuronal inclusions
development and neuronal degeneration (Jellinger 2003; Jellinger 2004; Dickson et al. 2010).
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Figure 1-03: Lewy bodies spread
Figure copied from (Braak et al. 2004)
A) Presymptomatic phase, marked by the appearance of LBs and LNs in brains of asymptomatic persons. In
symptomatic  phase  neuropathological  threshold  is  exceeded and an increasing  pathology  in  an increasing
variety of brain regions is represented by colored areas below the diagonal line.  B) Diagram representing the
ascending pathological process (white arrows) using the similar shading intensity that in A.
The  stage 3  is  characterized  by  Lewy  pathology  reaching  the  brainstem  as  well  as  the
amygdala and basal portions of the midbrain as well as the forebrain. During the stage 3 LBs
can be observed first in the substantia nigra without cell depletion. In stage 4, the disease
reaches the limbic circuit and starts spreading to the mesocortex and to the entorhinal cortex.
Stages 3 and 4 are correlated with typical clinical PD symptoms.
In terminal stages 5 and 6, LBs reach telencephalic cortex, sensory association cortex and
prefrontal areas. The spread of the disease leads to a widespread presence of LB involving
almost  the complete neocortex.  In  these late  stages,  cognitive  and psychiatric  symptoms
accompany severe motor deficits.
This theory is criticized in literature due to the fact that the substantia nigra is only affected in
stage 3 (Milber et al. 2012) and does not coincide with the age of onset observed in pre- and
early-symptomatic stages  (Burke et al.  2008).  As mentioned before, the role of  lesions in
neurodegeneration process is not clear. Thus, analysis of lesion spread to study the disease
progression has to be reconsidered.
A model  of  the  spread  of  pathology was  developed,  where  pathology  spreads  from the
brainstem to the midbrain involving downstream the limbic circuit and the neocortex. Since
even in an asymptomatic case LBs or/and LNs could be observed [reviewed in (Burke et al.
2008)], the symptomatic stage is defined when a neuropathological threshold is exceeded.
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2.4  Genetics
As described previously, PD is classically reported as a sporadic disease and may result from
a  combination  of  environmental  factors  (rare  cases  of  intoxication)  and  brain  aging.
Nonetheless,  these  factors  do  not  completely  explain  other  forms  of  disease  such  as
young-onsets of PD. With the development of genomic technologies, an increasing number of
genes,  mutations  and  polymorphisms  have  been  implicated  in  the  PD  pathogenesis,
suggesting that PD is rather a multifactorial disorder arising from a combination of genetic and
environmental factors [reviewed in (Klein & Westenberger 2012; Scholz et al. 2012; Cooper-
Knock et al. 2012; Houlden & Singleton 2012; Trinh & Farrer 2013)].
Monogenic forms of PD demonstrate usually a positive family history and provide robust study
cases accounting for approximately 10% of PD patients. These are related to more than 18
distinct chromosomal regions (also called chromosomal loci) termed PARK and numbered in
the chronological order of their identification (Table 1-03).
The  most  recent  classifications  of  PARK loci  are  incomplete  systems  with  a  number  of
inconsistencies (i.e. several loci could not be replicated, some loci do not have an identified
gene or locus, loci PARK4 and PARK1 are identical). However, despite inconsistencies, the
following  list  contains  the  six  most  established  heritable  monogenic  forms  unequivocally
linked to PD:
[1]  SNCA is  the  first  discovered  and  the  most  studied  gene  associated  with  PD.  SNCA
encodes a-syn, a key component of LBs and hallmark of PD, as previously described. Five
point mutations were reported in individuals who developed these rare autosomal dominant
PD forms, with all mutations situated on the amino-terminus domain of a-syn (Thomas & Beal
2007). Interestingly, point mutations were also reported to increase the propensity of a-syn to
aggregate, suggesting a possible toxic gain of function (Polymeropoulos et al. 1997; Krüger et
al. 1998; Zarranz et al. 2004; Kiely et al. 2013; Lesage et al. 2013; Proukakis et al. 2013;
Appel-Cresswell et al. 2013). Moreover, specific mutations of the SNCA gene (such as A30P
or A53T) provide unique modifications of a-syn folding and aggregation rate  (Conway et al.
1998). Duplication and triplication in the SNCA gene have been reported to lead to an early
onset of the disease with prominent dementia (Singleton et al. 2003; Ibáñez et al. 2004; Miller
et al. 2004)].
[2]  LRRK2 gene mutations [reviewed  (Biskup & West 2009; Corti  et  al.  2011; Houlden &
Singleton 2012; Trinh & Farrer 2013)]  have been reported to be the most frequent known
causes  of  autosomal  dominant  and  sporadic  PD [reviewed  in  (Nuytemans  et  al.  2010)].
LRRK2 (leucine-rich repeat kinase 2) is a large gene composed of 51 exons and encodes a
2527 amino  acids  cytoplasmic  protein.  The  protein  contains  a  leucine-rich  repeat  on  the
amino-terminus  and  a  kinase  domain  on  the  carboxy-terminus  with  various  conserved
domains  in  between.  More  than  50 different  missense  mutations  are  reported  and
interestingly most of the pathogenic changes are clustered in 10 exons, the majority encoding
the protein's carboxy-terminal region. The increasing importance of LRRK2 in the regulation
of protein homeostasis highlights the importance of protein degradation in PD, probably via
the  regulation  of  the autophagy-lysosomal  system  (Orenstein  et  al.  2013).  High levels  of
LRRK2 in  peripheral  monocytes and macrophages also suggest  a  role  for  LRRK2 in the
|23|
Introduction |
immune system [reviewed in (Dzamko & Halliday 2012)]. A role of LRRK2 in host response to
pathogen and microglial inflammatory response has also been suggested (Moehle et al. 2012;
Gardet et al. 2010). LRRK2 forms of PD usually show similarities with idiopathic forms of PD
including, (1) slow disease progression, (2) mid to late disease onset, and (3) a response to
levodopa. Neuropathological findings are variable within  LRRK2 mutation carriers, showing
both LBs pathology and nigral degeneration without LBs (Giasson et al. 2006).
Table 1-03: Monogenic forms of Parkinson's disease
PARK loci Gene position Disease onset Inheritance Gene Protein function Cellular function
PARK1  4Q21-22 Early and late
onset
Dominant SNCA Exact function unknown
Synaptic transmission
PARK2 6q25.2-q27 Early onset Recessive PRKN E3 ubiquitin ligase
Mitophagy regulator
PARK3 2p13 Late onset Recessive Unknown -
PARK4 4q21-q23 Early onset Dominant SNCA Exact function unknown
Synaptic transmission
PARK5 4p13 Late onset Dominant UCHL1 Ubiquitin-protein hydrolase
Proteasomal protein degradation
PARK6 1p35-p36 Early onset Recessive PINK1 Serine-threonine kinase
Mitophagy regulator
PARK7 1p36 Early onset Recessive DJ-1 Redox sensor
Redox-sensitive chaperone
PARK8 12q12 Late onset Dominant LRRK2 GTPase, kinase
Role in protein degradation?
PARK9 1p36 Early onset Recessive ATP13A2 Apoptosis 
Lysosomal ATPase
PARK10 1p32 Late onset Risk factor Unknown -
PARK11 2q36-27 Late onset Dominant GIGYF2 Tyrosine kinase receptor signaling?
PARK12 Xq21-q25 Late onset Risk factor Unknown -
PARK13 2p12 Late onset Risk factor HTRA2 Serine protease
Mitochondrial protein release
PARK14 22q13 Early onset Recessive PLA2G6 A2 phospholipase
Free fatty acids and
lysophospholipids generation
PARK15 22q12-q13 Early onset Recessive FBX07 Proteasomal protein degradation
E3 ubiquitin-protein ligase
PARK16 1q32 Unclear Risk factor Unknown -
PARK17 16q11.2 Late onset Dominant VPS35 Adapter protein
Endosome retrograde transport
PARK18 3q27.1 Late onset Dominant EIF4G1 Scaffolding protein
mRNA recruitment to ribosome
|24|
| Introduction
[3]  PARK2 was  the  second  identified  monogenic  form  of  PD and  a  common  autosomal
recessive form of PD. PARK2 codes for parkin, a 465 amino acids protein with an E3 ubiquitin
ligase activity.  Structurally,  parkin  contains an amino-terminus ubiquitin-like  domain (UBL)
sharing a high homology with ubiquitin and four consecutive RING domains (“really interesting
new gene”) (Riley et al. 2013). Of the large number of identified PARK2 mutations, about half
affect the region spanning exons 2–4 (coding for the UBL domain, the very beginning of the
RING0 domain and the linker region) highlighting their relevance to parkin's normal function
[reviewed in detailed in  (Klein & Westenberger 2012)].  Mutations in  PARK2 are the most
frequent known cause of the early onset form of PD, characterized by its slow development
(Lücking  et  al.  2000) and  sharing  similar  clinical  symptoms  with  idiopathic  PD  patients
(Lohmann et al. 2003). Post mortem findings indicate variable levels of LBs and neurofibrillary
tangle pathology depending on the  PARK2 mutation,  highlighting its atypical  development
when compared with IPD (Hayashi et al. 2000; Pramstaller et al. 2005).
[4]  Mutations  in  PINK1 [phosphatase  and  tensin  homologue  (PTEN)-induced  putative
kinase 1] gene are the second most common cause of early onset autosomal recessive forms
of  PD  (Rogaeva et  al.  2004;  Y.  Li  et  al.  2005;  Bonifati  et  al.  2005)].  PINK1 protein  is  a
581 amino acids ubiquitously expressed protein kinase containing a mitochondrial targeting
motif  at  the  amino-terminus,  a  serine-threonine  kinase  domain  and  a  carboxy-terminal
autoregulatory domain. PINK1 has been shown to control the outer mitochondrial membrane
integrity  and  mitophagy,  thus  playing  a  protective  role  against  oxidative-stress-induced
apoptosis [mechanisms of PINK1 function reviewed in (Deas et al. 2009; Corti & Brice 2013).
The importance of the PINK1 kinase activity is  highlighted by the loss of  kinase function
observed in patients (Valente et al. 2004). The clinical phenotype of PINK1 mutation carriers
is relatively similar to idiopathic PD, but  earlier symptoms onset and less severe pathology
progression could be observed (Bonifati et al. 2005).
[5]  Mutations in DJ-1 represent a less common form of PD and despite the few patients
reported in literature, more than 10 different point mutations and exonic deletions have been
described  (Pankratz  et  al.  2006).  DJ-1  is  a  189 amino  acids  protein  that  is  ubiquitously
expressed,  functioning  as  a  cellular  sensor  of  oxidative  stress  which  regulates  its
translocation to the outer mitochondrial membrane (Canet-Avilés et al. 2004; Martinat et al.
2004;  Junn et  al.  2005).  Mutated DJ-1  proteins  are  frequently reported  to  be  improperly
folded,  unstable,  and  rapidly  degraded  thus  reducing  its  antioxidant  and  neuroprotective
function  (Malgieri  &  Eliezer  2008;  Anderson  &  Daggett  2008).  Patients  carrying  DJ-1
mutations that  result  in  PD present  an  early onset  with  slow disease progression,  which
closely resembles to the disorder caused by PARK2 or PINK1 mutations.
[6] Mutations in  ATP13A2 have been found to cause an autosomal recessive and atypical
form of PD named Kufor Rakeb syndrome (Ramirez et al. 2006).  ATP13A2 is a large gene
comprised  of  29 exons  coding  for  an  1180 amino  acids  protein.  The  ATP13A2 protein  is
normally located in the lysosomal membrane, consisting of 10 transmembrane domains and
an ATPase domain.  About  10 different  pathogenic mutations have been found,  directly or
indirectly affecting transmembrane domains resulting in an unstable and truncated protein.
This  syndrome  has  a  juvenile  onset  with  rapid  disease  progression,  accompanied  by
dementia, supranuclear gaze palsy, and pyramidal signs (Ramirez et al. 2006).
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The rest of the PARK loci listed have been hypothesized to be l inked to the development of
PD condition, whereas their involvement as monogenic form of PD has not been confirmed
yet. More precisely, some monogenic forms of PD were observed only in one patient (such as
EIF4G1,  UCHL1, and  GIGYF2), other gene mutations provide minor features in a complex
phenotype (like FBXO7, PLA2G6), and finally the HTRA2 gene was involved as a risk factor
and not as a monogenic form of PD [reviewed in (Corti et al. 2011; Houlden & Singleton 2012;
Klein & Westenberger 2012; Trinh & Farrer 2013)].
Several genetic risk factors have been related in developing idiopathic PD. Variants in several
PARK loci (SNCA, UCHL1 and LRRK2) and a few other genes (MAPT, GBA, NAT2, INOS2A,
GAK, HLA-DRA, and APOE) have been associated with an increased risk of developing PD.
Most  significant  risk  factors  identified  are  1) polymorphisms  or  mutations  in  SNCA,
2) missense  single-nucleotide  polymorphisms  (SNPs)  in  the  LRRK2 gene  (G2385R  and
R1628P), and 3) GBA loss-of-function mutations (Gaucher's Disease).
Finally, a last group of genes (including SNCAIP,  NR4A2/Nurr1, POLG,  HSPA9, and PARL)
could  be  considered  pathogenic  based  on  their  translated  proteins  functions  and
interactomes. However, further detailed studies did not validate a major contribution of these
genes in the development of PD.
To conclude,  discovery and detailed analysis  of  monogenic forms and risk factors  of  PD
allowed a partial clarification of the complex etiology of the disease, highlighting pathways
critically involved in the process. Understanding the function and the involvement of these
genes in PD is probably the key to find out links between poorly understood neuropathological
mechanisms, cell loss and the spectrum of clinical features observed in PD.
3)  Physiopathological pathways
Genetic components of PD, as suggested by the PARK loci table, seem to converge on three
inter-connected  cellular  processes:  1) synaptic  exocytosis  and  endocytosis,
2) lysosome-mediated autophagy, and 3) mitochondrial quality control and stress response.
This sequence of pathological events (Fig. 1-04) is reviewed in detailed in (Hardy et al. 2006).
However, it is still unknown whether alterations of these pathways lead to different entities or
whether they finally converge at a common pathogenic denominator.
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Figure 1-04: Extrapolation of genetic findings to model Parkinson's disease 
process
Figure copied from (Trinh & Farrer 2013)
In  presynaptic  terminals,  1) high  levels  of  a-syn  inhibits  exocytosis,  a-syn  promote  the  formation  of  early
endosomes. Postsynaptically,  2) LRRK2 regulates the release of vesicles, neuronal polarity and arborization.
LRRK2 also play a role in chaperone-mediated autophagy, MAPT phosphorylation and microtubule stabilization.
3) VPS35 plays an essential  role in the retromer complex and especially in the cargo recognition complex.
These cargoes have several destinations such as lysosomal degradation, exosome secretion, and endosome
recycling by the Golgi apparatus or peroxisome. 4) Lysosomal acid hydrolases, including GBA, require retromer
complexes  for  receptor  recycling.  5–7) Loss-of-function  mutations  in  PARK2,  PINK1 and  DJ-1  affect
mitochondrial  biogenesis  and  induction  of  autophagy.  Parkin  is  involved  in  ubiquitination  and  proteasomal
function,  PINK1 and  parkin  are  involved  in  mitochondrial  maintenance.  8) ATP13A2  plays  a  role  in
lysosome-mediated autophagy. 9) MAPT helps to regulate cargo trafficking and delivery, primarily in axons.
3.1  Synaptic dysfunction
Expression analysis of key genes involved in the disease pathogenesis reveals that encoded
proteins are particularly concentrated at synaptic terminals (such as a-syn (Iwai et al. 1995) or
LRRK2 (Biskup et al. 2006)). Moreover, functional analysis also showed their association with
synaptic vesicles in animals lacking a-syn (Abeliovich et al. 2000) or overexpressing mutated
G2019S LRRK2 protein (Xianting Li et al. 2010) [reviewed in (Picconi et al. 2012) and detailed
in the section describing animal models of PD].
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Accordingly to the synaptic dysfunction hypothesis, damage to axons and axonal terminals
are preceding dopaminergic neuronal cell  loss, suggesting that pathology may start at the
axon terminal  level  [reviewed in  (Cheng et al.  2010)].  It  is  noticeable that an increase of
dopamine turn-over has been described in presymptomatic PD patients (Whone et al. 2003),
but origins and consequences of this observation are not completely understood. Altogether,
changes  of  nigrostriatal  excitability  may  have  a  profound  influence  on  striatal  synaptic
transmission efficacy and hint at a synaptic dysfunction in early PD [reviewed in (Picconi et al.
2012)].
3.2  Protein degradation
The presence of abnormal accumulations and aggregates, forming characteristic inclusions in
PD, suggests that impairment of protein degradation pathways might play a primary role in
the physiopathology of the disease  (Soto 2003; Ross & Poirier 2004). Maintenance of the
cellular proteome (entire pool of proteins located inside the cell and its membrane) involves a
complex and dynamic equilibrium, regulated on the one hand by the synthesis and on the
other  hand  by the  degradation  of  proteins.  Synthesis  and  usage  of  proteins  lead  to  the
generation  of  unwanted  proteins  including  incomplete,  mutant,  misfolded,  mislocalized,
denatured, oxidized, and otherwise damaged proteins. These modified proteins, if they are
not removed by the quality control system, could induce cytotoxicity due to their tendency to
aggregate, interfering with cellular processes by loss or gain of function [reviewed in (Dobson
2003; Balch et al. 2008)]. Impairment of the cellular protein quality-control system may lead to
partial degradation of damaged proteins. This impairment can result not only from one single
severe condition, but also from combination of different moderate conditions, which cannot
overwhelm the system on their own. Conditions leading to a reduced effectiveness of the
quality-control  system can  be  categorized  in  four  classes:  mutations,  protein  biogenesis,
environmental stress, and aging [reviewed in detail in (Tyedmers et al. 2010)].
Protein quality control has three main parallel strategies: 1) refolding of misfolded proteins by
molecular chaperones, 2) degradation of proteins via the ubiquitin-proteasome system or the
autophagy-lysosomal  pathway,  and 3) sequestration  of  misfolded proteins  in  inclusions or
large aggregates [reviewed in (Takalo et al. 2013)]. More recently, exosomal release has been
shown as a fourth alternative degradation pathway for the cell  [reviewed in  (Schneider &
Simons 2013)].
3.2.1  Molecular chaperones
To be functional, most proteins must adopt a defined three-dimensional structure representing
a specific tertiary structure termed native fold. This structure is determined by the folding of
intermediate elements (secondary structure constituted of small  numbers of closed amino
acids interacting with each other) into a 3D structure presenting functional regions (Anfinsen
1973). Incompletely folded proteins can be trapped in non-productive intermediates, such as
misfolded conformers, consequence of free energy minimal conformation.
As a small energy barriers usually separate native and non-native conformations, even native
proteins are at permanent risk of unfolding, especially under environmental stress  (Shortle
1996). Misfolded conformers and folding intermediates typically expose hydrophobic residues,
which are prone to aggregation and normally buried in the native structure (Dobson 2003).
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Chaperones  and  co-chaperones  are  the  first  line  of  defense  against  misfolded  proteins,
binding to unfolded proteins or aggregation-prone folding intermediates and playing several
roles:  1) stabilizing  proper  protein  folding,  2) refolding  proteins  in  their  native  state,
3) preventing  unwanted  interactions  between  hydrophobic  regions  with  their  neighboring
proteins, 4) dis-assembling larger protein aggregates, and 5) targeting proteins which cannot
be refolded for degradation [reviewed in (Goloubinoff & De Los Rios 2007; Witt 2010; Wolff et
al. 2014)].
The relevance of this defense mechanism's failure in PD pathogenesis is highlighted by the
observation in LBs of abnormally high levels of molecular chaperones and co-chaperones
[reviewed in (Licker et al. 2009)]. This is suggesting a mechanism involving massive protein
misfolding, exceeding the refolding capability of  the molecular chaperones, leading to the
depletion of chaperones in cells and resulting in a widespread aggregation (Kalia et al. 2010).
3.2.2  Proteolytic degradation
The ubiquitin-proteasome system and the autophagy-lysosomal pathway are the two major
cellular proteolytic systems participating in protein turn-over and removal of altered proteins.
Ubiquitin-proteasome system
Ubiquitin-proteasome system (UPS) is a molecular mechanism responsible for the selective
degradation  of  most  short-lived  intracellular  and  plasma  membrane  proteins,  as  well  as
misfolded  or  damaged  proteins  in  the  cytosol,  nucleus  or  endoplasmic  reticulum  (ER)
(Ciechanover 2005)]. Clearance of proteins by the UPS involves an elaborate sequence of
events, extensively reviewed in  (Glickman & Ciechanover 2002),  schematized  in Fig. 1-05
and resumed below:
[1] The process is initiated by the ubiquitin-activating enzyme (E1), linking its cysteine residue
to  the  ubiquitin  terminal  glycine  in  an ATP-dependent  manner.  Activated ubiquitin  is  then
transferred to a cysteine residue of the ubiquitin-conjugating enzyme (E2). Final binding of
ubiquitin to its target protein is driven by a specific ubiquitin-protein ligase (E3). Ubiquitin can
be attached to substrate proteins in several ways, generating a broad repertoire of signals
with different topologies and lengths, leading to various functional outcomes for the tagged
substrate protein.
[2] A single ubiquitin molecule attached to a target protein (termed monoubiquitinated) could
be extended to  several  sites (termed multi-monoubiquitinated),  or  could form an ubiquitin
chain (termed polyubiquitinated) via the appropriate E2/E3 pair or through ubiquitin-elongating
enzymes (E4). Polyubiquitination is the most frequent ubiquitination signal found on proteins,
and can occur  on  several  different  lysine  residues of  ubiquitin  (seven lysine  residues at
positions 6, 11, 27, 29, 33, 48, 63 and the N-terminal methionine). Polyubiquitination presents
a  large  repertoire  of  signals  depending  on  the  position  of  the  ubiquitin-ubiquitin  chain
elongation and on the length of the polyubiquitin chain. Thus, ubiquitin-dependent signaling
affects  almost  all  cellular  processes  [reviewed  in  (Pickart  &  Fushman  2004;  Kulathu  &
Komander 2012; Kravtsova-Ivantsiv & Ciechanover 2012)].
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Figure 1-05: 26S ubiquitin-proteasome degradation system
Figure copied from (Cook et al. 2012)
A) Activation of ubiquitin protein by ubiquitin-activating enzyme E1 in an ATP-dependent manner. B) Transfer of
activated ubiquitin to the E2. C) Ubiquitin transfer from the E2 to the substrate driven by specific E3 either prior
or after E3 conjugation to the substrate.  D) Additional ubiquitin molecules can be added to the internal lysine
residues of ubiquitin to form polyubiquitin chain on the substrate.  E) Ubiquitinated substrate is recognized and
degraded by the 26S proteasome complex,  leading to the release of short  peptides.  Ubiquitin can be then
recycled via the activity of deubiquitinases.
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[3] Degradation of the vast majority of intracellular proteins is performed by the proteasome
[reviewed in (Lamark & Johansen 2012; Kish-Trier & Hill 2013)]. The proteasome refers to a
variety of complexes, classically composed of the 20S proteasome (as catalytic core) and
regulatory subunits (forming ‘‘lid’’ or “cap” at the end of the 20S to regulate the entry and
catalytic  function  of  the  core).  The  20S  element  forms  a  barrel-shaped  structure  and  is
constituted of 28 protease subunits, two copies of seven different outer α-subunits and two
copies of seven different inner β-subunits. Three catalytic active subunits (β1, β2, and β5)
possess  caspase-,  trypsin-,  and  chymotrypsin-like  activities,  respectively.  Regulation  of
complexes containing the 20S element is still poorly understood, but two main mechanisms
(ATP-dependent  and ATP-independent)  are emerging. In  the ATP-dependent  regulation, a
19S complex is attached at one or both ends of the 20S to form the 26S proteasome. In this
structure,  19S  forms  a  regulatory  lid  and  selects  appropriate  targets  by  binding  to
ubiquitinated proteins via Rpn10 and Rpn13. The selected substrate is then unfolded and
translocated  into  the  20S  in  an  ATPase  dependent  manner.  In  the  ATP-independent
regulation, several protein complexes (such as 11S (or PA28), Blm10 (or PA200) as well as
PI31)  can  interact  at  one  or  both  ends  of  the  20S  to  form  alternative  isoforms  of  the
proteasome able to regulate ubiquitin-independent substrate degradation [reviewed in (Kish-
Trier & Hill 2013)].
The involvement of ubiquitin-mediated processes has been suspected in the physiopathology
of PD since immunoreactivity against ubiquitin was detected in Lewy bodies from samples of
sporadic  PD  patients  (Lennox  et  al.  1989).  Accordingly,  origin  of  the  disorder  has  been
hypothesized to be a consequence of an age-related decrease of UPS function (Gray et al.
2003).  This  hypothesis  is  supported  by  1) decreased  20S  proteasome  alpha-subunits
observed  in  patients  (McNaught,  Belizaire,  et  al.  2002),  2) reduced  20S  proteasomal
enzymatic activities in post mortem brain tissue extracted from PD patients (McNaught et al.
2001), 3) existence of rare genetic forms of PD affecting components and substrates of the
UPS  (i.e. PARK2 coding  for  parkin  which  is  an  E3  ligase  or  UCH-L1 coding  for  a
deubiquitinase),  and  4) numerous  in  vivo and  in  vitro studies  based  on  administration  of
proteasome inhibitors (hypothetically modeling and accentuating the natural decrease of UPS
observed with aging) also showing the importance of the UPS function in the formation of
cellular inclusions and neurodegeneration (McNaught, Mytilineou, et al. 2002; McNaught et al.
2004; Bedford et al. 2008).
Autophagy-lysosome pathway
The autophagy-lysosome pathway (ALP) is the general term used to describe the degradation
pathway of intracellular proteins and organelles in lysosomes (Fig. 1-06). According to the
different pathways by which cargo is delivered to the lysosome, autophagy can be divided into
three  main  types:  macroautophagy,  microautophagy,  and  chaperone-mediated  autophagy.
Lysosomes are cellular organelles composed of a single membrane vesicle, which maintain
an acidic pH through ATP-dependent proton pumps, and contain an assortment of soluble
acid-dependent hydrolases including proteases, lipases, and glycosidases.
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Figure 1-06: Autophagy-lysosomal degradation pathway
Figure copied from (Lynch-Day et al. 2012)
Schematic model of the three main autophagy types. Chaperone-mediated autophagy involves recognition of
substrates by HSC70 chaperones, translocating them across lysosomal membrane via interaction with LAMP-2A
oligomer. Various types of microautophagy-like processing selectively degrade organelles (such as peroxisomes
and  mitochondria)  via  their  sequestration  into  lysosomal  membranes.  Macroautophagy  involves  a  double
membrane  phagophore  to  sequester  cargo  consisting  of  cytoplasmic  component,  expanding  into  an
autophagosome and fusing with the lysosome to allow the cargo to be degraded.
Macroautophagy
Macroautophagy  [reviewed  extensively  in  (Lynch-Day  et  al.  2012;  Lamark  &  Johansen
2012) is a tightly regulated process consisting of several sequential steps: 1) initiation of the
process by the formation of a double-membrane structure (termed phagophore), 2) elongation
of the phagophore resulting in its closure (forming the autophagosome) and sequestering a
portion  of  the cytoplasm,  3) autophagosome transported along microtubules  from the cell
periphery to the microtubule-organizing center area, 4) fusion of the outer membrane of the
autophagosome with  the lysosome (forming the autophagolysosome) and resulting in the
degradation of their content by its acidic environment and by lysosomal proteases.
Although macroautophagy has commonly been described as a cellular adaptive response to
nutrient starvation, an important role has emerged in intracellular quality control to protect
cells  against  microbial  infection,  oxidative  stress,  proteasome  inhibition,  or  protein
aggregation  (Mizushima  et  al.  2008;  Deretic  2010).  Oxidative  stress  to  organelles  is  an
interesting  example  illustrating  the  critical  role  of  selective  autophagy  in  the  intracellular
quality control. In the particular mitochondrial case, damaged mitochondria will accumulate in
the  cell  and  lead  to  neuronal  cell  death  (Chen  &  Chan  2009) if  not  processed  by  the
autophagy (so called mitophagy) (de Vries & Przedborski 2013).
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In  contrast  to  starvation-induced  autophagy,  quality  control  autophagy  requires  specific
mechanisms allowing the selection and disposal of aberrant protein aggregates and damaged
organelles. Selective macroautophagy is driven by autophagic adapter proteins (such as p62
or NBR1) acting as autophagy cargo receptors due to their ability to bind to ubiquitinated
substrates and to be recruited for degradation by phagophores (Pankiv et al. 2007; Kirkin et
al. 2009; Johansen & Lamark 2011).
Microautophagy
Microautophagy is a non-selective lysosomal degradation process involving the direct delivery
and rapid digestion of cellular constituents (including organelles, lipids, or proteins) through
lysosomal  membrane invagination  engulfing  complete  regions of  the  cytosol  [reviewed in
detail  in  (Mijaljica  et  al.  2011;  Li  et  al.  2012)].  Despite  the  complexity  and  variety  of
microautophagy  mechanisms,  a  general  mechanism  can  be  observed:  1) initiation  of
microautophagy by the formation of a spontaneous pit on a localized area of the lysosomal
membrane and its extension leading to a characteristic tubular shape (termed autophagic
tube), 2) formation of a vesicle at the bottom of the tube, 3) vesicle expansion by specialized
enzymes binding to the inside of the nascent spherical structure, 4) vesicle pinch-off into the
lumen from the tube via an enzyme or a mechanic excision and, 5) vesicle degradation and
recycling by lysosomal hydrolases.
Microautophagy could be induced by starvation and rapamycin, but also occurs constitutively
(Dubouloz  et  al.  2005) and  simultaneously  or  in  synergy  with  other  types  of  selective
autophagy  stabilizes  intracellular  environment  and  sequestering  specific  organelles  with
arm-like protrusions (Todde et al. 2009).
Chaperone-mediated autophagy
Chaperone-mediated  autophagy  (CMA)  involves  the  identification  of  specific  unfolded
cytosolic proteins and their delivery to the lysosomal membrane. This mechanism is based on
the recognition of the specific KFERQ motif  via the chaperone hsc70 (70 kDa heat-shock
cognate  protein).  The  substrate/chaperone  complex  is  targeted  to  the  surface  of  the
lysosomes via its binding to the lysosome-associated membrane protein type 2A (LAMP-2A).
Assembly of a high molecular weight complex is promoted at the lysosomal membrane and
results  in  the  substrate's  translocation  into  the  lysosomal  lumen [reviewed extensively  in
(Majeski & Dice 2004; Kaushik & Cuervo 2012)].
A selectivity activation of protein degradation via CMA arises after nutrient deprivation and
cellular stress  (Cuervo et al.  1995),  underlining its importance to  the maintenance of the
protein quality control.
Involvement of proteolytic degradation in Parkinson's disease
They are increasing evidences that autophagy is deregulated in the physiopathology of PD. At
the  histological  level,  accumulation  of  abnormal  autophagic  vacuoles  was  observed  in
neurons of PD patients  (Anglade et al. 1997; Zhu et al. 2003). At the genetic level, genes
linked  to  autosomal  dominant  PD  are  also  playing  an  important  role  in  autophagy.  For
instance,  the mutated a-syn protein  was shown to  inhibit  the  CMA  (Cuervo et  al.  2004),
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LRRK2 mutations  were  also  shown to  regulate  both  CMA and  macroautophagy  (Alegre-
Abarrategui  et  al.  2009;  Tong et  al.  2010;  Orenstein  et  al.  2013) and mutated  ATP13A2
protein was described to provoke lysosomal dysfunction  (Ramirez et al. 2006). Accordingly,
the selective deletion of Atg proteins in mouse models (either Atg5 or Atg7 which both play a
critical  role  in  autophagy)  was  reported  to  induce  neurodegeneration  and  formation  of
ubiquitin-positive cytoplasmic aggregates (Hara et al. 2006; Komatsu et al. 2006).
Moreover,  the  progressive  impairment  of  specific  and  selective  protein  degradation
mechanisms with aging (such as proteasomal pathway and CMA) [reported in  (Gray et al.
2003;  Cuervo  &  Dice  2000) respectively]  is  reported  to  lead  to  an  upregulation  of  the
macroautophagy (Massey et al. 2006; Pandey et al. 2007). This excessive activation of a less
selective in-bulk degradation mechanism (macroautophagy) is on the one hand compensating
the reduced protein degradation, but on the other hand also associated with a lower capacity
to respond to stress conditions and can itself  induce stress to cells  (Massey et al.  2006).
Thus,  autophagosome formation  can  exert  toxicity  regardless  whether  it  leads  to  protein
degradation or accumulation [reviewed in (Maiuri et al. 2007)]. This could be illustrated at the
histological level by the presence of autophagic vacuoles in the brains of PD patients, which
are usually rarely detected (Anglade et al. 1997; Zhu et al. 2003). In this context, maintaining
a proper level of autophagy to reduce protein aggregation and damaged organelles could be
apply as a strategy to reduce neuronal damage (Lynch-Day et al. 2012).
3.2.3  The aggresome
Aggresomes are a specialized form of inclusion bodies found in the cytoplasm of mammalian
cells  (Johnston et al. 1998) and characterized by their localization in the centrosome at the
perinuclear site (Fig. 1-07). Their overall structure and size is variable, depending on cell type
and  aggregating  substrate.  Aggresomes  appear  usually  as  a  single  sphere  of  1 to 3 μm
diameters  or  as  an extended  ribbon and  are  composed mainly  of  a  core  of  aggregated
ubiquitinated proteins surrounded by a cage-like shell  composed of  vimentin intermediate
filaments [reviewed in (Kopito 2000)]. Aggresomes are not permanently present in cells, but
are induced by cellular stress as in the case of large amounts of unfold proteins (such as
proteasome inhibition).
These  dynamic  structures  are  able  to  recruit  various  cytosolic  components  such  as
chaperones, ubiquitination enzymes or proteasome components [generation of aggresomes
detailed  in  (Garcia-Mata  et  al.  2002)].  The  formation  of  aggresome  is  initiated  by  the
retrograde transport  of  small  and dispersed cytoplasmic aggregates to the centrosome to
form  enlarged  inclusions  of  aggregated-ubiquitinated  proteins  (Johnston  et  al.  2002;
McNaught,  Shashidharan, et  al.  2002).  This transport  mechanism is driven mainly by the
histone  deacetylase  6  (HDAC6),  binding  to  polyubiquitinated-proteins  so  that  the  dynein
motor complex can transport them along microtubules (Kawaguchi et al. 2003). Aggresomes
are  finally  degraded  by  macroautophagy  via  autophagosome,  underlining  the  role  of
aggresomes in the promotion of specific and efficient clearance of aggregation-prone proteins
(Fortun et al. 2003; Tanaka et al. 2004; Iwata et al. 2005).
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In  many  ways,  LBs  could  be  considered  as  a  form  of  aggresome.  First,  LBs  have  an
aggresome appearance (presence of a centrosome as well as aggresome-specific proteins
such as gamma-tubulin and pericentrin). Second, numerous discrete ubiquitinated aggregates
are transported from peripheral  sites to  the centrosome,  where  aggresomes are forming,
similarly to LBs which are also containing large quantity of ubiquitinated proteins. Finally, LBs
contain heat shock proteins as well as components of the UPS, which are also typically found
in the aggresomes [reviewed in (Olanow et al. 2004)].
Figure 1-07: Aggresome formation
Figure modified from (Garcia-Mata et al. 2002)
Proteins unfolding (or misfolding) may occur during polysome translation, proteins retrotranslocation from the ER
to  the  cytosol  or  during  cellular  stress.  These  abnormal  proteins  may  then  present  reduced  degradation
efficiency by the proteasome, and therefore form aggregates throughout the cells. Such aggregates can be
transported in a microtubule- dependent manner to the microtubule organizing center (MTOC) in a process
requiring dynein/dynactin complex.
3.3  Mitochondrial dysfunction, oxidative stress and inflammation
3.3.1  Mitochondrial dysfunctions
The concept of mitochondrial dysfunction in the physiopathology of PD was first seriously
investigated  after  the  discovery  of  1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine  (MPTP)
toxicity mechanism. MPTP is a synthetic heroin analog, discovered accidentally in drug users
who injected themselves this homemade compound; these subjects developed parkinsonism
within days consequence of irreversible lesions of dopaminergic neurons in the substantia
nigra pars compacta [reviewed in detail in (Hauser & Hastings 2013)].
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MPTP toxicity comes from its ability to cross the blood-brain barrier, penetrating into glial cells
and  being  converted  into  the  neurotoxin  1-methyl-4-phenylpyridinium  (MPP+).  MPP+  is
transported by the dopamine transporter into monoaminergic neurons, getting concentrated
into mitochondria where it specifically inhibits the complex I of the respiratory chain and leads
to ATP depletion, oxidative stress and apoptotic cell death.
Following this discovery, analysis of mitochondrial complex I activity in patients with sporadic
PD revealed a moderate deficit  in several  brain regions including substantia nigra, frontal
cortex but also peripheral tissues like skeletal muscle [reviewed in (Winklhofer & Haass 2010;
Hauser  &  Hastings  2013)].  Confirming  the  previous  findings,  the  administration  of  the
complex I inhibitor rotenone was reported to cause many of the pathological and behavioral
hallmarks of PD  (Betarbet et al. 2000). Therefore, this strategy provides an elegant animal
model allowing a better understanding of the physiopathology of PD. 
3.3.2  Oxidative stress
Mitochondria are involved in various cell functions, but are well known as an important source
of energy by generating ATP energy via oxidative phosphorylation. This metabolic pathway is
driven  by  the  transport  of  electrons  through  mitochondrial  complexes I–IV  in  the  inner
mitochondrial membrane via series of coupled redox reactions providing the energy to create
a proton gradient across the inner mitochondrial membrane and driving ATP synthesis from
ADP as protons re-enter the matrix. Under normal conditions, molecules and free radicals
derived from molecular oxygen participate in oxidative phosphorylation, providing the major
source of reactive oxygen species (ROS)  (Chance et al.  1979). ROS levels are regulated
under normal conditions by a battery of  protective systems sequentially reducing ROS to
water by the electron transport chain complexes  (Brand 2000). Certain situations (such as
mitochondrial dysfunctions) can cause ROS production to surpass the antioxidant capacity of
a cell (Trifunovic & Larsson 2008).
In this specific condition, termed oxidative stress, irreversible damage are caused to cellular
macromolecules (such as protein oxidation, lipid peroxidation, DNA and RNA oxidation) and
can lead ultimately to cell death. Several markers of oxidative stress, including high levels of
oxidatively modified lipids, proteins and DNA, have all been found in brain samples of PD
patients (Dexter et al. 1989; Floor & Wetzel 1998).
Thus,  mitochondria  are  at  the  same  time  essential  to  produce  energy  and  potentially
dangerous.  Therefore,  several  mitochondrial  quality  control  pathways  have  evolved  to
efficiently protect mitochondria from molecular damage and to maintain an overall  healthy
population [reviewed in (Fischer et al. 2012; Andreux et al. 2013)]. As reported previously in
this thesis, mutations in  genes involved in monogenic PD (PARK2,  PINK1 and  DJ-1) were
shown  to  impair  key  function  in  the  control  of  mitochondrial  morphology  and  integrity
[reviewed in (de Vries & Przedborski 2013)] via the degradation of damaged mitochondria by
macroautophagy [also termed mitophagy and reviewed in  (Youle & Narendra 2011)]. These
observations  suggest  that  the  autophagic  pathway  is  also  essential  for  the  turn-over  of
dysfunctional  mitochondria  and  its  failure  seems  definitely  involved  in  pathogenic
mechanisms of PD (Hirsch & Hunot 2009).
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3.3.3  Abnormal inflammation
Chronic inflammation is associated with a broad spectrum of neurodegenerative diseases
(McGeer  &  McGeer  2004).  Accordingly,  in  postmortem  PD  patient  brains,  an  increased
inflammatory  response  is  suggested  to  increase  levels  of  1) glial  activation  (resulting  in
microglial  activation  as  well  as  an  increase  in  astroglia  cells),  2) lymphocyte  infiltration,
3) pro-inflammatory mediators (such as tumor necrosis factor alpha (TNFα), interleukin1 beta
(IL-1β)  or  interferon  gamma  (IFNγ)),  and  4) inflammation-inducible  enzymes  (such  as
cyclooxygenase 2 (COX2) as well  as nitric  oxide synthase (iNOS))  [reviewed in  detail  in
(Hirsch & Hunot 2009)].
Unfortunately, the exact origin and role of the neuroinflammation is still unknown yet, despite
an increasing number of studies pointing to its relevance in the progression of the disease in
both animal models and clinical studies [reviewed in (Collins et al. 2012)]. In this context, the
involvement  of  the  neuroinflammation  process  as  a  cause  of  the  disease  or  as  a
consequence of neuronal degeneration is still highly debated.
4)  Animals models
PD is a complex disorder in which causes, mechanisms and neurodegeneration progression
are  still  unclear.  Due  to  their  interdependence,  studying  these  aspects  simultaneously is
probably  the  best  strategy  to  achieve  significant  advances.  However,  this  proposes  a
challenge  concerning  the  methodology as  it  requires  a  parallel  analysis  at  physiological,
cellular, molecular and biochemical levels.
Analysis of limited post-mortem material from patients implies methodology limitations that in
vivo model cannot emphasis. For example, the large variety of neuronal and non-neuronal
cell  types implies that  the complex physiopathology of PD cannot  be modeled in cellular
models.  These considerations lead to  the frequent  use of  animal  models,  and especially
mouse  models  because  of  their  similarity  with  human neuronal  network  as  well  as  their
well-known genome and behavior  (Waterston et  al.  2002).  Therefore,  in  the next  chapter
concerning animal models of PD, we will  mainly focus on mouse models, and provide an
overview of the most studied PD mouse models (Table 01-04).
Two  main  strategies  are  commonly  applied  to  generate  these  models:  1) neurotoxins  to
destroy the striatonigral system, 2) genetic modifications to model monogenic forms of the
disease  by  deleting  (knock-out)  or  replacing  (knock-in)  or  inserting  (transgenic)  gene(s)
involved in familial forms of PD.
Ideally,  a  PD mouse model  should  reproduce all  the disease features:  dopaminergic  cell
degeneration,  presence  of  LB  inclusions,  microglial  activation  and  non-motor  symptoms.
Despite  the  variety  of  methods  existing  to  generate  animal  models,  no  single  model
reproduced so far the combination of slow and progressive degeneration of dopaminergic
cells, presence of LBs and inflammation.
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Table1-04: Examples of Parkinson's disease mouse models
Method Injection/ 
expression
Dopaminergic
cell loss
Alpha-synuclein
aggregates
Progressive
pathology
Motor 
deficit
Reference
To
xi
n
MPTP IP injection Yes Conflicting No Yes Heikkila 1984
Fornai 2005
6-OHDA Intracranial 
injection
Yes No No Yes Faull 1969
Rotenone IP injection Yes Conflicting Yes Weak Heikkila 1985 
Betarbet 2000
Paraquat IP injection Conflicting No No No Brook 1999
Tr
an
sg
en
et
ic
TH WT, A30P
or A53T a-syn
Catecholamine
neurons
No Yes Yes No Matsuoka 2001
Thy-1 WT 
a-syn
Neuron 
specific 
No Yes Yes Mild Kahle 2000
Thy-1 A30P 
a-syn
Neuron 
specific 
No Yes Yes Mild Kahle 2000
Thy-1 A53T 
a-syn 
Neuron 
specific 
No Yes Yes Sever van der Putten 
2000
PrP WT a-syn Majority of 
neurons
No Conflicting Conflicting No Giasson 2002
Lee 2002
PrP A30P 
a-syn
Majority of 
neurons
Conflicting Conflicting Conflicting Mild Lee 2002
Gomez-Isla 2003
PrP A53T 
a-syn 
Majority of 
neurons
No Conflicting Yes Sever Lee 2002
Gispert 2003
PDGF WT 
a-syn
Majority of 
brain neurons
No Yes Yes Yes Masliah 2000
Lee 2002
Complete 
human SNCA
Widespread No Yes Yes Mild Kuo 2010
Hansen 2013
PDGFβ 
G2019S 
LRRK2
Majority of 
brain neurons
Yes No Yes Yes Ramonet 2011
DAT promoter
truncated 
parkin Q311X
Catecholamine
neurons
Yes Yes Yes Yes Lu 2009
K
O
Parkin KO _ No No No No Itier 2003 
Goldberg 2003
Pink KO _ No Conflicting Conflicting Mild Kitada 2007 
Gispert 2009
DJ1 KO _ Conflicting Conflicting Conflicting Mild Goldberg 2005 
Rousseaux 2012
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4.1  Neurotoxin-based model of Parkinson's disease
Administration of neurotoxic agents to inducing the degeneration of neurons is the classical
approach to model PD and to reproduce pathological and behavioral changes observed in
patients.  The most  common neurotoxins used to  induce dopaminergic  neurodegeneration
include1-methyl-5-phenyl-1,2,4,6-tetrahydropyridine (MPTP), 6-hydroxydopamine (6-OHDA),
rotenone, paraquat and maneb. A common feature of these neurotoxins is their  effect on
mitochondria, either by inhibiting mitochondrial complex I or by complex III, resulting in the
production of ROS, which induces microglia-mediated inflammation. Alternatively, the use of
lipopolysaccharides (LPS) to selectively activate microglial  cells also leads to an effective
degeneration of dopaminergic cells.
All of these models lead to a rapid and age-independent degeneration of dopaminergic cells
in rodents over a period of a few days. Unfortunately, this rapid progression represents the
major  drawback  in  these  models,  known  to  inadequately  translate  neuroprotective  or
regenerative strategies to human patients [reviewed in (Hirsch & Hunot 2009)].
Systemic administration of MPTP
MPTP was  discovered  in  a  group  of  drug  users  having  consumed  synthetic  meperidine
contaminated  with  MPTP  and  showing  a  severe  parkinsonism  responsive  to  L-dopa
treatment,  suggesting for the first  time a direct relationship between environment and PD
[reviewed in (Davis et al. 1979; Langston et al. 1983)].
Toxicity of MPTP results from its lipophilicity, allowing MPTP to cross the blood-brain barrier
[reviewed in  (Dauer & Przedborski 2003)]. When inside the brain, MPTP is metabolized in
astrocytes to an active toxic cation termed 1-methyl-4-phenylpyridinium (MPP+) which is then
released into the extracellular space through the organic cation transporter 3 and taken up by
dopaminergic  neurons and terminals  through the  dopamine transporter  (Cui  et  al.  2009).
Once accumulated in dopaminergic neurons, MPP+ inhibits complex I of the mitochondrial
electron transport chain, resulting in ATP depletion and increased oxidative stress (Forno et
al. 1993; Dauer & Przedborski 2003).
In mice, MPTP intoxication by intraperitoneal injections leads to a specific and reproducible
degeneration  of  the nigrostriatal  dopaminergic  pathway [reviewed in  (Nicklas et  al.  1985;
Mizuno et al.  1987)]. Generally, MPTP injection in mice does not lead to the presence of
intraneuronal  inclusions,  except  in  some models  receiving  chronically low dose of  MPTP
(Fornai et al. 2005). Behavioral motor deficits induced by MPTP are reversible by L-dopa or
dopamine agonists (Ogawa et al. 1985; Fredriksson & Archer 1994; Rozas et al. 1998).
6-OHDA
6-OHDA is a hydroxylated derivate of dopamine that is inducing a selective degeneration of
sympathetic adrenergic nerve terminals (Thoenen & Tranzer 1968; Tranzer & Thoenen 1973).
The high affinity of 6-OHDA to dopaminergic and noradrenergic transporters (Luthman et al.
1989) induces an accumulation of the molecule into the neuronal cytosol and leads to an
oxidative stress-related cytotoxicity (Saner & Thoenen 1971; Graham et al. 1978).
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6-OHDA is  usually  stereotactically  injected  unilaterally  into  the  substantia  nigra,  medial
forebrain bundle, or striatum and leading to the degeneration of dopaminergic neurons within
12 hours followed by a loss of striatal terminals occurring 2 to 3 days later  (Faull & Laverty
1969;  Jeon et al.  1995).  6-OHDA cannot efficiently pass the blood-brain barrier,  probably
because of its polar structure. Therefore neurodegeneration following 6-OHDA injection lacks
the progressive, age-dependent and aggregated structures typically found in PD.
Paraquat
Paraquat (N,N'-dimethyl-4-4'-bipiridinium) is a herbicide with a molecular structure similar to
MPP+ (Snyder & D’Amato n.d.). Relevance of paraquat intoxication for modeling and studying
PD is highlighted by several epidemiological studies, suggesting an increased risk for PD
after paraquat exposure (Hertzman et al. 1990; Liou et al. 1997; Kamel et al. 2007).
The exact mechanism leading to neurotoxicity in dopaminergic neurons is not well known
because despite structural similarity to MPP+, paraquat does not cross the blood-brain barrier
(Shimizu et al.  2001;  McCormack & Di  Monte 2003) and does not bind to the dopamine
transporter (Richardson et al. 2005). Paraquat is not a complex I inhibitor (Richardson et al.
2005), but leads to a strong oxidative stress consequence of its redox cycling  (Day et al.
1999).
Paraquat  injection  leads  to  motor  deficits  and  to  a  moderate,  but  specific  loss  of  nigral
dopaminergic neurons in a dose- (McCormack et al. 2002) and age- (McCormack et al. 2002;
Thiruchelvam  et  al.  2003) dependent  manner  without  affecting  striatal  dopamine  levels
(Thiruchelvam et al. 2000; McCormack et al. 2002). Furthermore, paraquat treatment induces
a-syn positive aggregates (Manning-Bog et al. 2002; Fernagut et al. 2007).
Rotenone
Rotenone is a pesticide with a high lipophilicity, able to cross the blood-brain barrier, but also
to penetrate cells without any transporter mechanism. Toxicity of  rotenone is linked to its
inhibition of the mitochondrial complex I.
High doses of rotenone via intravenous injections lead to widespread lesions beyond the
nigrostriatal system in mice (Heikkila et al. 1984; Heikkila et al. 1985; Ferrante et al. 1997).
Rotenone  in  low  doses,  via  chronic  intraperitoneal  injections,  induces  a  more  selective
nigrostriatal neurodegeneration with cytoplasmic inclusions positive for a-syn (Betarbet et al.
2000; Cannon et al. 2009).
Other nigrostriatal neurotoxic models
Other models have also been used to deplete striatal dopamine and to induce neurotoxicity in
the nigrostriatal pathway such as reserpine (depletion of monoamines), α-methyl-p-tyrosine
(inhibitor of tyrosine hydroxylase), amphetamine derivates (neurotoxin), isoquinoline derivates
(same neurochemical properties as MPTP) and lipopolysaccharides (activation of microglia
through  the  toll-like  receptor-4  receptor).  These  models  are  not  commonly  used,  mainly
because of their non-specific effects [reviewed in detail in (Tieu 2011)].
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4.2  Transgenic mouse models of Parkinson's disease
Since  the  discovery  of  familial  forms  of  PD,  pathological  similarities  and  shared  genetic
backgrounds in monogenic and sporadic forms of PD suggested an excellent potential  of
monogenic PD animal models (Blandini & Armentero 2012). 
Accordingly,  the  generation  of  animal  models  expressing  these  genes  has  been  already
expanding the comprehension of PD pathogenesis (Bezard & Przedborski 2011). The major
strength of the genetic models is their association with identified potential mechanisms known
to cause PD in humans (Meredith et al. 2008). But unfortunately at the present time, the major
weakness of these models is their relative mild phenotype and a low dopaminergic cell loss.
4.2.1  Alpha-synuclein
To date, various a-syn transgenic mice have been developed using 1) different promoters to
regulate  the  location  of  transgene  overexpression,  2) different  point  mutations  and/or
truncations to modulate its aggregation. These different strategies were shown to have an
important impact on the age of onset and pathology (such as motor dysfunctions and non-
motor dysfunctions including gastrointestinal alterations or olfactory deficits). These models,
developing usually a mild neurodegeneration, are an important tool to understand molecular
mechanisms leading to in vivo a-syn aggregation and neurodegeneration.
Alpha-synuclein expression under the tyrosine hydroxylase promoter
Tyrosine hydroxylase (TH) promoter allows the selective expression of transgenic proteins in
catecholaminergic neurons. Transgenic mice expressing a-syn under the TH promoter show a
down regulation  of  TH expression  without  evidence of  neuronal  cell  death,  an  increased
sensitivity to MPTP toxicity as well as a specific accumulation of a-syn within dopaminergic
cell bodies and in striatal terminals (Matsuoka et al. 2001; Rathke-Hartlieb et al. 2001; Maskri
et  al.  2004).  Moreover,  expression  of  mutant  forms  of  a-syn  leads  to  an  exacerbated
sensitivity  to  MPTP  as  well  as  a  more  pronounced  age-related  neuropathology  when
compared to  wild-type a-syn  (Richfield  et  al.  2002).  Similarly,  expression  of  a  C-terminal
truncated  a-syn  form  (1-120)  leads  to  relatively  strong  phenotype  presenting  a-syn
accumulation in the substantia nigra, axonal pathology in the striatum and the olfactory bulb,
reduced striatal dopamine levels and a locomotor impairment (Michell et al. 2007).
Alpha-synuclein expression under the thymus cell antigen 1 promoter
Expression  of  wild-type,  A30P  and  A53T  a-syn  under  the  brain  neuron  specific  Thy-1
promoter is sharing the formation of somatodendritic  accumulations of detergent insoluble
a-syn throughout the brain and the spinal cord as well as the development of a severe motor
phenotype (Kahle et al. 2000; van der Putten et al. 2000; Kahle et al. 2001; Rockenstein et al.
2002). Moreover, a time dependent decrease of striatal dopaminergic content, a reduced TH
expression in  the striatum,  movement  slowness and an increased susceptibility  to  MPTP
toxicity could also be observed (Song et al. 2004; Chesselet et al. 2012). It is interesting that
expression of the murine a-syn under the Thy-1 promoter shows a phenotype similarity with
expression of the human wild-type or mutant a-syn (Rieker et al. 2011).
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Alpha-synuclein expression under the prion protein promoter
Similarly to  the Thy-1 promoter,  transgenic mice overexpressing the A53T mutated a-syn
under  the  prion  protein  (PrP)  promoter  do  not  replicate  the  typical  dopaminergic
neurodegeneration observed in PD. However, these mice exhibit  neurotoxic fibrillization of
transgenic a-syn in the brainstem and spinal  cord, inducing a fatal  motor phenotype with
advanced age which is responsive to dopaminergic treatment (Giasson et al. 2002; M. K. Lee
et al. 2002). Mice overexpressing wild-type human a-syn or A30P mutated a-syn present a
relatively similar phenotype to mice overexpressing the A53T mutated a-syn, with a milder
neuronal cell loss and a later onset of motor phenotype (Gomez-Isla et al. 2003).
Alpha-synuclein expression under the platelet-derived growth factor promoter
Expression of wild-type a-syn under the CMV-enhanced human platelet-derived growth factor
β chain platelet derived growth factor (CMVE-PDGFβ)  promoter leads to a reduction of TH
positive terminals in the striatum without a loss of dopaminergic cells in the substantia nigra.
At the histological level, these mice develop electron dense inclusion bodies immunoreactive
for ubiquitin and a-syn. Inclusions are localized in brain structures usually affected in PD in
which amorphous non-filamentous a-syn could be detected (Masliah et al. 2000). Moreover, a
lysosomal pathology  (Rockenstein et al. 2005) and a reduced neurogenesis  (Winner et al.
2004; Winner et al. 2008) were reported in the whole brain and the olfactory bulb respectively.
Alpha-synuclein expression under the full human SNCA promoter
Models based on bacterial artificial chromosome (BAC) and P1-derived artificial chromosome
(PAC) technology were used to integrate the entire human SNCA gene to the mouse genome
in order to humanized mouse (carrying the human gene but lacking the endogenous one).
Transgenic mice overexpressing wild-type,  but  also A30P and A53T mutated a-syn,  were
generated using PAC and crossed into SNCA KO background (Kuo et al. 2010). All lines show
robust  abnormalities  in  the  enteric  nerve  system,  but  only  A53T  mice  develop  motor
abnormalities, however without inclusions in the central nervous system.
Another transgenic mouse model overexpressing GFAP tagged human a-syn using BAC was
created, presenting a slow aggregation of a-syn, a reduced striatal dopamine release and a
modest motor and olfactory impairment (Hansen et al. 2013).
Inducible and conditional models
The molecular “switch” provided by inducible models allows the creation of tissue-specific
and/or time-specific expression. Two systems have been used to control SNCA expression:
1) tet-OFF system, based on tetracycline transactivator (tTa) fusion protein, binding to DNA
present on specific tetracycline repressor (TetR) sequence, (Gossen & Bujard 1992)).
2) The Cre-ER system, which is an amelioration of the  Cre-loxP system. In the Cre-loxP
system, Cre recombinase excises DNA sequences flanked by two loxP sequences  (Sauer
1987). In Cre-ER system, Cre is fused to a modified human oestrogen receptor which control
Cre activity depending of receptor ligand concentration (Feil et al. 1997).
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Mice overexpressing wild-type human a-syn protein under the CaMKII promoter develop a
nigral and hippocampal neuropathology, as well as cognitive and motor decline (Nuber et al.
2008). In this model, drastic decrease of the transgene expression using tet-OFF system is
stopping the disease progression without reversing symptoms.
Cre-loxP based transgenic mouse models were also generated to induce specific expression
of E46K, A53T or truncated 119 a-syn in nigral neurons (Daher et al. 2009). These mice do
not present a dopaminergic neuronal cell loss or a-syn positive aggregates.
4.2.2  LRRK2
Familial forms of PD resulting from  LRRK2 mutations suggest that LRRK2 loss or gain of
function  may  play  an  important  role  in  neuronal  degeneration.  But  surprisingly,  LRRK2
knockout  mice  present  an  intact  dopaminergic  system  without  displaying  an  increased
susceptibility to MPTP (Andres-Mateos et al. 2009; Hinkle et al. 2012).
Overexpression  of  wild-type  LRRK2  in  BAC  transgenic  mice  is  inducing  an  increased
dopamine release in the striatum and a motor hyperactivity. Overexpression of the G2019S
mutated protein leads to an age-dependent reduction of the striatal content without nigral cell
loss (Xianting Li et al. 2010). Similarly, BAC transgenic mice overexpressing R1441G mutant
LRRK2 protein are presenting an age-dependent and a progressive reduction of dopamine
release as well as pathology of nigrostriatal dopaminergic projection resulting in motor-activity
deficits, which could be reversed by dopaminergic agents (Li et al. 2009). Remarkably, mice
overexpressing G2019S mutated LRRK2 under the  CMV-enhanced human platelet-derived
growth  factor  β  chain  platelet  derived  growth  factor  (CMVE-PDGFβ) develop  a  mild
age-dependent  degeneration  of  dopaminergic  nigral  neurons;  and  mice  overexpressing
R1441G mutated LRRK2 under the  CMVE-PDGFβ develops a more mild motor phenotype
(Ramonet et al. 2011).
4.2.3  Parkin
Familial PD forms resulting from the loss of parkin E3 ubiquitin ligase activity are highlighting
the critical function of parkin in neuron survival.  Accordingly, several parkin KO mice were
generated,  but  no  degeneration  of  nigral  dopaminergic  neurons  was  observed  despite  a
dysregulation of the dopaminergic system (Itier et al. 2003; Goldberg et al. 2003). Parkin KO
mice show a strong reduction of mitochondrial respiratory chain proteins and stress response
proteins which is accompanied by the accumulation of several parkin substrates  (Ko et al.
2006; Shin et al. 2011). But despite mitochondrial abnormalities present in parkin KO mice,
MPTP intoxication  does  not  acerbate  neuronal  toxicity  in  these  animals,  whereas  parkin
overexpression provides a protection against MPTP (Perez et al. 2005; Paterna et al. 2007;
Thomas et al. 2007).
BAC mice expressing C-terminal  truncated human mutant  PARK2 (Parkin-Q311X) via  the
murine dopaminergic transporter promoter (Slc6a3) exhibit an age-dependent degeneration of
nigral  dopaminergic  neurons accompanied by dopaminergic  loss in  striatum,  formation  of
a-syn positive inclusions, and development of a progressive motor deficit (Lu et al. 2009).
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4.2.4  Pink1
PINK1 loss of function mutations are leading to autosomal recessive PD. However, PINK1 KO
mice  do  not  exhibit  major  abnormalities  except  a  mild  mitochondrial  and  nigrostriatal
neurotransmission deficit (Kitada et al. 2007; Gispert et al. 2009). PINK1 KO mice show also
an increased susceptibility to oxidative stress and ROS production (Gautier et al. 2008).
4.2.5  DJ-1
Heritable PD forms resulting from mutations impairing DJ-1 function also lead to a higher
neuronal sensibility to oxidative stress. Similarly to parkin and to PINK1 KO mice, DJ-1 KO
mice also develop a mild dopamine neurotransmission deficit and mitochondrial dysfunction
without nigral dopaminergic neuron loss (Goldberg et al. 2005).
Consistent with its protective role against stress, dopaminergic neurons with DJ-1 deletion are
presenting an increased susceptibility for MPTP and 6-OHDA (Kim et al.  2005; Lev et al.
2013).  Recently,  a novel  DJ-1 KO was generated showing a dramatic early-onset loss of
nigral dopaminergic neurons and an age-dependent mild motor behavior  (Rousseaux et al.
2012).
4.3  Viral transfection
Generation of animal models using viral vectors offer various advantages, they are an easier
and  also  faster  alternative  to  KO  and  transgenic  approach,  and  they  do  not  present
developmental morbidity. Unfortunately, viral vector injection leads to a limited expression in
time but also in space.
The  most  striking  difference  between  transgenic  and  viral  models  is  the  strongest
neurodegeneration observed in  viral  induced models of  PD  (Kirik  et  al.  2002;  Kirik  et  al.
2003).  This  suggests  that  the  viral  vector  procedure  is  inducing  a  typical  inflammatory
response  that  may  synergize  with  the  effect  of  the  misfolded  protein  and  promotes
neurodegeneration [reviewed extensively in (Löw & Aebischer 2012)].
4.3.1  Alpha-synuclein
PD mouse models generated by using viral a-syn expression are presenting a slower and a
milder dopaminergic neuronal cell degeneration than rat models. Therefore, a large number of
rat models overexpressing human or rat a-syn, with a large panel of mutations or of post
transcriptional modifications were generated [reviewed in (Löw & Aebischer 2012)].
Despite this limitation, lentivirus-mediated overexpression of human A30P mutant a-syn in the
mouse substantia nigra under hCMV promoter results  in a 10–25% loss of  dopaminergic
neurons. Dystrophic morphology of striatal neurons and presence of inclusions was observed
10 to 12 months after viral injections (Lauwers et al. 2003).
AAV2/2 overexpression of wild-type human a-syn using CBA promoter and directly injected in
the substantia nigra resulted in a 25% nigral dopaminergic neuronal cell loss 24 weeks after
injection, accompanied by a decreased density of dopaminergic fibers in the striatum, but
without a-syn positive inclusions (St Martin et al. 2007).
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4.3.2  LRRK2 models
To reproduce LRRK-2 linked PD in mice, herpes simplex virus was used to deliver wild-type,
G2019S, D1994A (kinase dead) or G2019S/D1994A LRRK-2 under the immediate-early gene
4/5 promoter  (Lee et al.  2010). Expression of LRRK-2 G2019S is inducing a 50% loss of
nigral dopaminergic neurons, whereas wild-type, D1994A or EGFP expressing viruses caused
a 20% cell loss and suggesting that pathogenesis of LRRK2 is likely to result from aberrant
kinase activity.
5)  Alpha-synuclein
5.1  Discovery
The synuclein protein family was discovered in a screening performed in electromotor nuclei
of the Torpedo californica stingray by using an antiserum against cholinergic vesicles and by
expressing vector cDNA library from the isolated mRNA (Maroteaux et al. 1988). Synuclein's
name reflects the original observation of the protein's nuclear envelope localization in neurons
as well as at presynaptic nerve terminals. Different synuclein isoforms were first reported in
the rat brain after the discovery that the synuclein gene hybridizes to several clones in a rat
brain cDNA library  (Maroteaux & Scheller 1991). The alpha isoform was purified later from
amyloid depositions isolated from Alzheimer’s disease patients and termed non-amyloid β
component precursor (NACP); this study involved for the first time the synuclein family in the
neurodegenerative disease process (Uéda et al. 1993). In the meantime, beta-synuclein was
purified in a screening aiming to characterize specific brain proteins and their function based
on their  structure.  Synuclein  was isolated from bovine brain  as a phosphorylated 14 kDa
protein and designated as phosphoneuroprotein 14 (PNP 14) (Nakajo et al. 1990; Nakajo et
al.  1993).  NACP  and  phosphoneuroprotein 14  become  respectively  alpha-synuclein  and
beta-synuclein  based  on  their  amino  acid  sequence  homology  revealed  by  monoclonal
homology affinity (Jakes et al. 1994). The third and last synuclein member, gamma-synuclein,
was discovered independently by several laboratories several years later during the study of
different  forms of  cancer,  neurodegenerative  disorder  or  ocular  pathology  (Ji  et  al.  1997;
Lavedan et al. 1998; Buchman et al. 1998; Surguchov et al. 1999).
PD and a-syn were associated after the discovery of different SNCA genetic defects leading
to  familial  forms  of  parkinsonism  (Polymeropoulos  et  al.  1997),  including  SNCA
single-nucleotide polymorphisms enhancing the propensity of a-syn to aggregate (Conway et
al. 1998) as well as SNCA multiplication resulting in increased expression and accumulation
of a-syn (Singleton et al. 2003). The importance of a-syn was confirmed by the observation
that it is a major constituent of LBs (Spillantini et al. 1997), becoming rapidly the hallmark of
PD despite that the mechanisms underlying a-syn-dependent LB formation are still elusive.
5.2  Expression
SNCA maps to chromosome 4q21.3-q22 (Campion et al. 1995; Chen et al. 1995; Shibasaki et
al. 1995). Its expression was shown to be increased by nerve growth factor (NGF) or basic
fibroblast growth factor (bFGF) via the MAP/ERK and PI3 kinase pathway (Clough & Stefanis
2007) and to be decreased by poly-ADP-ribose transferase/polymerase-1 (PARP-1)  (Chiba-
Falek et al. 2005).
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The a-syn protein is expressed in the central nervous system and in numerous neuronal cells
of  the  peripheral  nervous systems.  Lower  concentrations  of  a-syn  are  also  detectable  in
various peripheral tissues including adult heart, lungs, kidneys, skeletal muscles, pancreas,
liver or red blood cells (Ltic et al. 2004; Barbour et al. 2008). It is interesting to note that a-syn
amounts are elevated when compared to the pool of soluble proteins in adult brain [up to
0.1% of total brain proteins] (Shibayama-Imazu et al. 1993).
Originally,  a-syn  was  described  in  most  nerve  cells  of  the  human  nervous  system,  with
highest concentration at synaptic terminals and nucleus (Jakes et al. 1994; Uéda et al. 1994;
Iwai et al. 1995; Irizarry et al. 1996). Detailed localization studies suggest a greater presence
of a-syn in nerve terminals rather than in the cell body, and more precisely in dendrites and
extrasynaptic sites along the axon (Mori et al. 2002). Presence of a-syn in cell nucleus has
been confirmed (McLean et al. 2000; Mori et al. 2002; Gonçalves & Outeiro 2013). However,
as the size of a-syn is lower than the molecular weight cut-off of the nuclear pore (at around
40 kDa) it  is  likely that  a-syn enters the nucleus based on simple diffusion [suggested in
(Kontopoulos et al. 2006)].
Within the cell, a-syn is commonly reported to be distributed between soluble and vesicle-
bound pools  (Maroteaux & Scheller  1991).  However,  high mobility of  a-syn and its  weak
association with synaptic vesicles suggest that the disruption of a-syn binding to synaptic
vesicles may occur during biochemical procedures. Therefore, the amount of soluble forms
usually measured may be artificially increased.  Furthermore, the absence of intravesicular
a-syn suggests a dynamic function of a-syn at the surface of vesicles (Shibayama-Imazu et
al. 1993).
5.3  Structure
The a-syn protein is 140 amino acids long and unusually well conserved among vertebrates
[reviewed in  (Clayton & George 1998)]. Human and mouse a-syn are highly identical and
differ  only  of  seven  amino  acids  in  their  whole  sequence:  A53T,  S87N,  L100M,  N103G,
A107V, D121G, and N122S. Interestingly,  the threonine 53 in murine a-syn is a mutation
observed in a familial form of PD (Polymeropoulos et al. 1997), and asparagine 87 in mice
prevents the phosphorylation found at serine 87 in humans.
Three different domains were identified on a-syn: 
(1)  The  positively  charged  N-terminus  (residues 1–64)  contains  repeats  of  11  residues
(XKTKEGVXXXX) including 7 imperfectly repeated hexamer (KTKEGV) motifs. This domain
forms 5 amphipathic helices similar to apolipoproteins, and plays an important role in lipid
binding (Segrest et al. 1992; George et al. 1995; Davidson et al. 1998). The N-terminal part
contains all mutations known to lead to autosomal dominant forms of PD (A30P, E46K, H50Q,
G51D, and A53T).
(2) The non-amyloid beta component domain (residues 65–90), abbreviated NAC, is the most
hydrophobic portion of the protein and is critical for the aggregation of a-syn (Yoshimoto et al.
1995; Bodles et al. 2001; Lin et al. 2006). The NAC domain enables a-syn to form beta-sheet
structures and furthermore to form amyloid-like protofibrils and fibrils (Giasson et al. 2001; el-
Agnaf & Irvine 2002).
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(3) The less conserved and ordered C-terminus (residues 91–140), generally exhibiting an
acidic nature due to glutamate residues, is proposed to regulate amyloid aggregation (I. V. J.
Murray et al. 2003). This domain is relatively resistant to proteolytic degradation (Kim et al.
2006; de Laureto et al. 2006) and is also important for the chaperone-like activity of a-syn
(Souza, Giasson, Lee, et al. 2000).
Interestingly, the structure of the three isoforms of synuclein is relatively similar  (Fig. 1-08).
Beta-synuclein is lacking one third of the NAC domain and gamma-synuclein C-terminus is
shorter than in the other isoforms. These slight modifications result in a quasi-absence of
amyloid fibril formation by beta-synuclein and in a strong reduction of amyloid fibril formation
of  gamma-synuclein;  moreover,  presence  of  one  of  these  isoforms  inhibits  a-syn  fibril
formation in vitro (Uversky, Li, et al. 2002).
SNCA is composed of six exons but only the five last are translated. Three isoforms were
described: a-syn140 the longest isoform, and two splicing variants a-syn126 and a-syn112
[(Fig. 1-09) and reviewed in detail in (Beyer 2006)].
Figure 1-08: Alignment of alpha-synuclein
Figure modified from (Lavedan 1998)
Alignment of the a-syn proteins by species using the human protein as reference. Residues conserved in all
three classes of synuclein proteins throughout the species are shown in blue. Residues specific to a particular
class of synuclein proteins are marked in red.
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Figure 1-09: Alpha-synuclein isoforms
Figure modified from (Pihlstrøm & Toft 2011)
Representation of a-syn isoforms. Isoform a-syn126 results from the in-frame deletion of the exon 3 from the
amino acids 41–53 located in the N-terminal of a-syn. Isoform a-syn112 results from an in-frame deletion of the
amino acids 103–140 in exon 5 located in the C-terminal of a-syn.
5.4  Conformation
Monomeric  a-syn  is  reported  to  exist  in  two  different  fractions:  1) bound  to  plasma
membranes  or  vesicles,  involving  an  alpha-helix  composed  of  the  11-residue  imperfect
repeats distributed among the N-terminal and the NAC domain regions (Davidson et al. 1998;
Eliezer  et  al.  2001) and 2) soluble in  the cytoplasm as an  intrinsically disordered protein
potentially allowing the formation of more ordered structures due to its dynamic and flexible
conformation (Weinreb et al. 1996; Eliezer et al. 2001).
Several long-range interactions within the a-syn protein were reported including 1) C-terminus
interaction with the NAC domain (Bernadó et al. 2005), 2) N-terminal interaction with the NAC
domain (Wu et al. 2009), and 3) C-terminal region interaction with the N-terminus (Ullman et
al.  2011).  Long-range  interactions  between  NAC  domain  and  protein  termini  have  been
suggested  to  protect  the  NAC domain  from  other  interactions,  thereby  minimizing  a-syn
(Bertoncini et al. 2005; Bernadó et al. 2005; Wu et al. 2009), however long-range contacts
between the N- and C-termini  were also suggested to  place the NAC domain in a more
solvent exposed conformation (Ullman et al. 2011). Consequently, the potential role of a-syn
long-range interactions to regulate a-syn aggregation is not clear.
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As a  natively  unfolded protein,  a-syn  was  shown to  be  able  to  adopt  a  large variety  of
conformers (Fig. 1-10), including monomers, oligomers, spherical and linear protofibrils, and
fibrils [reviewed in (Bendor et al. 2013)]. Therefore, a model of a-syn aggregation kinetics was
proposed based on a nucleation dependent polymerization mechanism [reviewed in detail in
(Lashuel et al. 2012)]. This mechanism consists of an initial lag phase (nucleation) followed
by a growth phase (elongation) until a thermodynamic equilibrium between aggregates and
monomers is reached.
Figure 1-10: Mechanisms of alpha-synuclein aggregation
Figure modified from (Lashuel et al. 2012)
Aggregation of a-syn is taking place either in the cytoplasm or associated with the cellular membrane. In the
cytosol,  unfolded a-syn monomers form unstable dimers and slowly grow to generate oligomers of  varying
morphologies that eventually convert to fibrils. Oligomers of a-syn are following equilibrium with monomers and
are  converted  to  fibrils  by  monomer  addition  via  a  nucleated  polymerization  mechanism.  Accumulation  of
amyloid  a-syn fibrils  leads to  the formation of  LBs.  Monomeric  a-syn bound to  the membrane is  adopting
predominantly an alpha-helical conformation, but high concentrations of a-syn undergo a conformational change
to form membrane-bound beta-sheet rich structures self-associating to oligomers, including trans-membrane
amyloid pores and fibrils.
5.5  Functions
Despite numerous efforts to understand the normal function of a-syn, many hypotheses have
been  suggested  but  none  have  been  generally  accepted  [schematized  in  Fig. 1-11  and
reviewed in (Bendor et al. 2013)]. A role in presynaptic function is suggested by its purification
from cholinergic  vesicles  (Maroteaux et  al.  1988),  its  abundance in  presynaptic  terminals
(Kahle et  al.  2000) and a high association mobility to  presynaptic  vesicles depending on
neuronal activity  (Fortin et al. 2005). Interestingly, the overexpression of a-syn is impairing
synaptic vesicle exocytosis and leads to a reduction of neurotransmitter release (Yavich et al.
2004;  Larsen et  al.  2006;  Scott  et  al.  2010).  Moreover,  a-syn knockout  mice present  an
impaired  refilling  and  trafficking  of  synaptic  vesicles  confirming  a  role  of  a-syn  in
neurotransmitter release  (Abeliovich et al. 2000; Cabin et al. 2002). Therefore, a-syn may
play a role in synaptic function  [reviewed in  (Chua & Tang 2011; Bendor et al. 2013)]  and
more precisely in synaptic vesicle pool size regulation in mature neurons (Murphy et al. 2000)
or in synaptic vesicle mobilization at nerve terminals (Cabin et al. 2002; Larsen et al. 2006).
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Figure 1-11: Alpha-synuclein 
functions
Figure modified from (Eisbach & Outeiro 2013)
Under  normal  homeostatic  conditions,  native
a-syn species play a role in axonal trafficking
and  vesicle  formation.  Several  discrete
trafficking  steps  are  impaired  in
synucleinopathies  including  1) Golgi
fragmentation,  probably  resulting  from  the
inhibition  of  ER-to-Golgi  trafficking  and
impairing  transport  of  newly  synthesized
proteins inside the cell, 2) impairment of axonal
transport  (and  especially  microtubule-
dependent  trafficking),  impairing  proteins
transport,  vesicle  pool  size,  and  cell  shape
integrity,  and  3) disturbance  of  SNARE
complexes  impairing  vesicle  endo- and
exocytosis.
The  a-syn  chaperone-like  activity  was  shown  to  play  an  important  role  in  assembly,
maintenance and distribution of the presynaptic SNARE (sensitive factor attachment protein
receptor) complex (Chandra et al. 2005; Burré et al. 2010). SNARE is a large protein family
required for facilitating membrane fusion events-like neurotransmission [reviewed in (Südhof
& Rizo 2011)].  Accordingly,  the binding of a-syn to VAMP2 (vesicle-associated membrane
protein 2) was shown to drive vesicle fusion with plasma membrane and is implicated in the
release of neurotransmitters including dopamine  (Chandra et al.  2004; Burré et al.  2010).
Additionally,  a-syn  was  shown  to  protect  nerve  terminals  by  enhancing  SNARE proteins
cooperation with CSPα, a synaptic vesicle protein acting as a co-chaperone, essential  for
neurotransmitter release (Chandra et al. 2005).
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Furthermore, the interactions of  a-syn with several  other non-SNARE proteins reinforce its
important role in vesicle endocytosis or exocytosis [reviewed in  (Chua & Tang 2011)]. For
example, a-syn interacts with phospholipase D2 (PSD2) and reduces its activity [(Jenco et al.
1998; Ahn et al. 2002) reviewed in  (Bendor et al. 2013)] leading to a decreased number of
endosomes  and  resulting  in  a  reduced  release  of  dopamine.  Another  example  is  the
sequestration of proteins important for the transport of vesicle such as Rab GTPase [reviewed
in (Eisbach & Outeiro 2013)] which can be observed in a-syn inclusions both in DLB patients
and a-syn transgenic mice  (Dalfó, Barrachina, et al. 2004; Dalfó, Gómez-Isla, et al. 2004).
However,  it  is  yet  unclear  if  this  dysregulation  is  the  origin  or  the  consequence  of  this
impairment.
It is interesting to note that a-syn and fatty acid-binding proteins are sharing similarities in the
primary structure  (Sharon et al. 2001), allowing the modulation of fatty acid metabolism or
transport  via  their  binding.  For  example,  recruitment  of  fatty  acids  from  the  aqueous
environment to synaptic vesicles is promoted by a-syn and leads to the formation of early
endosomes (Castagnet et al. 2005; Golovko et al. 2005).
Finally, a-syn was observed to directly reduce dopamine release by interfering with dopamine
reuptake  and  synthesis  in  dopaminergic  neurons.  For  example,  dopaminergic  transporter
(DAT)  was  shown  to  be  inhibited  by  a-syn,  reducing  the  mediated  uptake  of  synaptic
dopamine (Sidhu et al. 2004). Moreover, the catalytic activity of tyrosine hydroxylase (TH), the
rate  limiting  enzyme  in  dopamine  synthesis,  was  shown  to  be  regulated  by  a-syn
phosphorylation (Perez et al. 2002; Drolet et al. 2006).
5.6  Toxicity
The  discovery  of  fibrillar  a-syn  structures  in  LBs  and  in  LNs  (Spillantini  et  al.  1998;
Trojanowski  &  Lee  1998) suggested  a  potential  neurotoxic  role  of  these  specific  a-syn
aggregate species (Hashimoto et al. 1998; Conway et al. 1998; Giasson 1999). Nowadays,
this hypothesis is challenged by multiple studies reporting that toxic forms of soluble a-syn
drive oxidative damage [reviewed in  (Lotharius & Brundin 2002a)], proteolysis [reviewed in
(Ebrahimi-Fakhari et al. 2012)] and vesicle transport impairment [reviewed in  (Cheng et al.
2011)], and thus relaying a-syn aggregation to a potential consequence of a-syn toxicity.
5.6.1  Conformational gain of function
The toxicity of LBs in PD is a highly debated topic, the propensity of a-syn to form structured
species  (Hashimoto et al. 1998) as well as the presence of a-syn filamentous inclusions in
LBs (Spillantini et al. 1997) has generated a strong interest on highly ordered a-syn species
and on mechanisms involved in  the generation of  these structures  (Conway et  al.  1998;
Giasson  1999).  Intense  efforts  spent  in  studying  the  formation  and  the  toxicity  of  highly
ordered a-syn  species  highlighted complex and divergent  mechanisms leading to  neuron
dysregulation but not always to a direct cell toxicity [reviewed in  (Bendor et al. 2013)]. The
most  common  observation  is  the  strong  tendency  of  a-syn  to  aggregate  spontaneously
(Hashimoto  et  al.  1998) leading  to  the  formation  of  various  higher  structured  species,
including  oligomers,  protofibrils  and fibrils  (Fink  2006).  Interestingly,  only  small  oligomers
(Lashuel et al. 2002) and protofibrils (Bucciantini et al. 2002) were reported to induce toxicity.
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It is important to note that many parameters were shown to modulate a-syn fibril formation:
1) in  vitro culture  parameters,  such  as  low  pH,  high  temperature,  presence  of
detergents/organic solvents/metal  ions  (Hashimoto et al.  1999),  and concentration of  fatty
acids  (Perrin et al. 2001; Sharon et al. 2003; Karube et al. 2008); 2) presence of beta- or
gamma-synuclein,  (Uversky,  Li,  et  al.  2002),  a-syn concentration,  a-syn species (such as
oligomers, fibrils), missense mutations (Conway et al. 1998; El-Agnaf et al. 1998; Conway et
al. 2000), post-translational modifications (such as phosphorylation (Fujiwara et al. 2002; Sato
et al. 2013) or ubiquitination  (Nonaka et al. 2005)); and 3) cellular stress such as oxidative
stress (Hashimoto et al. 1999) and proteolysis (Crowther et al. 1998; Serpell et al. 2000; I. V.
J. Murray et al. 2003; Dufty et al. 2007).
Oligomers
Oligomers are complex structures abundantly found in the cell  and composed of identical
(termed homo-oligomeric proteins) or different polypeptide chains (termed hetero-oligomeric
proteins). Most proteins have the potential to form oligomers (Klotz et al. 1970). It has been
suggested that protein oligomerization may be an advantageous feature from the perspective
of protein evolution (Ali & Imperiali 2005), leading to a subtle control of protein functions via
allosteric regulation or via complex formation [reviewed in (Hlavacek et al. 2003)].
The  exact  purpose  of  oligomerization  has  not  been  established  for  numerous  proteins,
consequence of the complexity of oligomer structures. To illustrate this complexity, numerous
oligomerization analyzes have shown a critical role of pH, ionic strength, protein constituent
and their respective concentration levels on their formation mechanisms. These parameters
do  not  only  vary  between  different  cell  types,  but  also  locally  within  the  cell  and  its
compartments. Even within the same protein family, different members can exhibit different
oligomeric properties (Weitzman & Kinghorn 1978). Fortunately, most prevalent oligomers are
rather small homo-oligomer (Jones & Thornton 1996; Goodsell & Olson 2000) which can be
classified by their subunit type, subunit association kinetics and folding resulting from subunit
associations.
Most interestingly, the assembly formation and folding of oligomers allow the prediction and
modeling of polypeptide interactions (Chothia & Janin 1975). These analysis highlighted the
fundamental  differences  between  ‘transient’  oligomers  (equilibrium based  on  kinetic)  and
‘permanent’  oligomers  (single  unstable  proteins  without  formation  of  a  stable  oligomer
structure) (Nooren & Thornton 2003).
Very little is known about the conformational state(s) of a-syn in the different compartments of
the  living  cell.  Classically,  a-syn extracted from biological  samples migrates  as a  14 kDa
protein in denaturing gels, and as a 57–60 kDa protein when evaluated by non-denaturing
gels or size exclusion chromatography columns (El-Agnaf et al. 1998; Luk et al. 2009). These
data  suggest  the  possible  formation  of  a-syn  tetramers  as  a  native  equilibrium between
different  conformational  and/or  oligomeric  states  of  a-syn.  This  hypothesis  is  highly
controversial  [reviewed  in  (Lashuel  et  al.  2012)]  as  a-syn  has  a  natively  unfolded
conformation (Weinreb et al. 1996; Fauvet et al. 2012) which may impact the measurement of
its molecular weight.
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However, detergent resistant a-syn oligomers are a consistent pathological hallmark of PD
(Campbell et al. 2001; Pountney et al. 2005) which could be easily isolated from post mortem
brain of PD patients (Sharon et al. 2003). In general, SDS resistant oligomers can be divided
into small (~2–5 mers), medium (~5–15 mers), and large (~15–150 mers) oligomers (Danzer
et  al.  2007;  Cremades  et  al.  2012),  with  the  smallest  oligomers  promoting  neuronal
degeneration and abnormal calcium currents when added to cultured primary cortical neurons
(Danzer  et  al.  2007).  Interestingly,  a-syn  oligomers  may  acquire  spherical,  chain-like,  or
annular  morphologies  depending  on  the  in  vitro conditions  and  the  presence  of  a-syn
mutations (Conway et al. 2000; Ding et al. 2002; Lashuel et al. 2002).  Altogether, it is clear
that  a-syn  exists  as  a  monomer  without  excluding  the  possibility  that  it  can  form stable
multimers and/or adopt different structures in vivo.
Protofilaments
Experimentally,  a-syn  molecular  crowding  in  vitro was  shown  to  lead  to  an  equilibrium
between a-syn monomers and various oligomeric species, resulting in a slow fibrils formation
via metastable oligomeric species such as protofibrils (Volles & Lansbury 2002). Accordingly,
the existence of a critical a-syn concentration range, in which protofibrils but not fibrils can be
formed, confirms the role of a-syn oligomers and protofibril intermediates in the formation of
fibrils (Volles & Lansbury 2002). During this assembly, major conformational changes of a-syn
are observed and especially in its secondary structure. Most noticeable is the decrease of the
helical  content  resulting  from  the  conversion  of  spheroidal  oligomers  (with  high  helical
content) (Apetri et al. 2006) to protofibrils (mainly cross-beta sheet) (Serpell et al. 2000).
It is tempting to speculate that oligomers may contribute to cell toxicity at an early aggregation
point  whereas fibrillar  and amorphous insoluble  a-syn aggregates contribute only later  to
synucleinopathy (Ding et al. 2002).
5.6.2  Mechanisms of toxicity
Mechanisms leading to cell toxicity are a complex issue. For example, it may seem obvious
that aggregation leads to toxicity via the capture of a-syn and results in decreased levels of
native a-syn. However, it is rather unlikely that a lack of a-syn drives the toxic mechanism
since a-syn KO mice show a rather increased than decreased resistance to MPTP-induced
loss of dopaminergic neurons (Dauer et al. 2002).
Permeabilization of membranes
The formation of oligomers has been shown to increase synthetic lipid vesicle leaking (Volles
& Lansbury 2002) and  therefore  might  cause  damage to  cellular  membranes  in  vivo  by
altering the balance of ions within the cells, thus triggering apoptosis (Danzer et al. 2007).
It  has been suggested that a-syn could fold  into the membrane structure via  anti-parallel
arranged alpha-helicoidal regions, able to form pores and permeabilize membranes (Volles &
Lansbury 2002). Another hypothesis suggests the capture of some phospholipids by folded
a-syn structures on the membrane surface which can induce membrane disruption (Comellas
et al. 2012). Protofibrils were also shown to exert a similar toxicity, forming amyloid pores
resembling to beta-sheet pore-forming toxins (Varkey et al. 2013).
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It is unclear if and how membranes influence the conformation and oligomerization of a-syn in
cells. This is illustrated on the one hand by the description that a-syn oligomers form helical
conformation on membranes  (Ding et  al.  2002) and on the other by anionic phospholipid
membranes converting helical a-syn into fibrils (Furukawa et al. 2006).
Finally, it was also observed that a-syn-related pathology could result from defective vesicle
secretion  and  recycling  (Unni  et  al.  2010).  This  hypothesis  is  confirmed  in  cell  models
overexpressing a-syn, in which dopamine release is inhibited while an increase of the number
of vesicles docked to the plasma membrane is observed  (Larsen et al. 2006). Accordingly,
animals  overexpressing  a-syn  present  abnormal  vesicle  clustering  as  well  as  unusual
non-uniform vesicle sizes (Nemani et al. 2010; Scott et al. 2010).
Dopamine toxic effect
In cell  culture, endogenous dopamine production was shown to acerbate drastically a-syn
associated toxicity (Conway et al.  2001).  This critical  role of  dopamine was shown to be
indirect  and  to  require  oxidative  stress  conditions  facilitating  dopamine  (and  other
catecholamines)  conversion  to  highly  reactive  metabolites,  such  as  dopamine  quinones
(Cadet  &  Brannock  1998).  When  reactive  dopaminergic  metabolite  levels  exceed  the
anti-oxidative buffering capacity of neurons, these species can bind covalently to proteins. In
vivo, dopamine quinones block a-syn fibril formation, stabilizing toxic a-syn protofibrils at the
expense of fibrils (Xu et al. 2002; Petrucelli et al. 2002).
As  suggested  previously,  a  possible  role  of  a-syn  on  vesicles  clustering  and  on
permeabilization  of  membranes  (Scott  et  al.  2010;  Nemani  et  al.  2010;  Lundblad  et  al.
2012) is  supported  by  the  localization  of  oligomers  in  axons  and  presynaptic  terminals.
Therefore, it is likely that a-syn leads to an improper sequestration of dopamine into vesicles
(Lotharius & Brundin 2002a) explaining the vicious cycle resulting in the higher sensitivity of
dopaminergic neurons to a-syn toxicity.
Transport mechanism disruption
As described previously, the formation of LNs preceding the development of LBs (Eisbach &
Outeiro 2013) suggests an early accumulation of a-syn in axons which could result from a
disrupted protein transport in neurons. Accordingly, a-syn was reported to inhibit trafficking
from the  ER to  the  Golgi  in  yeast  over-expressing  a-syn  (Jellinger  2003;  Jellinger  2004;
Dickson et  al.  2010),  probably via  the  inhibition  of  docking  or  fusion  of  the  ER to  Golgi
membranes (Cooper et al. 2006).
Thus, the disruption of the newly synthesized proteins' transport by a-syn (Gitler et al. 2008) is
critical for synaptic maintenance in neurons. This is especially true in dopaminergic cells in
which the dopaminergic machinery (such as the vesicular monoamine transporter) has to be
delivered  to  synaptic  sites  to  avoid  accumulation  of  dopamine  and  its  by-products.
Accordingly,  accumulation of  dopamine in  the synaptic  cytoplasm was shown to  result  in
oxidative stress (Thayanidhi et al. 2010).
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Protein degradation impairment
Accumulation  of  a-syn  in  PD strongly suggests  a  dysfunction  of  the  protein  degradation
system [reviewed in (Thayanidhi et al. 2010)]. Whether a-syn aggregation is the cause or the
consequence  is  unclear  but  numerous  reports  suggest  a  direct  role  of  a-syn  on  protein
degradation impairment, for example 1) increased a-syn levels inhibit autophagy via Rab1a
(Manzoni  &  Lewis  2013),  2) a-syn  mutations  associated  with  PD  decrease  lysosomal
functionality and reduce the autophagic flux (Winslow et al. 2010) and 3) a-syn mutations are
blocking CMA as a consequence of their strong binding to the transporter protein LAMP-2A
(Cuervo et al. 2004).
Furthermore,  a-syn  may  itself  play  an  important  role  in  protein  degradation.  Previous
observations pointed to the role of a-syn in the SNARE function which are required for the
regulation of vesicle trafficking and fusion. Protein degradation pathways, such as autophagy,
are  also  based on vesicle  trafficking  and fusion,  suggesting  a  potential  link  between the
physiological role of a-syn and these pathways (Burré et al. 2012).
Cells  overexpressing  a-syn  present  lysosomes  containing  aggregated  a-syn  species
suggesting lysosomal dysfunctions (Gispert et al. 2009). Interestingly, accumulation of a-syn
prefibrillar aggregates was shown to disrupt lysosomal activity (Krenz et al. 2009; Smith et al.
2010), initiating a vicious cycle as lysosomal degradation is critical for a-syn turn-over [a-syn
degradation is described later in this thesis, and reviewed in (Stefanis et al. 2001)].
Mitochondrial impairment
The first link between high levels of a-syn and mitochondrial dysfunction was proposed soon
after the discovery of a-syn's role in PD based on the observation of increased free radical
levels which were suspected to trigger a-syn oxidation and aggregation  (Hsu et al.  2000).
Nowadays,  an  increasing  body  of  evidence  suggests  that  a-syn  has  a  toxic  effect  on
mitochondria [reviewed in (Mullin & Schapira 2013)]. For example, a-syn knockout mice are
resistant to mitochondrial damage caused by complex I inhibitor toxins  (Dauer et al. 2002;
Klivenyi  et  al.  2006),  and  mice  overexpressing  a-syn  are  developing  a  mitochondrial
pathology (Song et al. 2004; Martin et al. 2006).
Despite that a-syn is predominantly cytosolic, it has been identified to interact directly with
mitochondrial membranes (Li et al. 2007; Parihar et al. 2008; Parihar et al. 2009), probably
because of its mitochondria targeting sequence present on the N-terminal domain (Devi et al.
2008).  The interaction between a-syn and mitochondrial  membranes was shown to inhibit
mitochondrial fusion, leading to their fragmentation (Kamp et al. 2010) but only under certain
environmental factors (Zhu et al. 2012). Moreover, high levels of a-syn were also suggested
to decrease mitochondrial protein transport via reduction of TOMM40, a translocase of the
outer mitochondrial membrane (Bender et al. 2013).
Despite the excitement generated in the neurodegenerative diseases field by mitophagy, an
autophagy-based  mitochondrial  control  mechanism,  (Palikaras  &  Tavernarakis
2012) involvement of a-syn in this process is controversial  (Sampaio-Marques et al. 2012;
Watanabe et al. 2012).
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5.6.3  Post-translational modifications
Intensive research on a-syn has highlighted the influence of a variety of different factors on its
structure.  We are  going  to  review only the  main  modifications  of  a-syn,  as  well  as  their
repercussions  on  a-syn  structure/conformation  and  the  resulting  modulation  of  a-syn
aggregation at the morphological and kinetic level.
Serine and tyrosine phosphorylation of alpha-synuclein
The  most  studied  modification  of  a-syn  is  certainly  its  phosphorylation  (Stefanis  2012),
probably  because  protein  phosphorylation  is  one  of  the  most  common post  translational
modifications  regulating  protein  function.  Protein  phosphorylation  consists  of  the  covalent
addition of a phosphate group on a serine, threonine or a tyrosine residue by a protein kinase.
The phosphorylation of a-syn was observed early in the history of a-syn discovery (Nakajo et
al.  1993).  Experimentally  both  serine  and  tyrosine  phosphorylation  of  a-syn  could  be
observed in Ser87, Ser129, Tyr125, Tyr133, and Tyr136  (Okochi et al. 2000; Pronin et al.
2000; Fujiwara et al. 2002; Negro et al. 2002). However, only a-syn phosphorylation at Ser87,
Ser129, and Tyr125 sites were validated in vivo.
The enzymes that modulate a-syn phosphorylation have been of major interest as they may
provide  a  potential  therapeutic  target  [reviewed in  (Braithwaite  et  al.  2012)].  A subset  of
protein kinases has been shown to phosphorylate a-syn in vitro and in vivo. Involvement of
polo-like kinases (PLKs) in the phosphorylation at Ser129  (Inglis et al. 2009; Mbefo et al.
2010) has been largely demonstrated and multiple stages of a-syn aggregation have been
proved to influence its phosphorylation status (Mbefo et al. 2010; Waxman & Giasson 2011).
Casein kinases 1 and 2 (CK1 and CK2) have been demonstrated to phosphorylate a-syn at
Ser129, and CK1 appears to phosphorylate also Ser87 in vitro while CK2 appears to be able
to phosphorylate only soluble a-syn species (Okochi et al. 2000; Waxman & Giasson 2008;
Waxman  &  Giasson  2011).  Finally,  G-protein-coupled  receptor  kinases  can  also
phosphorylate a-syn at the Ser129 residue (Pronin et al. 2000; Sakamoto et al. 2009).
A possible interplay between a-syn and LRRK2 was suggested [reviewed in (Cookson 2010)],
and illustrated by LRRK2 presence in LBs (Alegre-Abarrategui et al. 2008). But unfortunately
the exact role of LRRK2 in synucleinopathy remains controversial  as illustrated by  in vivo
studies showing conflicting modulation of synucleinopathy by LRRK2 in mouse models (Lin et
al.  2009; Daher et al.  2012). In this unclear context, a direct phosphorylation of a-syn by
LRRK2 was reported (Qing et al. 2009), but this effect failed to be replicated in other studies
or systems.
Several  phosphatases  were  shown  to  dephosphorylate  a-syn  in  vitro.  For  example,
phosphatase 2A (PP2A) dephosphorylates Ser129 (Peng et al. 2005) and was confirmed in
vivo (Lee et al. 2011). PP2C also dephosphorylates a-syn at Ser129  (Waxman & Giasson
2008).
Tyrosine phosphorylation  of  a-syn has been less studied than its  serine phosphorylation,
phosphorylation at Tyr125 could be driven by Src and Fyn (Ellis et al. 2001; Nakamura et al.
2001), as well as by Lyn and Frg (Negro et al. 2002). Furthermore, Syk has also been shown
to phosphorylate a-syn at residues Tyr125, Tyr133, and Tyr136 (Negro et al. 2002).
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Phosphoserine 129
In  post  mortem human  brain  studies,  a-syn  present  in  LBs  has  been  shown  to  be
hyperphosphorylated at Ser129 (Fujiwara et al. 2002; Anderson et al. 2006). Moreover, this
post-transcriptional  modification could also be observed in  pre-LB stages (including Lewy
threads  and  axons)  and  seems  to  progress  with  advancing  disease  (Saito  et  al.  2003).
Additionally,  transgenic  mice  overexpressing  a-syn  (Wakamatsu et  al.  2007;  Schell  et  al.
2009; Lee et al. 2011) also present accumulation of Ser129 phosphorylated a-syn (pSer129),
confirming that it's accumulation is a common phenomenon during the disease progression.
In vitro studies have suggested that pSer129 a-syn promotes formation of a-syn filaments and
oligomers  (Fujiwara et  al.  2002) as a consequence of  change in  charge distribution  and
hydrophobicity in the protein's carboxy-terminal region (McLean & Hyman 2002). But as the
levels  of  pSer129 are not  very high in  the neuronal  cytosol  of  PD brain  samples,  it  was
suggested that a-syn may be phosphorylated after its deposition into LB  (Anderson et al.
2006).  This  hypothesis  is  supported  by the  abundant  presence of  proteinase K resistant
pSer129 a-syn in cytoplasmic inclusions but not in presynaptic inclusions (Tanji et al. 2010).
The investigation of pSer129's role in synucleinopathy development is a challenging process
as it is technically impossible to track pSer129 levels in brain of PD patients and even difficult
to  localize  and  quantify  it  in  living  animal  models.  Therefore,  most  of  studies  relied  on
chromatography and specific antibodies for phosphorylated (Fujiwara et al. 2002; Saito et al.
2003) or unphosphorylated forms of a-syn  (Lee et al.  2013) to investigate distribution and
levels of pSer129 either in vitro, in blood or in post mortem tissues. Interestingly, expression
of  phospho-mimic  such  as  [S129D]  a-syn  in  cell  and  fly  models  leads  to  an  enhanced
aggregation and cytotoxicity  (Smith et al. 2005; Chen & Feany 2005) despite a decreased
fibrillation  of  [S129D]  a-syn  in  vitro (Paleologou  et  al.  2008).  Similarly,  expression  of
non-phosphorylable [S129A] a-syn does not present more toxicity than wild-type a-syn in vivo
(Gorbatyuk et al. 2008; Azeredo da Silveira et al. 2009). However, even if these strategies are
debatable (as phospho-mimics [S129E/D] a-syn) were shown to poorly reproduce the effect of
phosphorylation on the structural and aggregation properties of a-syn in vitro), and the cellular
defense mechanism reported is questioning pSer129's role in synucleinopathy development.
Accordingly, phosphorylation of a-syn reduces its phospholipid-binding properties, suggesting
its involvement in the regulation of a-syn binding to synaptic vesicle membranes [reviewed in
(Lotharius & Brundin 2002a; Lotharius & Brundin 2002b)].  Furthermore, the phosphorylation
of a-syn is inhibiting phospholipase D2 (PLD2)  (Pronin et al. 2000; Payton et al. 2004), an
enzyme involved in lipid-mediated signaling cascades and vesicle trafficking. However, PLD2
mechanisms  and  functions  are  still  unclear.  Therefore  a  direct  link  between  a-syn
phosphorylation and dysregulation of dopamine neurotransmission is still hypothetical.
Phosphoserine 87
Phosphorylation of a-syn Ser87 (pSer87 a-syn) is one of the few differences between the
human and the mouse a-syn and might carry an important function in the development of
synucleinopathy present in human, but not in mouse.
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Ser87 is located in the hydrophobic NAC region of a-syn, expanding its hydrophobic structure,
increasing its conformational flexibility, blocking its fibrillization in vitro and reducing its binding
to membranes (Paleologou et al. 2010). An increasing body of evidence suggests that pSer87
a-syn may also play an important role in the regulation of synucleinopathies, as suggested by
the presence of pSer87 a-syn in LBs (Paleologou et al. 2010). Interestingly, rat injected with
adenovirus  expressing  phospho-deficient  [S87A]  a-syn  were  showing  a  synucleinopathy
similar to the expression of human wildtype a-syn,  but  no change could be observed for
phospho-mimic Ser87 [S87E] a-syn expression. This suggests that mimicking pSer87 inhibits
a-syn aggregation and protects against a-syn induced toxicity in vivo (Oueslati et al. 2012).
Phosphotyrosine 125
As previously noticed, tyrosine phosphorylations are less studied than serine phosphorylation.
However,  it  was  shown  that  phosphorylated  Tyr125  a-syn  (pTyr125)  prevents  potential
nitrosylation of this residue (Nakamura et al. 2002).  Furthermore, the observation of Tyr125
nitration  inducing  the  formation  of  a-syn  oligomers  (Takahashi  et  al.  2002) suggests  a
neuroprotective  function  of  pTyr125  a-syn,  especially  under  nitrative  stress.  Accordingly,
decreased levels of pTyr125 a-syn could be observed during the normal aging process in
humans, and notably in cortical tissue from PD patients (Chen et al. 2009).
Oxidation
Presence of  nitrotyrosine  immunoreactivity  in  LBs is  reflecting  an oxidative  cellular  injury
leading to the nitration of protein tyrosine residues by peroxynitrite  (Good et al. 1998), and
suggesting a link between oxidative and nitrative damage and synucleinopathies (Duda et al.
2000; Giasson et al.  2000).  Although  mechanisms leading to a-syn oxidation are not well
understood, covalent modifications of a-syn by quinones (derived from dopamine) have been
observed  (Conway et al. 2001), and one main nitrated residue has been identified on the
Tyr125 (Giasson et al. 2000).
Nitration of a-syn has been observed robustly  in vivo using antibodies specific for nitrated
a-syn: 1) in PD patients (Giasson et al. 2000), 2) in toxin-based PD animal models (Ara et al.
1998) and 3) in transgenic mice developing PD (Neumann et al. 2002; Papay et al. 2002).
Interestingly, presence of a-syn aggregates lacking nitrotyrosine immunoreactivity suggests
that  a-syn nitration is  not  required for  its  deposition and may occur  after  the fibrillization
process (Gómez-Tortosa et al. 2002). Accordingly, it was observed that soluble and nitrated
a-syn  species  do  not  fibrillize  unless  preformed  fibrils  are  treated  with  nitrating  agents.
Fibrillization in presence of nitrated agents leads to the stabilization of nitrated fibrils through
dityrosine cross-linking,  resulting in the formation of SDS and heat stable dimers  (Souza,
Giasson,  Chen,  et  al.  2000;  Takahashi  et  al.  2002;  Yamin  et  al.  2003;  Hodara  et  al.
2004) which  limits  a-syn  fibrillogenesis  (Conway  et  al.  2001) and  blocks  a-syn  folding
rendering it resistant to proteasomal degradation [reviewed in (Malkus et al. 2009)].
Relevance of a-syn's methionine oxidation (four methionine residues for a-syn), reported to
inhibit fibrillization of unmodified a-syn  (Uversky, Yamin, et al. 2002), was challenged in a
more recent study focusing on oxidative stress induced by dopamine (Norris et al. 2005).
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Glycosylation and glycation
Glycosylation is an important protein post-translational modification, attaching enzymatically
different glycans to proteins in the endoplasmic reticulum (ER) before they are targeted to
their action sites [reviewed in (Moremen et al. 2012)]. Glycosylation of a-syn in vitro results in
a  22 kDa  protein  (Shaikh  &  Nicholson  2008) mainly  occurring  in  the  Golgi  apparatus
(Tompkins et al. 2003) and indicating a possible processing of a-syn before its localization into
the synapse and nucleus.  Furthermore,  PARK2 mutations leading to autosomal recessive
forms of PD present an accumulation of soluble glycosylated a-syn (Shimura et al. 2001) and
the role and function of glycosylated a-syn species in idiopathic forms of PD is unclear.
Binding of a glucose molecule in a non-enzymatic manner (so called glycation) may rather
result from normal metabolism, aging or oxidative stress  (Ahmed 2005). Rearrangement of
proteins  following  the  binding  of  a  glucose  molecule  undergoes  multiple  and  diverse
irreversible  modifications  such  as  dehydration,  condensation,  fragmentation,  oxidation  or
cyclization. These reactions are leading to the disruption of the protein structure as well as to
an  accumulation  of  reactive  species  [reviewed  in  (Takeuchi  &  Yamagishi  2009)].
Immunoreactivity for glycated proteins was reported at the periphery of LBs (Castellani et al.
1996).  Moreover,  PD patients  report  an  abnormal  increase of  glycated protein  levels  (so
called advance glycation end products (AGEs)) (Dalfó et al. 2005). Glycation of a-syn in vitro
via its 15 lysine residues leads to the formation of smaller globular-like aggregates instead of
the typical  fibrils  formed by native a-syn,  suggesting a potential  role  in  the nucleation of
aggregates  (Padmaraju  et  al.  2011) and  in  the  chemical  crosslinking  and  proteolytic
resistance of the protein deposits [reviewed in (Vicente Miranda & Outeiro 2010)].
Glycation  of  a-syn  in  vitro was  also  described  to  alter  DNA  integrity,  probably  via
conformational  changes of  DNA stabilizing the uncoil  scDNA  (Padmaraju et  al.  2011).  As
a-syn oligomers are suspected to form pores in membranes, it has been hypothesized that
glycated a-syn could enter the nucleus leading to an increased oxidative stress and direct
DNA damage inside the nucleus (Guerrero et al. 2013).
Ubiquitination of a-syn
Presence of ubiquitinated proteins in LBs from PD patients (Kuzuhara et al. 1988; Lennox et
al.  1989;  Gai  et  al.  1995) highlighted  a  potential  role  of  ubiquitination  pathways  in  the
aggregation pathway. This hypothesis was confirmed later in LBs (Wakabayashi et al. 1997;
Spillantini et al. 1997) involving single or multiple ubiquitinated lysine residues of a-syn such
as  ubiquitination  at  K12,  K21  and  K23  (Anderson  et  al.  2006) which  are  also  found  in
inclusions from animal models (Hasegawa et al. 2002; Lee & Lee 2002; Giasson et al. 2002).
More  precisely,  a-syn  harbors  15 lysine  residues  located  mostly  at  its  N-terminus.
Ubiquitination  assays  of  soluble  a-syn  in  vitro showed  ubiquitination  of  multiple  lysine
residues K21,  K23,  K32,  and  K34  (and  in  lower  extend  K10,  K43,  K96).  Interestingly,
recombinant a-syn fibrils were also shown to be ubiquitinated at K6, K10 and K12 (Nonaka et
al. 2005).
|59|
Introduction |
Ubiquitinated a-syn in LBs is predominantly phosphorylated at Ser129 but is absent in the
soluble fraction in PD brain lysates despite a high levels of phosphorylated a-syn, suggesting
that the observed ubiquitination may occur after the deposition of phosphorylated a-syn into
LBs  (Sampathu et al.  2003; Anderson et al.  2006). Another hypothesis is that N-terminus
ubiquitination of a-syn stabilizes the monomeric form of the protein and thus prevents its
oligomerization and fibrillogenesis in vitro (Oueslati et al. 2010).
Three different enzymes have been identified to play an important role in the ubiquitination of
a-syn  in vitro and  in vivo: parkin (E3 ubiquitin ligase), UCH-L1 (deubiquitinase) and SIAH
(seven in absentia homologue, E3 ubiquitin ligase) (Liani et al. 2004; Lee et al. 2008; Rott et
al. 2008). It is noticeable that both, parkin and UCH-L1 were described previously to be linked
genetically to familial forms of PD [reviewed in (Nuytemans et al. 2010)].
In two transgenic animal models developing a-syn pathology (drosophila  (Yang et al. 2003;
Haywood & Staveley 2004) and rat  (Lo Bianco et al.  2004)), parkin was shown to play a
protective effect without modifying a-syn levels. In transgenic mice overexpressing a-syn but
lacking endogenous parkin a potential protective effect on pathology development is debated
(Fournier et al. 2009; von Coelln et al. 2006). Therefore, parkin may not directly modulate
a-syn levels, and its protective role in a-syn deposition in vivo need to be resolved.
In cell culture, endogenous SIAH colocalizes with a-syn and is, in part,  responsible for its
mono- and di-ubiquitination  (Lee et al. 2008; Rott et al. 2008). SIAH also enhances a-syn
aggregation, leading to the formation of a-syn positive inclusions. These observations suggest
that ubiquitination by SIAH may enhance a-syn aggregation (Rott et al. 2008).
UCH-L1 monomer catalyzes the recycling of free ubiquitin by cleaving ubiquitinated peptides
produced  by  proteasomal  degradation  of  polyubiquitinated  proteins  (Larsen  et  al.  1998;
Ciechanover & Schwartz 1998). Unlike monomers, UCH-L1 dimers display ubiquitin ligase
activity that elongates K63- rather than K48-linked ubiquitin-chains (Liu et al. 2002). Therefore
UCH-L1 dimers can polyubiquitinate mono- or di- but not non-ubiquitinated a-syn. It is still
unclear whether S18Y mutation in UCH-L1 results in a gain or loss of function, resulting from
observations of PD-related pathology in transgenic mice overexpressing the human mutated
protein  (Setsuie et al. 2007) and in mice naturally lacking UCH-L1 (Saigoh et al. 1999), but
surprisingly not in engineered KO mouse models (Shimshek et al. 2012).
Interestingly, coexpression of ubiquitin and a-syn is reducing synucleinopathy in a fly model
(Lee et al. 2009). Furthermore, this effect is driven by expression of the K48R, and not K63R
ubiquitin mutants, suggesting that the ubiquitin-mediated neuroprotective effect is potentially
dependent  on  the  K48  polyubiquitin  linkage,  highlighting  complex  roles  of  a-syn
polyubiquitination in PD.
5.6.4  Degradation
As a-syn accumulation have been linked to toxicity, a better understand of the degradation of
a-syn in neurons may lead to the generation of novel therapeutics [schematized in Fig. 1-12
and reviewed in (Ebrahimi-Fakhari et al. 2012; Xilouri et al. 2013)]. Therefore, much effort has
been applied to  reduce a-syn levels  by increasing its  clearance using a pharmacological
approach, but has resulted in a large body of controversial results.
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Figure 1-12: Proteolytic pathways involved in alpha-synuclein processing
Figure copied from (Xilouri et al. 2013)
Proteasome  and  lysosomal  pathways  play  a  major  role  in  the  final  degradation  of  a-syn.  The
ubiquitin-proteasome system (UPS)  is  degrading  A) ubiquitin-tagged a-syn and  B) non-ubiquitinated a-syn.
Three  different  lysosomal  pathways  have  been  described  to  also  degrade  a-syn,  C) chaperone-mediated
autophagy (CMA) selectively target a-syn (presenting a KFERQ-like motif) into the lysosomes after binding to
the lysosomal receptor LAMP-2A,  D) macroautophagy sequesters intracellular constituents (including various
forms of a-syn such as oligomers) by a double membrane (phagophore) that finally generates the autophagic
vacuole, which then fuses with the lysosome; and microautophagy in which substrates are directly delivered into
the lumen through invaginations of the lysosomal membrane. Moreover, other proteases such as E) calpains or
F) neurosin  have  been  implicated  in  the  cleavage  of  normal  or  aggregated  forms  of  intracellular  a-syn.
Interestingly, G) secreted neurosin and H) metalloproteases have been found to cleave extracellular a-syn.
Ubiquitin-proteasome system
Despite many evidences suggesting an important role of the UPS in the degradation of a-syn,
altered  UPS degradation  involvement  in  the  initiation  of  synucleinopathy is  controversial.
Moreover, it is still unclear whether a-syn can modulate UPS activity.
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More  precisely,  a  general  impairment  of  UPS  is  observed  in  PD  and  is  reflected  by  a
decreased proteasomal function  (McNaught & Jenner 2001) as well  as by a decrease of
proteasomal subunit levels  (McNaught, Belizaire, et al. 2002; Chu et al. 2009). Accordingly,
a-syn possesses a short turn-over which is increased drastically  in vitro by UPS inhibition
(Bennett et al. 1999; Webb et al. 2003).
Accordingly, inhibition of the proteasome leads to intracellular inclusions immunoreactive for
a-syn, ubiquitin and the chaperone Hsp70 in apoptotic  cells  (McNaught,  Mytilineou,  et  al.
2002; Rideout & Stefanis 2002). Similarly, rodent models treated with proteasome inhibitors
develop a progressive parkinsonism as well as neuronal degeneration and a-syn positive LBs
in  different  brain  regions  (McNaught  et  al.  2004).  But  it  is  important  to  note  that  other
independent studies failed to reproduce these reported effects (Bové et al. 2006; Kordower et
al. 2006). Interestingly, the importance of UPS in the initiation of PD is also highlighted in a
mouse model  expressing a conditional  deletion of the Rpt2/PSMC1 subunit  (19S ATPase
regulatory complex) and developing neurodegeneration as well  as a-syn positive inclusion
bodies (Bedford et al. 2008).
The presence of ubiquitinated a-syn inclusions is classically associated with  an abnormal
decrease of a-syn degradation by the UPS (Stefanis et al. 2001; Tanaka et al. 2001; Petrucelli
et  al.  2002).  But  accumulation  of  ubiquitinated  a-syn  is  not  invariably  associated  with  a
significant impairment of proteasome function  (Tofaris et al. 2003), and correlation between
the load of ubiquitinated inclusions and the degree of UPS activity is not evident (Giasson et
al. 2002; Neumann et al. 2002). Accordingly, a-syn degradation by the proteasome has been
shown to  be independent  of  its  monoubiquination  (Rott  et  al.  2008) and ubiquitination in
general (Tofaris et al. 2001).
In this context, cellular models have shown that expression of high levels of a-syn (or mutated
a-syn forms) leads to the formation of oligomers and aggregated structures and result  in
proteasomal activity inhibition (Stefanis et al. 2001; Tanaka et al. 2001; Snyder et al. 2003).
However this effect was not replicated in vivo (Dyllick-Brenzinger et al. 2010).
Autophagy
An increasing  body of  evidence  suggests  a  dysfunction  of  ALP in  brain  of  PD patients:
1) increased  presence  of  autophagic  vacuoles  (Anglade  et  al.  1997),  2) increased
autophagosome  markers  (Crews  et  al.  2010;  Higashi  et  al.  2011;  Tanji  et  al.  2011),
3) decreased  lysosomal  markers  (Chu  et  al.  2009;  Dehay  et  al.  2010) and  4) increased
selective autophagy substrates (Tanji et al. 2011).
Since  aggregates  of  a-syn  are  a  substrate  of  autophagy,  ALP  could  be  regarded  as  a
complementary system to compensate an overwhelmed UPS, as well as to cope with specific
aggregated substrates not targetable by the UPS [reviewed in (Ebrahimi-Fakhari et al. 2012;
Xilouri  et  al.  2013)].  Degradation of a-syn by the lysosome  (Paxinou et al.  2001),  initially
thought to promote the clearance of a-syn aggregates by macroautophagy  (Rideout et al.
2004), plays an important role in the degradation of soluble proteins and soluble oligomers
under physiological conditions (H.-J. Lee et al. 2004; Mak et al. 2010).
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Interestingly,  a-syn has been suggested to inhibit  macroautophagy at very early stages of
autophagosome formation via inhibition of the small GTPase Rab1A (Winslow et al. 2010;
Winslow &  Rubinsztein  2011).  This  hypothesis  was  confirmed in  mice  lacking  a-syn  and
showing an increased autophagy activity (Corrochano et al. 2012).
Decreased levels  of  the  CMA adapter molecule LAMP-2A and of the lysosomal protease
cathepsin D in brain of PD patients suggests a potential function of CMA in the pathogenesis
(Alvarez-Erviti  et al.  2010; Chu et al.  2009).  Interestingly, a-syn is normally internalized in
lysosomes  for  degradation  via  the  adapter  molecule  LAMP-2A.  But  as  mutant  and
dopaminergically  modified  a-syn  present  a  strong  binding  to  LAMP-2  on  the  surface  of
lysosomes, these a-syn species have been shown to inhibit the CMA (Cuervo et al. 2004;
Martinez-Vicente et al. 2008), resulting from cellular stress due to the alteration of all proteins
dependent on CMA degradation (Cuervo et al. 2004; Vogiatzi et al. 2008).
Crosstalk between autophagy and proteasome protein degradation
Depending on a-syn conformational states and on the cellular conditions, both proteasomes
and lysosomes were shown to be capable of degrading recombinant a-syn (Liu et al. 2003;
Cuervo et al. 2004). However, mechanisms determining a-syn degradation by UPS or ALP
are yet to be resolved.
One simplified view is to consider that only less complex soluble forms of a-syn are degraded
by UPS because more complex structures may get jammed inside the proteasome and block
its activity [proposed in  (Lynch-Day et al. 2012)]. These species, as well as more complex
soluble forms of a-syn, may also be degraded by the CMA. However, it is likely that the CMA
is not a viable long term degradation alternative for a-syn as mutant or modified species of
a-syn have a high binding affinity to the CMA receptor, blocking uptake and degradation of
CMA substrates  (Cuervo et al. 2004; Martinez-Vicente et al. 2008). Finally, UPS and CMA
inhibition  was shown to  promote  macroautophagy activation as  a  potential  compensatory
mechanism to  maintain  normal  protein  degradation  levels  and  also  to  remove  abnormal
cytosolic  toxic  and  aggregated  proteins  (Pandey  et  al.  2007;  Massey  et  al.  n.d.).
Unfortunately, the drawback of this cellular strategy is the production of cellular stress as a
consequence of the in-bulk non-selective degradation [reviewed in (Cherra & Chu 2008)].
This degradation model is also supported by an increasing body of evidence demonstrating
distinct roles of UPS and ALP in a-syn degradation. For example, in vivo observation of a-syn
turn-over in mouse brain using multiphoton imaging supports 1) the critical role of the UPS
both  in  non-transgenic  mice  and  in  mice  overexpressing  a-syn,  2) a  more  pronounced
age-dependent  UPS  impairment  in  transgenic  mice  overexpressing  a-syn  than  in
non-transgenic controls and 3) the optional involvement of autophagy in the degradation of
endogenous levels of  a-syn and its  critical  recruitment  in transgenic mice overexpressing
a-syn to eliminate excess protein levels [reviewed in (Ebrahimi-Fakhari et al. 2012)].
Much effort has been put on explaining molecular mechanisms involved in the shift of a-syn
degradation  using  the  process  of  a-syn  ubiquitination.  Monoubiquitination  of  a-syn,  for
example  by  USP9X  (Rott  et  al.  2011),  promotes  its  degradation  by  the  UPS  whereas
deubiquitination, for example by SIAH1 (Rott et al. 2008), inhibits its degradation.
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However,  either  UPS or  ALP inhibition  in  cell  models  overexpressing  a-syn  leads  to  an
accumulation of monoubiquitinated a-syn and formation of cytosolic inclusions  (Rott  et al.
2008), obscuring degradation mechanisms involving a-syn monoubiquitination.  Furthermore,
polyubiquitination at the residue 63, for example by the E3 ligase Nedd4 (Tofaris et al. 2011),
mediates a-syn degradation by the ALP. Accordingly, proteasomal inhibition does not lead to
an accumulation of a-syn or polyubiquitinated forms of a-syn (Bennett et al. 1999; Rideout &
Stefanis 2002; Ebrahimi-Fakhari et al. 2011) suggesting that the Lys63-linked ubiquitination of
a-syn is a possible specific signal for ALP degradation.  Finally, several studies suggest that
a-syn does not require ubiquitination to be degraded by the proteasome (Tofaris et al. 2001;
Kravtsova-Ivantsiv & Ciechanover 2012).
Taken together, no clear mechanism of a-syn degradation can be formulated due to conﬂicting
results described in literature. This may result from the large variety of models used to induce
a-syn  accumulation  as  well  as  the  methods used to  modulate  and measure  degradation
pathways. However, the elucidation of ubiquitin roles, as well as the functions of UPS and
ALP in a-syn degradation, had just began.
Other proteolytic systems
Additionally to the ALP and to the UPS, proteases (such as calpains, neurosin, caspases and
metalloproteases) have been observed to process a-syn [reviewed in  (Xilouri et al. 2013).
Truncation of a-syn by calpain-1 could be observed in vitro, in animal models overexpressing
a-syn and in LBs  (Mishizen-Eberz et al. 2003; Dufty et al. 2007). Calpains are intracellular
calcium-dependent  cysteine  proteases  [reviewed  in  detail  in  (Ono  &  Sorimachi  2012)],
cleaving mainly a-syn close to its C-terminus (amino acid 120). Interestingly, calpains can
also cleave a-syn at its NAC domain (amino acid 57) and this cleavage is blocked by the
A53T mutation. Finally, a-syn truncation by calpains leads to a-syn aggregation and to the
formation of beta sheet structures (Dufty et al. 2007).
Neurosin (also termed kallikrein-6) is a secreted serine protease, suggesting an enzymatic
activity in the extracellular compartment [reviewed in (Wang et al. 2008)]. The main cleavage
site  of  a-syn  by  neurosin  is  inside  the  NAC  region  (amino  acid  80).  Interestingly,
phosphorylated Ser129 and A30P a-syn are less susceptible to be cleaved. Neurosin was
suggested to play a role in PD since LBs are immunoreactive for neurosin  (Ogawa et al.
2000), and neurosin inhibition in cell models results in a decrease of a-syn fragments and
aggregation (Kasai et al. 2008).
Matrix  metalloproteinases  (MMPs)  are  another  family  of  extracellular  proteases.  These
enzymes  are  zinc-dependent  and  up-regulated  upon  oxidative  and  nitrative  stress  that
accompany  various  neurodegenerative  conditions.  MMPs  have  been  shown  to  cleave
recombinant a-syn (Sung et al. 2005; Levin et al. 2009). More precisely, MMP-3 is cleaving
a-syn both at its C-terminus and within its NAC regions. Additionally a-syn was also showed,
to a lesser extent, a substrate of MMP-14, MMP-2, MMP-1, and MMP-9 (Sung et al. 2005).
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Concerning  caspases,  analysis  of  a-syn  truncation  patterns  extracted  from  LBs  did  not
present any possible caspase sequences, and recombinant a-syn digestion by caspase 3 did
not  present  any  truncation  pattern,  suggesting  that  a-syn  is  probably  not  an  important
substrate for caspase-mediated cleavage (Dufty et al. 2007).
Truncated a-syn
It  is interesting to note that LBs are abundant truncated C-terminal a-syn, however, these
species were also reported to be increased in the soluble fraction of synucleinopathy brain
extract along with full-length a-syn (W. Li et al. 2005). As described previously, several animal
models  overexpressing  truncated  forms  of  a-syn  were  reported  to  develop  a  severe
phenotype (Michell et al. 2007), even stronger than in mice overexpressing full-length a-syn
(Wakamatsu et al. 2008; Daher et al. 2009).
These  observations,  coupled  with  in  vitro investigations  showing  that  truncation  of  a-syn
C-terminus increases its propensity to form fibrils  (Crowther et al.  1998), suggest that the
aggregation of a-syn may be initiated or enhanced by the generation of a-syn fragments.
Accordingly, expression of C-terminal truncated forms of a-syn increase the aggregation and
the toxicity of a-syn  when compared to the full-length protein in vitro (I. V. J. Murray et al.
2003), suggesting that the C-terminal part of a-syn regulates its aggregation by protecting the
hydrophobic NAC domain.
Several  further  hypotheses  were  proposed  to  explain  the  formation  of  a-syn  C-terminal
fragments [reviewed in  (Ritchie & Thomas 2012)],  including additionally the UPS via 20S
subunit truncation  (C.-W. Liu et al. 2005) and the ALP via lysosomal protease cathepsin D
(Sevlever et al. 2008; Qiao et al. 2008). Finally, it is still unclear whether the formation of
C-terminal truncated a-syn species results from an abnormal or incomplete degradation of
a-syn, or whether these species are normal intermediates of the a-syn catabolism.
In vitro data also suggests a role of the a-syn N-terminus in a-syn aggregation (Kessler et al.
2003), but relevance of these truncation products were less studied and are therefore less
understood.
5.7  Interacting partners 
Cellular a-syn has been described to be available for physical interactions, as suggested by
its  chaperone  functions.  Accordingly,  a-syn  conformation  or  aggregation  states  could  be
modified by protein interactions  (Chung et al. 2001; Uversky et al. 2001; Hasegawa et al.
2002; Alim et al. 2002; H.-J. Lee et al. 2002). Numerous interactions of a-syn with proteins
were  already  reported  [reviewed  in  (Surguchov  2008)],  involving  a-syn  in  several  key
signaling pathways such as protein degradation system, synaptic functionality, regulation of
oxidative stress, mitochondrial function or gene regulation [(Zhou et al. 2004; Woods et al.
2007; Wakabayashi et al. 2007) reviewed in (Dev 2003)].
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Briefly, best defined interacting partners are:
1) Synphilin-1, encoded by the  SNCAIP (SNCA interacting partner) gene, present in
LBs and enhancing a-syn aggregation  (Engelender et al.  1999; Wakabayashi et al.
2000; O’Farrell et al. 2001).
2) Beta- and  gamma- synuclein,  inhibiting  a-syn  fibril  formation  (Biere  et  al.  2000;
Uversky, Li, et al. 2002).
3) Tubulin,  a  basic  structural  constituent  of  microtubules,  purified  by
immunoprecipitation of a-syn (Alim et al. 2002), initiating polymerization of a-syn and
resulting in a-syn fibril formation.
4) Cysteine-string protein-a (CSPa),  a synaptic  vesicle protein with  a co-chaperone
activity, leading to the binding of a-syn to phospholipids (Chandra et al. 2005) and most
likely playing a key role in synaptic function (Bonini & Giasson 2005).
5) 14-3-3, a ubiquitous eukaryotic adapter protein involved in the regulation of cell-
cycle  control,  signal  transduction,  protein  tra cking  and  apoptosis  ﬃ (Hermeking  &
Benzinger 2006), forming high molecular weight complexes with a-syn and found in
LBs (Xu et al. 2002).
6) Rab,  a  group  of  GTP-binding  proteins  implicated  in  the  targeting  of  different
transport vesicles within the cell (Park 2013), interacting with a-syn (Dalfó et al. 2005).
More precisely, Rab3a, Rab5, and Rab8 were shown to interact with a-syn.
7) Agrin, a large proteoglycan playing a major role in the formation of acetylcholine
receptors during synaptogenesis (Daniels 2012). Agrin binds to a-syn and induces its
aggregation (I.-H. Liu et al. 2005).
8) Histones, affecting histones acetylation and promoting neurotoxicity  (Goers et al.
2003; Kontopoulos et al. 2006).
9) Chaperones, such as Hsp27, Hsp70, Hsp90, and aB-crystallin, interact with a-syn
and are present in LBs  (Outeiro et al. 2006). Chaperones play an important role in
a-syn aggregation (Kilpatrick et al. 2013).
10) Tau, modifying both proteins' fibrillization  (Giasson et al. 2003; Guo et al. 2013).
Tau enhances a-syn aggregation and toxicity in  cellular  models of  synucleinopathy
(Badiola et al. 2011).
Unfortunately, a-syn's complex and large interaction range is obscuring the general molecular
functions of its interactome, which is further complicated by the change of a-syn properties by
post-transcriptional modifications such as ligand binding or truncation. It's interesting to note
that a-syn was suggested to be a substrate recognition protein for ubiquitinated substrates
such  as  synphilin-1  (Chung  et  al.  2001),  TH  (Perez  et  al.  2002;  Døskeland  &  Flatmark
2002) or glycosylated forms of a-syn (Guerrero et al. 2013), facilitating their degradation (Dev
2003).
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6)  Synphilin-1
6.1  Discovery
Synphilin-1 (sph1) was first identified in a yeast two-hybrid screen aiming to better understand
a-syn  function  and  role  in  LBs  formation  by  elucidating  its  protein  interaction  partners
(Engelender  et  al.  1999).  Confirmation  of  the  interaction  was  performed  in  cell  models
overexpressing both a-syn and sph1, showing an increase of a-syn inclusions. These data
suggest a link between sph1 and a-syn aggregation.
Presence of sph1 in LBs in brains of sporadic PD patients (Wakabayashi et al. 2000), as well
the identification of R621C mutation in the sph1 gene (SNCAIP) in a PD patient (Marx et al.
2003) pointed out an important functional link between sph1 and neurodegeneration in PD
(Jung & Grune 2012).
6.2  Expression
SNCAIP maps to chromosome 5q23.2 and encodes the sph1 protein. Sph1 is expressed in
the central nervous system, as well as in various peripheral tissues including heart, lungs,
kidneys,  liver  and  blood  cells  (Safran  et  al.  2003).  During  neuronal  development,  sph1
gradually translocates from neuronal cell bodies to nerve terminals where it accumulates and
associates with synaptic vesicles (Ribeiro et al. 2002).
6.3  Structure
Sph1 is  a  919 amino acid  protein  containing six  ankyrin-like (ANK) repeats,  a  coil-coiled
domain  and  an  ATP/GTP-binding  site  (uniprot,  protein  reference  Q9Y6H5).  Interestingly,
ankyrin repeats suggest a role of sph1 in protein-protein interaction (Crowther et al. 1998; Kim
et  al.  2002;  I.  V.  J.  Murray et  al.  2003) and the  coiled-coil  domain  suggests  a  possible
multimerisation  of  the  protein.  Furthermore,  murine  sph1  showed  a  high  homology  with
human sph1 and particularly in the coiled-coil and ankyrin-like motif domains (Kish-Trier & Hill
2013).
6.4  Conformation
Analysis of human brain extracts revealed sph1 as a predominantly soluble 90 kDa protein,
but a less soluble 120 kDa form as well as fragments of 65 kDa and 50 kDa have also been
observed,  supporting  an  alternative  splicing  (or  post-translational  processing)  potentially
playing a role in sph1 function or distribution (I. J. Murray et al. 2003). Accordingly, a splicing
isoform of synphilin-1, termed synphilin-1A, was associated with an enhanced aggregatory
and neurotoxic properties (Eyal et al. 2006).
6.5  Function
The function of sph1 was scarcely investigated. Its presence in nerve terminals as well as its
interaction with phospholipids  (Takahashi et al. 2006) suggests a potential role of sph1 for
maturation or modulation of synapse but also for mediating synaptic roles attributed to a-syn
(Ribeiro et al. 2002).
Since its discovery,  sph1 was described to promote a-syn aggregation  (Engelender et  al.
1999).  More  precisely,  aggregates  formed by a-syn  and  sph1  shared  morphological  and
molecular characteristics of aggresomes (Tanaka et al. 2004), including 1) a round structure
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with a core and halo organization, 2) a juxtanuclear localization, 3) an active formation of
inclusions depending on the microtubular cytoskeleton and 4) a protective effect against a-syn
induced toxicity.
The  formation  of  aggresomes,  as  well  as  their  protective  effectiveness,  could  also  be
observed in vivo (Smith et al. 2010). Accordingly, several studies pointed out that aggresome
formation may represent a specific cellular response to a failure of the proteasome/chaperone
machinery  (Zaarur  et  al.  2008;  Wong  et  al.  2008;  Wong  et  al.  2012).  Accordingly,
aggresome-like inclusions generated in cells overexpressing a-syn and sph1 are amenable to
clearance  by  autophagy  (Wong  et  al.  2008).  This  mechanism was  shown  to  be  directly
dependent on sph1's ANK1 domain when undergoing K63 ubiquitination, probably reducing
the mobility of aggregating proteins in the aggresomes (Wong et al. 2012).
Therefore, K63 polyubiquitination of sph1 may play a critical role on aggresome formation,
and several E3 ubiquitinase candidates such as parkin (Chung et al. 2001) and dorphin (Ito et
al. 2003) were identified to ubiquitinate sph1. It is predictable that ubiquitin binding proteins
are  recognizing  small  aggregates  and  facilitating  their  association  to  motor  proteins,
promoting  their  transport  to  the  centrosome  and  connecting  ubiquitination  of  abnormal
polypeptides  to  their  accumulation  in  aggresomes  (Tsai  et  al.  2012).  As  an  example,
microtubule-associated histone deacetylase HDAC6 was shown to interact with aggregates of
ubiquitinated proteins via its ubiquitin binding BUZ domain and facilitate their association with
the dynein motor protein that drives this cargo to the aggresomes (Meriin et al. 2010). Other
ubiquitin binding proteins-like PLIC or ataxin-3 may also target these abnormal complexes to
the aggresomes (Heir et al. 2006; Burnett & Pittman 2005). Interestingly, sph1 overexpression
in  A53T  a-syn  mouse  models  promotes  the  formation  of  aggresome-like  structures  that
protect  neurons  against  degeneration  via  multiple  cellular  pathways  including  ALP  and
apoptosis (Smith et al. 2010).
Phosphorylation of sph1 by casein kinase II (CKII) (Tanji et al. 2003) plays an important role in
the interaction between a-syn and sph1. This is suggested by the impaired protein binding in
presence of CKII inhibitor, but not in the case of the  non-phosphorylable [S129A] a-syn  (G.
Lee et al. 2004). Phosphorylation of sph1 also results from a decreased ubiquitination of sph1
by SIAH (Avraham et al. 2005), inhibiting sph1 degradation by the UPS (Nagano et al. 2003).
Moreover, sph1 was reported to interact with the regulatory proteasomal protein S6 ATPase
(tbp7) and to reduce proteasomal activity (Marx et al. 2007). In this context, sph1 was shown
to inhibit high potassium-induced dopamine release from PC12 cells (Nagano et al. 2003), but
it is still unclear if this observation resulted directly from a-syn or sph1 disturbance.
6.6  Toxicity
Originally,  toxicity  of  sph1 was  suggested  after  its  discovery  in  LBs  (Wakabayashi  et  al.
2000) and  after  observing  that  sph1  coexpression  in  a-syn  models  was  increasing
aggregation  (C.-W.  Liu  et  al.  2005).  However,  this  hypothesis  was  challenged  by  the
discovery of a point mutation in  SNCAIP in a PD patient (Marx et al. 2007) as well as the
improved cell viability with aggresome formation in models overexpressing a-syn (Tanaka et
al. 2004).
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6.6.1  Synphilin-1 interaction with alpha-synuclein
Sph1 and a-syn were shown to interact via their C-terminus, but also more weakly via their
N-terminus (Kawamata et al.  2001). These data were challenged by a more recent study
reporting the interaction of the central coiled-coil domain of sph1 with the N-terminal stretch of
a-syn  (Xie et al.  2010), inducing the formation and the accumulation of cellular inclusions
(represented in Fig. 1-13). Interaction of mutant A53T a-syn with sph1 was described to be
higher than with wild-type or the A30P a-syn, but R621C mutated sph1 does not modify its
binding to a-syn.
Figure 1-13: Representation of the interaction between synphilin-1 and 
alpha-synuclein
Figure copied from (Xie et al. 2010)
Formation of a dimer of sph1 interacting via its central coiled-coil  domain. Binding of a-syn to the opposite
coiled-coils dimerization surface of sph1 via a-syn's N-terminal stretch.
Coexpression of sph1 specifically increases half-life of a-syn by inhibiting its degradation by
the  UPS,  probably  by  hiding  the  a-syn  sequence  necessary  for  its  recognition  by  the
proteasome more than by reducing UPS activity (Alvarez-Castelao & Castaño 2011).
Binding of sph1 to synaptic vesicles has been shown to be negatively modulated by a-syn
(Ribeiro et al. 2002). Thus, sph1 seems to be a synaptic partner of a-syn and imply that this
interaction mediates the synaptic effects of a-syn.
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6.6.2  Synphilin-1 mutation
A mutation in  SNCAIP, leading to R621C substitution in sph1, was reported in a PD patient
(Marx et al. 2003). This mutation was also shown to reduce the number of inclusions as well
as the a-syn turn-over by the UPS leading to apoptotic stimuli in cells overexpressing a-syn.
Accordingly, mice overexpressing the mutated sph1 showed an enhanced neurotoxic effect
and a motor phenotype when compared to mice overexpressing the wild-type sph1 (Nuber et
al.  2010).  However,  frequency  of  the  R621C  substitution  was  reported  to  be  equivalent
between  PD and  control  subjects  (Myhre  et  al.  2008),  questioning  the  relevance  of  this
mutation in PD physiopathology.
6.6.3  Synphilin-1A isoform
Synphilin-1A is an alternative splice variant of sph1 lacking exons 3 and 4 and containing the
exon 9A  of  the  SNCAIP gene,  generating  a  different  N-terminus (Eyal  et  al.  2006).
Interestingly, synphilin-1A is also present in LBs and could be detected in detergent insoluble
fractions of brain protein samples. These data are supported by the observation of altered
mRNA expression levels of sph1 isoforms in PD (Humbert et al. 2007). 
Synphilin-1A was also described to be toxic for cells (Eyal et al. 2006), binding to sph1 and
forming aggregates containing a-syn.  But even more interestingly,  synphilin-1A inactivates
SIAH ubiquitinase activity and SIAH autoubiquitination, resulting in accumulated sph1 and
decreased a-syn monoubiquitination (Szargel et al. 2009). Altogether, these findings suggest
that sph-1 isoform expression may play a significant role in PD pathogenesis.
6.6.4  Mouse models
Transgenic mice expressing human sph1 under the mouse prion protein promoter presented
a motor phenotype accompanied by ubiquitinated insoluble structures all over the brain (Jin et
al. 2008). These findings were confirmed in another transgenic mouse overexpressing wild-
type and mutant sph1 under the mouse prion protein promoter. Both sph1 forms showed a
motor phenotype and the presence of inclusions; however the effects were more robust in
mutant sph1 mice (Nuber et al. 2010).
Transgenic mice generated via injection of viral vectors were also used to study the effects of
wild-type  and  R621C  mutated  sph1  in  dopaminergic  neurons.  Both  sph1  species  were
reported  to  lead  to  an  equal  neuronal  degeneration  and  an  equal  increase  of  inclusion
formation in wild-type mice (Krenz et al. 2009).
Finally, a protective effect of sph1 expression was observed in mice overexpressing A53T
a-syn (both transgenes expressed under the mouse prion protein promoter). This protection
was illustrated by an increased life span, milder motor abnormalities and decreased astroglia
reactions  accompanied  by  the  formation  of  aggresome-like  structures  and  increased
autophagy.  This  suggests  that  sph1  alters  multiple  cellular  pathways  to  protect  against
neuronal degeneration (Smith et al. 2010). However, these results were challenged by a study
using a viral vector to coexpress human sph1 in mice overexpressing A30P a-syn, in which
loss of dopaminergic neurons was increased by sph1 coexpression (Krenz et al. 2009).
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7)  Aim of the thesis
The role of a-syn aggregation in synucleinopathy is controversial.  On the one hand a-syn
aggregation was clearly shown to lead to cell toxicity and to be involved in PD pathogenesis.
On the other hand a protective role of aggregates is emerging in diverse synucleinopathy
models and also in PD. The overall aim of this study is to investigate the impact of a-syn
aggregation  on the  development  of  synucleinopathy using the  genetic  enhancer  of  a-syn
aggregation sph1.
It  is noticeable that similar approaches have already been tested. However, the impact of
sph1  in  a-syn-mediated  toxicity  was  inconsistent.  Several  reasons  may  explain  these
divergent  results,  including  the  variety  of  models  used  to  induce  synucleinopathy,  the
relevance of methods or biological markers used to analyze pathology and the absence of
inclusion characterization in these studies. Therefore, the initial point of this study is to better
characterize the impact of sph1 on a-syn aggregation by studying changes in a-syn protein
levels,  solubility  and post  transcriptional  modifications  in  detail  (including  potentially  toxic
truncated,  oligomerized and fibrillized a-syn forms).  Hallmarks of  neuropathology were be
investigated using a-syn aggregation or inflammation markers. The relevance of histological
marks of pathology in our model were correlated to the pathology observed at the behavioral
levels using motor performances or cognition tests.
Several functions of sph1 in protein degradation were suggested: sph1 was first reported to
interact and to impair the UPS, and more recently sph1 was reported to promote inducible
autophagy. However, these suggested functions have opposite consequences on proteolysis.
Therefore, this study was focusing in a second step on the impact of sph1 overexpression on
proteolysis in vivo, focusing more particularly on a-syn degradation.
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Materials and Methods
1)  Characterization of the double transgenic model at the 
biochemical level
1.1  Cross-breeding strategies
Two transgenic mice generated previously were used in this study and described in (Kahle et
al.  2000;  Nuber  et  al.  2010).  The first  mouse model  is  overexpressing  the  human A30P
mutated a-syn under the Thy-1 promoter (designated as A30P mice in this study), and the
other mouse is overexpressing the human synphilin-1 under the PrP promoter (designated as
sph1  mice  in  this  study).  Mice  expressing  both  transgenes  are  designated  as  double
transgenic mice in this study.
The breeding strategy is schematized in the Fig. 2-01. We first cross-bred homozygous A30P
and sph1 mice (P) to generate a group of hemizygous double transgenic mice (so called F1).
The F1 generation, composed exclusively of hemizygous, mice was cross-bred to generate a
group of both homozygous and hemizygous sph1, A30P and double transgenic (so called F2)
based on Mendelian inheritance.
Hemizygous double transgenic mice, hemizygous A30P mice, hemizygous sph1 mice, and
nTg mice, were generate by crossed-breeding homozygous A30P, homozygous sph1 and nTg
mice with non-transgenic C57BL/6NCrt littermates (Charles River Laboratories, Wilmington,
USA) from the same litter (so called F3).
Figure 2-01: Schematic representation of breeding strategy
Homozygous single transgenic mice were crossbred to generate hemizygous double transgenic F1. F1 was
cross-bred to generate homozygous A30P, sph1, double transgenic as well as non-transgenic mice F2. F2 was
cross-bred  to  a  group  of  wild-type  littermates  to  generate  the  experimental  groups.  +/+:  homozygous;  +/o
hemizygous
1.2  DNA extraction
Animal's genomic DNA was extracted to determine their genotype, using 0.5 cm diameter ear
biopsy and the Roche High Pure PCR Template Preparation Kit  (Roche Applied Science,
Mannheim, Germany). Manufacturer buffers, filters and recommendations were used.
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Briefly, tissues were digested with proteinase K overnight at 55°C in microcentrifugation tubes
(Eppendorf  Safe-Lock Tubes; Eppendorf,  Hamburg, Germany)  using 40 µl  of  proteinase K
and 200 µl  of  lysis  buffer.  After  addition of  isopropanol  and binding buffer,  samples were
vortexed for 5 sec and centrifuged. Supernatant was filtered through a High Pure Filter Tube.
DNA was washed using inhibitor removal buffer, to prevent DNA loss during washing steps,
and washed twice with washing buffer. Excess of washing buffer was removed by an extra
centrifugation step and DNA was then eluted in 200 µl of 70 °C prewarmed elution buffer.
DNA was stored for short time at 4 °C or for longer period at -20 °C.
1.3  Polymerase chain reaction (PCR)
PCR allows the amplification of a target sequence of DNA using polymerase reaction. Briefly,
polymerase  amplification  requires  the  presence  of  a  DNA template  (in  our  case  mouse
genomic DNA) and a free 3'-OH (in  our  case sequence-specific  oligonucleotide primers).
Reaction could be decomposed in three main steps: denaturation by heating (at 95°C, for
30 sec,  to  render  DNA single-stranded),  annealing  (temperature  and  time  depending  on
length  and  GC  content  of  primers,  to  allow  the  binding  of  primers  to  the  appropriate
complementary  DNA strand)  and  the  extension  (optimal  temperature  depending  of  the
polymerase, time depending of the length of the amplicon and of the extension speed of the
polymerase, to amplify the primers to an amplicon).
Transgenic animals were identified by PCR using DNA polymerase (OneTaq; New England
BioLabs, Ipswich, USA) and primers designed to amplify the transgenic PrP or the Thy-1
fragment (Table 2-01; Metabion, Martinsried, Germany).
Table 2-01: Mouse genotyping primers
Transgene Primer sequence DNA stranddirection
Amplicon
size
Annealing
temp.
Thy-1 hum SNCA 5′-ATGGATGTATTCATGAAAGG-3′ Forward 400 bp 50 °C
Thy-1 hum SNCA 5′-TTAGGCTTCAGGTTCGTAG-3′ Reverse 400 bp 50 °C
Thy-1 hum SNCA 5′-TGTAGGCTCCAAAACCAAGG-3′ Forward 200 bp 55 °C
Thy-1 hum SNCA 5′-TGTCAGGATCCACAGGCATA-3′ Reverse 200 bp 55 °C
PrP hum SNCAIP 5′-CAGAACTGAACCATTTCAACC-3′ Forward 400 bp 60 °C
PrP hum SNCAIP 5′-GGGCTTCCAAGTCTTCTTC-3′ Reverse 400 bp 60 °C
PrP hum SNCAIP 5′-TTTGGAATATGTTTGCGCTG-3′ Forward 200 bp 55 °C
PrP hum SNCAIP 5′-GTGCCATGTTGGATGATGAG-3′ Reverse 200 bp 55 °C
Mouse ACTB 5′-GATCTGGCACCACACCTTCT-3′ Forward 200 bp 55 °C
Mouse ACTB 5′-TCTTCTCCCGGTTAGCTTTG-3′ Reverse 200 bp 55 °C
A 25 µl reaction mixture was prepared for PCR and composed of 5 pM/µl primers (Metabion,
Martinsried, Germany), 10 mM dNTP mix (11814362001; Roche), 25 unit/ml taq polymerase,
1× Standard or GC Reaction Buffer (One Taq; NEB), approximately 100 pg DNA and water to
adjusted for 25 µl per reaction (Ampuwa; Fresenius Kabi, Germany). Reaction was performed
in a 96 well plate (4ti-0750-5; 4titude, Wotton, UK) or in 0.2 mL microcentrifuge tubes (2-2600;
NeoLab, Heidelberg, Germany).
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Amplicons generated were visualized using 1% agarose gel (Invitrogen; Karlsruhe, Germany)
containing 0.5 μg/ml ethidium bromide (2218; Roth, Karlsruhe, Germany). Specificity of the
amplification was confirmed by comparing amplicon size in base pair to a DNA size ladder
(100 bp DNA-Ladder; Invitrogen).
1.4  Quantitative PCR genotyping
Zygosity was determined performed by estimating the relative number of gene copies using
quantitative real-time polymerase chain reaction (qPCR) on a LightCycler 2.0 (Roche) and
FastStart DNA MasterPlus SYBR Green (Roche), a dye becoming fluorescent when binding
to double stranded DNA. Reaction mixture used for qPCR contained 10 pmol of each primer,
20 pg of DNA and 1× SYBR Green Mix (Roche) and was adjusted to 10 µl per reaction using
water (provided with the kit). Reaction was measured in a 384 well plate (4Ti-0382; 4titude).
Relative  quantitative  PCR was  quantified  using  ΔΔCp  method.  Crossing  point  value  (Cp
value) of PCR reaction was calculated by the LightCycler software (version 4.0) using the
maximum  of  the  second  derivative  of  the  amplification  curve  fluorescence  representing
fluorescence signal acceleration (method resulting in more consistent results). The ΔCp of the
samples was calculated by subtracting the Cp of the transgene of interest from the Cp of the
reference gene beta-actin. The ΔΔCp was determined by subtracting the ΔCp of the sample
from the ΔCp of hemizygous control  animals.  Relative gene copy number was calculated
using 2-ΔΔCp. Specificity of PCR reactions was assessed using melting curve, a method based
on the slow warm up of the final PCR product, leading to the formation of double stranded
DNA able to bind SYBR and resulting to fluorescence increase. As the temperature resulting
to double stranded DNA formation depends of  DNA length and GC content,  presence of
different amplicons results to multiple distinct fluorescence increase at different temperatures.
1.5  Tissue preparation
Single  mice  were  sacrificed  by  asphyxiation  using  accumulation  of  CO2  in  home-cage
preferentially and using a low gas pressure (lower as 0.5 bar). A coronal cut approximately at
bregma –3 mm was performed on mouse brain to separate forebrain and hindbrain region.
Brain region were then prepared and snap frozen in a 2 ml cryotube (126261; Greiner Bio
One, Kremmsmuenster, Austria) and stored at -80ºC for future biochemical analysis.
1.6  Tissue lysate
Proteins were lysed from brain tissue in 10 volume of lysis buffer in order to perform gel
electrophoresis. Brain tissues were disrupted 30 sec using a homogenizer (T10 ultra turrax;
VWR, Radnor, USA) in ice. Lysis buffers were selected depending of the solubility of studied
proteins. Cytosolic proteins were extracted using Tris-saline lysis buffer (10 mM Tris, 150 mM
sodium chloride,  pH 8.0),  cytosolic  and  membrane  bound  proteins  were  extracted  using
NP-40 lysis buffer (50 mM Tris, 150 mM sodium chloride, 1.0% NP-40, pH 8.0), and whole cell
extract including less soluble proteins were extracted using RIPA buffer (50 mM Tris, 150 mM
NaCl, 1.0% NP-40, 0.5% sodium deoxycholate, 0.1% SDS, pH 8.0).  All  lysis buffers were
supplemented  with  protease  inhibitor  (Complete;  Roche  Diagnostics).  After  the
homogenization, samples were incubated for 30 min at 4 °C and spun for 20 min at 12 000 g
for NP-40 or RIPA lysis buffer and 30 min at 120 000 g for Tris-saline lysis buffer. Proteins
lysate supernatants were supplemented with 10% glycerol before long storage at -80 °C.
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1.7  Sequential protein extraction
A sequential protein extraction based on detergent solubility of these proteins was performed
to quantify a-syn aggregation using buffers with different salinity, detergent concentration, and
intermittent ultracentrifugation steps as described previously (Tofaris et al. 2003) with minor
modifications (Fig. 2-02).
Brain samples were homogenized in 5 volumes of TBS+ (Tris-buffered saline plus complete
protease inhibitor (Complete; Roche)) using a homogenizer for 30 sec, incubated for at least
1 h  and  spun  for  30 min  at  120 000 g.  The  resulting  supernatant  represented  the  TBS+
soluble fraction. The pellet was then extracted sequentially with 1) 1 ml of TBS+ containing
1%  of  Triton  X-100,  2) TBS+  containing  1 M  sucrose,  3) RIPA buffer  (50  mM  Tris-HCl,
175 mM  NaCl,  5 mM  ethylenediaminetetraacetic  acid  [EDTA],  1%  NP-40,  0.5%  sodium
deoxycholate, 0.1% sodium dodecyl sulfate (SDS), pH 7.4) and 4) 2 M urea/5% SDS. Pellets
were suspended 10 times in buffer using three needles of decreasing diameter (Nr.1, Nr.14,
Nr.18; BD).
Figure 2-02: Sequential protein extraction protocol
Originally, 8 M of urea was used to suspend RIPA detergent-insoluble proteins  (Liang et al.
1999), but we used 2 M of Urea to preserve higher molecular a-syn structures (Paleologou et
al.  2009).  In  all  extracts,  10% of  glycine was added as  cryoprotectant  before storage at
-80 °C.
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1.8  Protein concentration measurement
We determined protein concentration using Bradford method (Protein Assay Dye Reagent
Concentrate; Bio-Rad, Munich, Germany). This method is based on the proportional shift of
Coomassie dye from red to blue when binding to protein, absorbance of samples at 595 nm
was performed and concentration of samples was calculated by standard curve extrapolation.
Standard curve of BSA (0, 10, 20, 50, 100, 150 and 200 µg/ml) and sample were diluted in
800 µl of water and 200 µl of Bradford reagent was then added in each tube and incubated for
5 min at room temperature.
1.9  Western blotting
Separation and identification of proteins in tissue lysate or tissue sequentially extracted was
performed based on molecular weight using SDS-polyacrylamide gel electrophoresis followed
by protein transfer and immunostaining of membrane.
Samples were prepared by diluting protein lysates in PAGE buffer (0.2 M glycine, 25 mM Tris,
1% SDS) to a final volume of 15 µl. Samples were denatured at 95 °C for 10 min in loading
buffer  (80 mM Tris,  2% SDS, 5% 2-mercaptoethanol,  10% glycerol,  0.005% bromophenol
blue, pH 6.8) to denature proteins and shortly centrifuged for 30 sec at 400 g. 
Proteins were separated by electrophoresis using homemade SDS-PAGE gel (Table 2-02) or
precast  gradient  gels  (SERVAGel  Vertical  Tris-Glycin  Gel  2D  8-16%;  Serva,  Heidelberg,
Germany).  Gels  containing  proteins  were  washed for  5  minutes  in  transfer  buffer  (0.2 M
glycine,  25 mM  Tris,  10–20%  methanol)  to  remove  excess  of  SDS  and  transferred  to
membranes  labeled  with  pencil  and  equilibrated  in  transfer  buffer  for  10 min  for  a
homogenous transfer to the membrane. Transfer was performed for 1h30 to 2 h at 80 V at
4 °C. Several membranes were used to blot protein as nitrocellulose membranes (Optitran or
Protran; Millipore, Billerica, USA) or PVDF membranes (Immobilon-P; Millipore). Choice of
membranes was done depending of the molecular weight of proteins of interest or of the
antibody used for the immunoblot detection. For PVDF membranes, some extra steps were
required. Prior equilibration in transfer buffer for 10 min, PVDF membranes were activated
30 sec in methanol and washed with distilled water. After the transfer, membrane PVDF were
dried for 15 min to enhance protein binding and re-hydrated in TBS  (10 mM Tris,  0.15 M
NaCl, pH 7.5) before blocking.
Table 2-02: Western blot gel composition
Running gel (5 ml) 8% 10% 12% 15% 17% Stacking gel (3ml) 5%
H2O 2.3 ml 2 ml 1.65 ml 1.15 ml 0.8 ml H2O 2.1 ml
30% acrylamide 1.35 ml 1.65 ml 2 ml 2.5 ml 2.35 ml 30% acrylamide 0.5 ml
1.5M Tris (pH 8.8) 1.25 ml 1.25 ml 1.25 ml 1.25 ml 1.25 ml 1.0M Tris (pH 6.8) 380 µl
10% SDS 50 µl 50 µl 50 µl 50 µl 50 µl 10% SDS 30 µl
10% APS 50 µl 50 µl 50 µl 50 µl 50 µl 10% APS 30 µl
TEMED 3 µl 3 µl 3 µl 3 µl 3 µl TEMED 3 µl
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To prevent any antibody non-specific binding to the membrane surface, immunoblot  were
washed  5 min  in  TBS  buffer  and  blocked  using  5%  non-fat  milk  (Slim  Fast;  Slim  Fast
Deutschland,  Wiesbaden,  Germany)  or  5% BSA (Sigma-Aldrich;  Steinheim,  Germany)  in
TBS. Membranes were then washed twice 5 min in TBST and incubated with the primary
antibody over night at 4 °C, or 2 h at room temperature depending of the antibody specificity
(primary antibodies used in this study are listed in table 2-03).  After incubation with the first
antibody, membranes were washed four times (5 min each) with TBST. Membranes were then
incubated for 75 min with the secondary antibody coupled to horseradish peroxidase (GE
Healthcare, Freiburg,  Germany).  After four washing steps with  TBST (5 min each),  bands
were  visualized using  the  enhanced chemiluminescence method (ECL+;  GE Healthcare).
Light signal was detected using X-ray films (Hyperfilm ECL; GE Healthcare) and a developer
(CP100; Agfa, Mortsel, Belgium).
Films were scanned at 300 dpi (HP Scanjet 3970; Hewlett-Packard, Dübendorf, Switzerland)
and exported as 8-bit  TIFF. Image were then quantified using densitometry (ImageJ; NIH,
USA) following (Gassmann et al. 2009) and background correction was done with the default
settings of ImageJ (rolling ball radius=50). To define the band profiles, rectangular boxes of
the exact same size were defined arbitrarily. Intensity of the signal was quantified using the
area under the curve of the gray intensity level plotted by the size of the band.
Table 2-03: Antibodies and staining conditions
Antibody Epitope Specie Reference Company Conc. (WB) Blocking (WB) Conc. (IHC)
human and mouse  alpha synuclein NAC domain mouse 610786 Transduction 1:3000 Slim fast 5% 1:1000
human and mouse  alpha synuclein N-terminus rabbit SAB4502831 Milipore 1:200 Slim fast 5% -
human alpha synuclein C-terminus rat 804-258-L001 Enzo Life Science 1:50 Slim fast 5% 1:20
myc mab A14 rabbit sc-789 Santa Cruz 1:200 Slim fast 5% 1:100
myc polyclonal rabbit 2272 Cell Signaling 1:1000 Slim fast 5% -
myc mab 9b11 mouse 2276 Cell Signaling 1:1000 Slim fast 5% 1:500
myc mab 71d10 rabbit 2278 Cell Signaling 1:1000 Slim fast 5% -
myc polyclonal rabbit 9106 Abcam 1:500 Slim fast 5% -
myc Mab 9E10 mouse m4439 Sigma 1:200 Slim fast 5% -
synphilin-1 N-terminus rabbit S5946 Sigma 1:500 Slim fast 5% 1:200
synphilin-1 C-terminus rabbit S6071 Sigma 1:500 Slim fast 5% -
synphilin-1 polyclonal rabbit AB6179 Abcam 1:500 Slim fast 5% -
synphilin-1 polyclonal mouse 9627-B01 Novus 1:1000 Slim fast 5% -
synphilin-1 N-terminus mouse 9627-M01 Novus 1:1000 Slim fast 5% -
beta-actin C-terminus mouse A4700 Sigma 1:5000 Slim fast 5% -
alpha-tubulin mab DM1A mouse cp06 Milipore 1:10000 Slim fast 5% -
GAPDH mab GA1R mouse AB125247 Abcam 1:3000 Slim fast 5% -
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proteasome 20S α5 subunit unknown mouse PW8125 Enzo Life Science 1:1000 Slim fast 5% 1:200
proteasome 20S α1,2,3,5,6,& 7 subunits unknown mouse PW8195 Enzo Life Science 1:1000 Slim fast 5% 1:200
proteasome activator 11S beta subunit polyclonal rabbit PW8240 Enzo Life Science 1:1000 Slim fast 5% 1:200
proteasome activator 11S alpha subunit polyclonal rabbit PW8185 Enzo Life Science 1:1000 Slim fast 5% 1:200
proteasome 19S Rpt2/S4 polyclonal rabbit PW8160 Enzo Life Science 1:1000 Slim fast 5% 1:200
proteasome 19S Rpt2/S4 polyclonal rabbit PW8305 Enzo Life Science 1:1000 Slim fast 5% 1:200
LC3 polyclonal rabbit MBL-PD014 Biozol 1:1000 Slim fast 5% 1:500
LC3 mab 5F10 mouse 0231 Nano Tools 1:500 Slim fast 5% -
p62 N-terminus mouse 610497 BD Bioscience 1:200 Slim fast 5% -
LAMP2 polyclonal rabbit 5571 Santa Cruz 1:200 Slim fast 5% -
LAMP2A polyclonal rabbit AB12528 Abcam 1:1000 Slim fast 5% 1:500
beclin-1 N-terminus mouse 48341 Santa Cruz 1:500 Slim fast 5% -
beclin-1 polyclonal rabbit NB500-249 Novus 1:1000 Slim fast 5% -
gamma-tubulin mab GTU-88 mouse T6557 Sigma 1:200 Slim fast 5% 1:100
ubiquitin polyclonal rabbit Z0458 dako 1:1000 Slim fast 5% 1:500
ubiquitin mab ubi-1 mouse MAB1510 milipore 1:1000 Slim fast 5% -
K63 ubiquitin mab D7011 rabbit 5621 Cell Signaling 1:1000 Slim fast 5% 1:500
K48 ubiquitin mab D9D5 rabbit 8081 Cell Signaling 1:1000 Slim fast 5% 1:500
TH polyclonal rabbit 657012 Milipore 1:1000 Slim fast 5% -
DAT mab DAT-nt rat MAB369 Milipore 1:1000 Slim fast 5% -
GFAP polyclonal rabbit Z0334 Dako - Slim fast 5% 1:200
IBA1 polyclonal rabbit 019-19741 Wako - Slim fast 5% 1:100
phospho Ser129 alpha synuclein Ser129 mouse 014-20281 Wako 1:200 BSA 5% -
phospho Ser129 alpha synuclein Ser129 rabbit AB51253 Abcam 1:500 BSA 5% -
phospho Ser129 alpha synuclein Ser129 rabbit 2014-1 Epitomics 1:500 BSA 5% -
oligomer A11 polyclonal rabbit AHB0052 Invitrogen 1:500 Slim fast 5% -
oligomer Fila1 polyclonal rabbit From Pr. Jensen 1:100 Slim fast 5% -
1.10  AGERA
To  analyze  high  molecular  weight  ubiquitinated  proteins  and  a-syn  species,  SDS-PAGE
cannot be used as proteins do not migrate in the resolving acrylamide and stay blocked in the
stacking  gel  because  of  their  elevated  molecular  weight.  Therefore,  we  performed
electrophoresis in agarose gel as described previously (Weiss et al. 2008).
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Hindbrain and forebrain of mice were homogenized into 10 volumes of Tris-buffered saline
(0.1 M Tris, 0.15 M NaCl, pH 7.4) completed with protease inhibitor (complete; Roche) using a
1 ml  cylinder  dounce  homogenizer  (8530742;  Sartorius,  Goettingen,  Germany)  and
40 suspensions on ice. Samples were aliquoted and kept at -80°C.
75 ml  agarose  gels  were  prepared  by  dissolving  1.5 g  of  agarose  (161-3101;  Biorad)  in
Tris-buffered saline (0.375 M Tris-HCl, pH 8.8) and SDS was added after agarose dissolution
to a final concentration of 0.1%. Samples were heat denatured for 5 min at 95°C into 1:1 non-
reducing Laemmli sample buffer (0.15 M Tris-HCl, 33% glycerol, 1.2% SDS and bromophenol
blue, pH 6.8).
After loading, gels were run in running buffer (192 mM glycine, 25 mM Tris-base, 0.1% SDS)
at 100 V, and blotted on PDVF membranes (Immobilon-P; Millipore, Zug, Switzerland) at 80 V
for 2 h in transfer buffer (192 mM glycine, 25 mM Tris-base, 0.1% SDS, 15% methanol). After
transfer, immunoblots were detected exactly like in the western blot section.
1.11  Dot blot
Dot  blots  were  used to  make semi-quantitative  analysis  of  a-syn oligomers as  described
previously  (Colla et al.  2012). Nitrocellulose membranes (Optitran; Millipore) were washed
first  with 100 μl of  deionized water under vacuum. 10 µg of protein samples extracted for
AGERA analysis were diluted in 50 μl of TBS (10 mM Tris, 0.15 M NaCl, pH 7.5), spot on the
nitrocellulose membrane under vacuum and washed once using 100 μl of TBS.
Immunoblots were detected exactly like in the western blot section. Total amount of protein
was estimated by staining membranes with amido black staining solution (0.1% amido black,
25% isopropanol, 10% acetic acid) for 5 min and washed twice 5 min with water.
1.12  Proteasome activity measurement
To  measure  enzymatic  activity  of  the  proteasome,  substrates  specific  for  different  20S
protease activities were used (described in Fig. 2-03). Mouse brain tissue was prepared and
directly (without being frozen) homogenized in 10 volume of hypotonic buffer (10 mM Tris,
5 mM MgCl2, 5 mM ATP, pH 7.0) using dounce homogenizer and ultrasonicated (Sonopuls;
Bandelin,  Berlin,  Germany)  at  40%  power  for  30 pulses  of  0.5 second  each  (waiting
0.5 second between pulses) to reduce sample viscosity. For storage at -80°C, 10% of glycerol
was added to lysate.
Proteasomal activity (Proteasome-Glo 3-Substrate Assay System; Promega, Madison, USA)
was measured in 25 µl of detection reagent containing luciferin detection reagent and specific
substrate  for  chymotrypsin-,  trypsin-  or  caspaselike  activity  of  the  proteasome.  Detection
reagent was incubated for 30 min at room temperature before the measurement to reduce
free aminoluciferin and reduce background luminescence.
Proteasomal  activity was monitored for  15 µg proteins diluted in 25 µl  hypotonic  buffer in
presence or absence of 10 µM of the proteasome inhibitor lactacystin (bml-PI104-0200; Enzo
Life Sciences, Lörrach, Germany) in 96 well plate (735-0199; VWR) using microplate reader
(Synergy HT; Bio-Tek, Winooski, USA) for 1 h at room temperature.
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Figure 2-03: Bioluminescent measurement 
of proteasome activities
Figure copied from (Moravec et al. 2009)
Cleavage of the substrate by the proteasome leads to the release
of aminoluciferin serving as the substrate for firefly luciferase. The
light  produced  as  a  result  of  the  luciferase  reaction  is  then
detected using a plate reader.
1.13  Preparation of tissue for histological analysis
Mice were deeply anesthetized by CO2 inhalation and transcardially perfused using a pump
first with room temperature PBS (10 mM phosphate, 150 mM NaCl, pH 7.4) until most of the
blood  is  flushed,  and  then  using  cold  4% paraformaldehyde  (PFA)  in  PBS.  Brains  were
removed carefully from the skull  and post-fixed 24 h in  4% PFA, alcohol-dehydrated and
embedded  in  paraffin (Table 2-04)  using  a  tissue  processor  (TP1020;  Leica  Instruments,
Nussloch,  Germany). Samples were embedded in paraffin blocks using a tissue embedding
station (EG1160; Leica) and stored at room temperature. Paraffin blocks containing brains
were cool on ice block and cut in  7 μm thick sections using a microtome (RM2155; Leica).
Section were placed in 45 °C water bath (Hl1210; Leica) for flattering, collected on a glass
slide (SuperFrost; R. Langenbrinck, Emmendingen, Germany), dried in an incubator at 50 °C
for 1 h (Bachoffer, Reutlingen Germany) and stored at room temperature.
Table 2-04: Brain fixation
Buffer Time
70% ethanol 4 h
96% ethanol 10 h
96% ethanol 14 h
100% ethanol 5 h
100% ethanol 5 h
100% ethanol 6 h
xylene 5 h
xylene 5 h
xylene 6 h
paraffin 2 h
paraffin 2 h
paraffin 4 h
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Table 2-05: Section dewaxing and dehydration
Dewaxing Buffer Time Dehydration Buffer Time
xylene 5 min 70% ethanol 5 min
xylene 5 min 80% ethanol 5 min
xylene 5 min 96% ethanol 5 min
100% ethanol 5 min 100% ethanol 5 min
100% ethanol 5 min 100% ethanol 5 min
96% ethanol 5 min xylene 8 min
96% ethanol 5 min xylene 8 min
80% ethanol 5 min xylene 8 min
70% ethanol 5 min
50% ethanol 5 min
30% ethanol 5 min
PBS
1.14  Immunohistochemistry
Sections  were  deparaffinized  in  xylene  and  rehydrated  in  decreasing  ethanol  series
(Table 2-05) using an automatic slide stainer (Autostainer XL; Leica). Heat antigen retrieval
was performed for 15 min using a microwave set at 1000 W and using 10 mM sodium citrate
(pH 6.0) and sodium citrate was refilled every 5 min to avoid the slides to dry. Sections were
then washed 3 times 3 min in PBS and incubated 20 min in 0.3% hydrogen peroxide to block
endogenous peroxidases.
After washing the slides 3 times 3 min in PBS, non-specific binding was blocked for 40 min by
treating sections with 5% normal serum of the secondary antibody host animal (goat serum S-
1000; Vector, Burlingame, USA) (rabbit serum, S-5000; Vector)(donkey serum 017-000-001;
Dianova, Hamburg, Germany) diluted in PBS and supplemented with 0.3% Triton X-100 to
permeabilize cell membranes. After washing the slides 3 times 3 min with PBS, sections were
incubated overnight with the primary antibody diluted in PBS containing 1% normal serum.
The next day, slides were washed 3 times 3 min with PBS Brij (0.005%) and incubated for 1 h
with a biotin conjugated secondary antibody (mouse: BA-9200, rabbit: BA-1000, rat: BA-4000;
Vector) diluted 1:250 in PBS containing 1% normal serum.
Sections were washed 3 times 3 min with PBS Brij and then incubated with an avidin-biotin
enhancer complex coupled with peroxidase (ABC Elite; Vector) at room temperature for 1 h.
After  washing  3 times  3 min  with  PBS  Brij,  sections  were  detected  using  3,3′-
diaminobenzidine  (DAB;  Sigma)  providing  a  brown  precipitate  when  oxidized  by  the
peroxidase linked to the secondary antibody.  Reaction was stopped by washing slides in
distilled water after 5–15 min. Slides were counterstained with hematoxylin (1.09249.0500;
Merck, Darmstadt, Germany), washed 3 times 1 min in 70% ethanol containing 1% HCl and
immediately dehydrated in increasing ethanol series (Table 2-06) using an automatic slide
stainer. For microscopy, slides were mounted using a coverslipping media (CV mount; Leica),
dried overnight, and stored at room temperature.
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Similarly,  double  immunofluorescence  staining  of  paraffin  embedded  sections  was  also
performed  using  heat  antigen  retrieval,  but  without  endogenous  peroxidase  inhibition.
Sections were blocked for 40 min in 10% normal serum diluted in TBS and supplemented with
0.3% Triton X-100. After washing 3 times 3 min with TBS, sections were double stained using
two primary antibodies pooled together in TBS supplemented with 0.3% Triton X-100 and 1%
normal serum for 2 h at room temperature. After washing the slides 3 times 5 min with TBS,
slides were incubated for 1 h with the secondary antibodies (Table 2-06) pooled together and
diluted 1:250 in TBS supplemented with 0.3% Triton X-100 and 1% normal serum at room
temperature  in  dark.  After  washing  3 times  5 min,  cell  nuclei  were  stained  by incubating
sections 5 min with  1 µg/ml DAPI (D1306; Invitrogen) solved in TBS and washed 2 times
3 min  in  TBS.  Sections  were  cover  slipped  with  an  aqueous  mounting  medium (Mowiol;
Merck,  Darmstadt,  Germany)  supplemented  with  25 mg/ml  of  the  antifade  1,4-
diazabicyclo[2.2.2]octane (DABCO, D27802; Sigma-Aldrich).  Slides were stored in dark at
4°C and investigated within 2 weeks.
Staining  was  visualized  using  a  microscope  (Axioplan 2;  Carl  Zeiss  Microimaging,
Oberkochen, Germany) equipped with a color camera (Axio-Cam MRc; Zeiss) and imaging
software package (AxioVision 4.6; Zeiss). To visualize fluorescence stainings, a fluorescence
lamp was used with suitable filter sets and a monochrome camera (Axio-Cam MR; Zeiss) was
preferred to the color camera.
Table 2-06: Secondary antibodies and staining conditions
Dye Specificity Host specie Reference Company
Alexafluor 488 mouse donkey 715-545-150 Dianova
Alexafluor 488 rabbit donkey 711-545-152 Dianova
Alexafluor 595 mouse donkey 715-585-150 Dianova
Alexafluor 595 rabbit donkey 711-585-152 Dianova
Alexafluor 595 rat donkey 712-585-150 Dianova
1.15  Proteinase K digestion on nitrocellulose membrane
Aggregate load location was investigated by using proteinase K digestion of paraffin sections
blotted on nitrocellulose membranes as described previously (Neumann et al. 2002). Paraffin
embedded tissues were cut using a microtome and 5 μm thick sections were placed in 55 °C
water bath and collected on a wet 0.45 μm nitrocellulose membrane (162-0116; Bio-Rad), and
dried for at least 8 h at 55 °C. Blotted sections were stored at room temperature.
Sections on nitrocellulose membrane were deparaffinized with xylene and rehydrated using a
descending  ethanol  series  (Table 2-06).  Membranes  were  washed  with  TBST  (10 mM
Tris-HCl, 100 mM NaCl; 0.05% Tween-20, pH 7.8), and digestion of sections was performed
with 50 μg/ml proteinase K (P-6556; Sigma) in TBSB (10 mM Tris-HCl, 100 mM NaCl, 0.1%
Brij-35, pH 7.8) for 12 h at 55°C.
After three washing steps using TBST, proteins blotted on sections on the membranes were
denatured to allow a better access to epitopes to antibodies for 10 min (10 mM Tris-HCl, 3 M
guanidine isothiocyanate, pH 7.8).  Aspecific antibody bindings to membrane were blocked
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using  0.2%  casein  in  TBST for  30  min.  Sections  were  immunostained  for  8 h  with  the
monoclonal 15G7 anti-a-syn antibody diluted 1:50 at 4 °C. After three washes in TBST, signal
was  enhanced  using  a  bridging  rabbit  anti-rat  antibody  diluted  1:500  incubated  1 h  on
membranes at room temperature and were incubated 1 h with alkaline phosphatase coupled
to  a  goat  anti-rabbit  antibody  (DO487,  DAKO).  After  five  washes  of  10 min  in  TBST,
membranes were adjusted to alkaline pH using two incubations of 5 min in NTM (100 mM
Tris-HCl,  100 mM NaCl;  50 mM MgCl2,  pH 9.5).  Detection  of  the  antibody staining  was
performed using a mixture of formazan and nitrotetrazolium blue/5-bromo-4-chloro-3-indolyl
phosphate p-toluidine salt. Membranes were dried overnight at room temperature and stored
at room temperature.
1.16  Proteinase K digestions on glass slide
Aggregate load location was also investigated by using proteinase K digestion of  paraffin
sections on slides as described previously (Tanji et al. 2010). Sections were deparaffinized in
xylene, rehydrated in a descending ethanol series (Table 2-06) and  washed twice in PBS.
Sections  were  digested  with  50 μg/ml  proteinase K  (P-6556;  Sigma)  in  TBSB  (10 mM
Tris-HCl, 100 mM NaCl; 0.1% Brij-35, pH 7.8) for 30 min at 55 °C and reaction was stopped
by washing slides in PBS. Immunohistochemical staining was then performed as described in
paragraph 1.14.
1.17  Immunohistological quantification of stained cells and neurites
To  avoid  bias  during  the  quantification,  animal  section  genotypes  were  coded  prior  the
analysis. Brain regions of interest were mapped using an overlapping process represented in
Fig. 2-04.  To  avoid  over- or  under- represented  regions,  pictures  were  taken  using  10×
objective only adjusting mapping pattern and focus. The mean of 8 fields was investigated on
4 to 8 sections per animal. Pictures were saved as high quality color TIFF files and were
analyzed using ImageJ (NIH). To increase the reproducibility of the counting, a predetermined
threshold  (triangle  autothreshold)  was  establish  on  a  positive  control  section  using
absorbance for DAB staining (or fluorescence intensity) to highlight the signal.
For  most  simple  and  clear  stainings,  such  as  proteinase K  digestion  followed  by  a-syn
staining, a small batch based on size and circularity of signal was used to count automatically
the  number  of  cells  and  processings.  Results  were  manually  confirmed  on  a  subset  of
pictures (around 10% of the complete set). For more complex stainings, such as thioflavin S,
original pictures were overlaid with the calculated threshold to determine number of stained
cells. For glial cell staining, only cells with more than three clear process were counted.
Figure 2-04: Representation of brain 
region mapping
Picture of mouse brain using macroscope. An example of
brainstem  mapping  is  represented  by  black  rectangles
numbered from the most caudal and ventral regions to the
most cranial and dorsal regions. In our study, the mean of 8
fields was investigated on 4 to 8 sections per animal. 
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2)  Animal housing
Mice were housed in a group of maximum five animals per cage on a 12:12 hours light:dark
cycle.  Cages  used  for  the  housing  [Eurostandard  Type II  L  cage;  365 × 207 × 140 mm;
(1284L,  Tecniplast,  Italy)]  were  autoclaved  and  bedding  was  added  prior  to  use.  Mice
received ad libitum access to water and to chow.
2.1  Animal marking
In order to identify animals within the same cage ear punch marking was applied to 6 weeks
old mice and biopsies were collected to investigate animal genotypes. Prior each marking,
preparation tools (ear-punch tools and tweezers) were cleaned with 70% propanol, rinse with
distilled  water,  and  dried  before  the  procedure  to  avoid  infection  or  biopsy  cross
contamination. Individual mice were selected randomly and exposed for a short time (less
than 1 min) to isoflurane (Forene, Abbott, Abbott Park) into an induction chamber to render
them unconscious. Ear punching was performed using ear-punch tool to provide a unique
number  and  biopsies  were  collected  in  1.5 ml  microcentrifuge  tubes  (Safe-Lock  Tubes,
Eppendorf).  Mice  were  returned  to  their  home-cage  and  observed  till  the  end  of  the
anesthesia.
2.2  Mouse genetic background
To  reduce  possible  effect  of  genetic  background  on  gene  expression  [ i.e. (Coleman  &
Hummel 1973; Carlson et al. 1997)], all mice were cross-breed to the same inbreed stain
C57BL/6NCrl mice (designated as nTg, reference strain: 027, Charles River, USA).
2.3  Mouse breeding
To provide an experimental group within the same age range, females were mated in the
same cage couple at least  4 weeks prior starting to  breed mice to  synchronize hormone
cycles  (Whitten  Effect  (WHITTEN  1957)).  For  optimal  breeding  setup  and  to  avoid
overpopulation, one male and two females at sexual maturity (between 2 and 6 months) were
chosen according to their genotype. To increase breeding performances, mice were housed in
the male cage 1 h before the end of the light phase. The next day, a plug-check examination
was  performed  on  females.  To  avoid  cannibalism,  females  were  isolated  as  soon  as
pregnancy was detected  (Lane-Petter 1968). Females that were not positive for a plug for
3 consecutive days were separated from the breeding cage. Pups were weaned at 21 days
and were marked by ear biopsy as described previously.
2.4  Validation of animal health before behavioral analysis using 
SHIRPA procedure
In order to assess the general health of animals, a short battery of tests was perform to detect
any potential behavioral or neurological abnormalities (Rogers et al. 1997). Mice were placed
in a clean transparent plastic tube (20 cm diameter × 20 cm length) and observed. Activity, as
well  as  abnormal  behavior  like  tremors  or  convulsions,  was  assessed.  Inside  the  tube,
palpebral closure (animal able to close their eyelid), coat appearance (presence of any fur
scratch or biting),  whiskers appearance (regularity of  the hairs),  defecation,  urination and
presence of abnormal lacrimation were recorded. Reflexes were observed by rolling slowly
the mouse in the investigation plastic tube.
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Mice were then transfer to a metal grid and reactions of the mice to the new environment
were  examined  (duration  of  freezing  behavior).  Fluidity  of  movements  was  observed
(elevation of the pelvis during walking process, position of the tail). To observe reaction to the
noise, mice were exposed to a timer alarm located around 30 cm above the arena; stimulation
of escape behavior was performed by approaching finger from their nose.
When holding animals by their tail, handling behavior and grasping of front- or hind- limbs was
observed. The handling behavior was also studied by holding animals by the neck, allowing
the investigation of plantar and digit surface. Vocalization and aggressiveness was recorded.
3)  Phenotyping of double-transgenic mice
3.1  Behavioral tests
To avoid bias induced by repeated behavioral experiments in a short interval of time (McIlwain
et al. 2001), the order of the behavioral tests was determined in regard of stress induced to
the animals and a break of at  least 48 h was applied between two different experiments.
Experimenter  was  blind  to  mouse  genotype  during  the  behavioral  testing  to  reduce
experimenter expectancy effects. Before each experiment, mice were acclimatized for at least
15 min to the experimental room. Experimental group of animals was composed originally of
12 mice.
3.2  Weight investigation
In order to follow the weight gain in every line, mice routinely put in behavioral tests were
weighted every 6 weeks. This procedure was performed at the end of the light phase before
any behavioral test.
3.3  Motor function evaluation
3.3.1  Motor skill learning and motor coordination assessment using rotarod
Motor  skill  learning and motor  coordination were measured using rotarod [represented in
Fig. 2-05 (RotaRod Advanced, TSE Systems, Bad Homburg, Germany)]. The rotarod consists
of  an  elevated  rotating  cylinder  with  rotation  speed  programmable  by  the  user  (speed
expressed in revolutions per min (RPM)).
Mice were placed on the rotating rod and latency to fall was recorded. To optimize rotarod
outcome, experiment was performed during dark phase (Hossain et al. 2004) and mice were
trained in the apparatus before starting the motor skill performance. During the first training
day,  animals get  used to  the system by being placed 3 trials  at  low and constant  speed
(4 RPM for 5 min, 10 RPM for 5 min and 20 RPM for 5 min). A second training was made to
familiarized mice to higher speed and acceleration (10 RPM for 5 min, 20 RPM for 5 min and
4-40 RPM for 7 min).
During training, animals were placed back on the rotating cylinder after falling. To limit stress,
mice were brought back on the rod 5 times maximum. Test was repeated for 3 consecutive
days and latency to fall from the rod was measured 4 times per day at constant acceleration
(4-40 RPM in 7 min).
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Mice  falling  accidentally  before  the  first  30 sec  were  put  back  on  the  rod.  An  inter-trial
recovery time of at least 1 h was allowed between trials. Assessment of motor ability was first
measured in 4 month-old mice and repeated every 6 weeks over a 12 months period.
Motor coordination was investigated by evaluating the progression of latency to fall over using
the average of the 16 trials per time point and using two-way ANOVA. Motor skill learning was
analyzed by evaluating the progression of latency to fall over the 4 days of testing within an
age point using the average of all trials per day and using two-way ANOVA.
Figure 2-05: Rotarod
Picture copied from TSE System GmbH commercial  
brochure: RotaRod Advanced 2013
Apparatus  consists  of  a  rotating  grooved  drum  to  
provide animals an optimal grip. Panels divide the drum
into separate lane each suited for an individual animal.
3.3.2  Motor coordination assessment using challenging beam traversal
To gain more insight on motor coordination and fine movement alterations, mice were tested
in challenging beam walk as described previously (Goldberg et al. 2003; Fleming et al. 2006).
Mice  were  trained  for  two  days  to  traverse  a  beam  without  stopping.  The  beam  was
constituted of a transparent thermoplastic beam consisting of 4 sections (25 cm each, 1 m
total  length)  of  different  width  (3.5 cm to  0.5 cm by 1 cm increments)  and leading to  the
animals’ home-cage. 
For the experimental  day, a mesh grid of 1 cm squares was placed 1 cm over the beam
surface and time to traverse the beam was measured three times.
4, 12, and 18 month-old mice were tested, behavioral test was performed during the dark
phase and the mean of the three trials was analyzed using one-way ANOVA.
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3.3.3  Automatized gait analysis using CatWalk
To assess motor functions and coordination in voluntarily walking mice, gait analysis were
performed (Fig. 2-06A and B) using an automatic system (CatWalk, Noldus, Wageningen, The
Netherlands). 18 month-old animals were trained to cross the runway without any interruption.
Five  runs  with  a  speed  variation  below  30% and  without  any  abnormal  walking  pattern
resulting of exploration (climbing walls) or abnormal print (prints distorted because of a dirty
glass plate) were analyzed. From these data, multiple parameters were calculated via the
CatWalk software as intensity of the paw contact, print area, stand (duration of paw contact
with the glass plate in a step cycle), swing (duration of no contact with the glass plate in a
step cycle), swing speed (speed of the paw during swing), stride length (the distance between
successive placements of the same paw), number of steps to cover walk way distance and
locomotor speed.
Data were explored using a R script (R Development Core Team 2008) calculating the mean
of 3 to 5 runs per animals and analyzed using one-way ANOVA.
Figure 2-06: CatWalk
Picture copied from CatWalk user manually
CatWalk consists of a horizontal glass runway illuminated by LED light and reflecting footprints captured by a
high-speed  video  camera  positioned  underneath  the  walkway.  Because  an  increasing  luminosity  in  the
experimental room decreases the contrast of the illuminated footprint, experiment was performed during dark
phase and under indirect red light illumination.
3.3.4  Spontaneous home-cage activity assessment using LabMaster/PhenoMaster
Spontaneous  activity  in  home-cage  environment  of  4,  12  and  18 month-old  mice  was
assessed using an automatic system allowing the tracking of single-housed mice represented
in Fig. 2-07 (LabMaster/PhenoMaster, TSE). LabMaster/PhenoMaster is a system consisting
of  infrared  beams  surrounding  a  home-cage,  recording  ambulation  of  mice  using  beam
breaks. Mice were acclimatized to the experimental room for at least 30 min before being
transferred in the automatic system and recorded for three consecutive days. Data analysis
was performed by calculating the mean of a parameter of interest for a fixed time interval
using a R script (script in annex).
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Novelty exploration was defined as the activity during the first 15 min of experiment. Total
spontaneous activity (during complete dark or light phase) was assessed by binning data by
interval of 30 minutes. Acclimatization to the system was investigated by comparing the mean
of a parameter of interest over successive dark or light periods separately.
These data sets were analyzed using two-way ANOVA. Food and water intake was assessed
by comparing the total amount of food or of water consumed by animal over three days and
analyzed using one-way ANOVA.
Figure 2-07: Automated cages 
LabMaster/PhenoMaster is a system for single housed 
mice consisting of infrared beam surrounding a home 
cage, recording ambulation of mice  using  beam  
breaks.
3.3.5  Exploratory and anxiety behavior assessment using open field
Exploratory and emotional behavior was tested in open field test (represented in Fig. 2-08) in
4, 12, and 18 month-old mice. Mice were placed in a 100 × 100 cm arena with 50 cm high
walls and activity was recorded for 10 min using video tracking software (VideoMot2, TSE). 
Figure 2-08: Open field
Screen shot of tracking system before the beginning of 
an experiment. Center of the field was determined in 4 
concentric squares of 100, 60, 40 and 20 cm in order to
test robustness of data.
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Light intensity in the center of the arena was set at l000 lux. Open field was separated in
four area: the region 1 is the rim with  a width of  8 cm; region 2, 3,  and 4 are square of
respectively 60, 40, and 25 cm side length and representing 36, 16, and 6% of the overall
area respectively.
Mice were  acclimatized in  a  separated room with  a luminosity fixed at  25 lux for  15 min
minimum prior the analysis. Mice were put in a corner of the open field pseudo-randomly
chosen. Total distance, distance and time spend in each areas as well as the latency to reach
each regions were analyzed using one-way ANOVA.
3.4  Smell test assessment using olfactory preference test
Olfactory preference tests (represented in Fig. 2-09) were conducted in 18 month-old mice to
investigate potential olfactory perception deficit in mice. Mice were put into a rat type IV cage
(595 × 380 × 200 mm box) that was separated into two equal compartments. The separating
wall had a 6 × 10 cm opening that the mouse could move from one compartment to the other. 
Experiment was performed during dark cycle under low light (animals kept at 25 lux, field at
50 lux) and video tracked (VideoMot2, TSE). Before the test, mice were acclimatized at least
30 min to the experimental room.
In a first experiment, one compartment of the cage was filled with 1–2 cm of clean bedding
using a dustpan, and the other compartment was filled with 2–3 cm of 2 days old home-cage
bedding. Mice were monitored for 10 min and bring back into their home-cage.
After testing all animals of the same home-cage, we added in the compartments containing
the clean bedding of the system 1–2 cm of two days old rat bedding. Mice were introduced in
the rat bedding and tracked for 10 min. Latency to leave the compartment as well as distance
and time spent in each compartment were analyzed using one way ANOVA.
Figure 2-09: Smell test
Screen shot of video tracking system before  
smell  test.  Type IV cage was  separated into  
two  equal  compartments  by  a  plastic  wall  
containing a 6 × 10 cm opening to separated  
mouse home-cage bedding (here region on the
bottom 1) from the experimental region (here  
bedding from rat cage on the top 2).
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3.5  Cognitive function assessment using water maze
To identify any potential  cognitive deficits, we used the Morris water maze experiment as
described previously (Freichel et al. 2007). A 2 m diameter and 50 cm high water-tank filled
with opaque white water (21 °C  ± 1 °C) was placed in a room containing extra maze cues
(Fig. 2-10). Light intensity in water maze was set at l00 lux and mice were acclimatized to the
same  room.  Mouse  swim  paths  were  monitored  with  a  camera  connected  to  the  video
tracking  software  (VideoMot2,  TSE).  Animals  were  introduce  into  a  closed  water  tank
compartment  of  the  water  maze  in  a  pseudo-randomly  order.  Before  opening  the
compartment and beginning the test, mice were acclimatized to the water for around 5 sec.
The maximum trial duration was fixed at 60 sec. At the end of each trial, mice were standing
on the platform for 30 sec (or were put on it if they did not found it). An inter-trial interval of
10 min was observed. Mice removed from the water were dried using paper towels and were
warmed up in a cage illuminated by a red heat lamp for 5 minutes before putting them back
on their home-cage.
Mice were first trained to find a 20 cm in diameter visible platform to escape from the water for
2 days and 4 trials per day. Spatial learning curve was calculated using latency or distance
needed to find the platform and was analyzed using two-way ANOVA.
After the training, mice were tested for 2 days and 4 trials per day to find the same platform,
located at the same place but hidden under the water. Spatial testing  curve was calculated
using  latency  or  distance  needed  to  find  the  platform  and  was  analyzed  using  two-way
ANOVA.
The last day, mice were placed in the pool in the water tank compartment in front of the
platform. Platform was removed and mice strategy to find the platform was tracked for 60 sec.
Spatial  memory  was  investigated  by  calculating  the  percentage  of  time  spent  in  each
quadrant and by comparing the time spend in the quadrant containing previously the platform
compared to the other using one-way ANOVA.
Figure 2-10: water maze
Screen shot of video tracking system during the cued
test.  Black platform and flag where used in order to
facilitate spatial learning. Moreover, cued inside both
the experimental room and the water tank were used
to improve the spatial learning.
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Results
The aim of this work is to investigate the potential effect(s) of the human synphilin-1 (sph1) on
the progression of neuropathology in a mouse model of Parkinson's disease (PD). For this
purpose, we cross-bred transgenic sph1 mice with  mice overexpressing the human A30P
mutated alpha-synuclein (a-syn) under the neuron specific promoter Thy-1 and presenting a
progressive synucleinopathy extensively characterized (Kahle et al. 2000; Kahle et al. 2001;
Neumann et al. 2002; Freichel et al. 2007; Schell et al. 2009).
1)  Generation of the double transgenic animals
Double transgenic mice (designated as  double) resulting from cross-breeding homozygous
mice expressing the human A30P mutated a-syn (A30P) with mice expressing the human
sph1 (sph1) were viable,  fertile,  normal in size and did not display any gross physical or
behavioral abnormalities. To generate a homogeneous group of double transgenic mice, we
cross-bred homozygous A30P mice, sph1 mice, double-transgenic mice and non-transgenic
(nTg) mice with C57BL/6N littermates.
Mice were genotyped using genomic DNA isolated from ear biopsies and presence of the
transgene was investigated using PCR (Fig. 3-01).
Figure 3-01: Animals genotyping
Animal genotype was determined using PCR from genomic DNA. Specific primer pairs for either a-syn or sph1
transgenes generated amplicons migrating at 400 and 800 base pairs (bp) respectively using electrophoresis of
PCR products in 1% agarose gel containing 0.5 μg/ml ethidium bromide.
Zygosity  was  confirmed  via  quantitative  real-time  PCR  (Fig. 3-02A)  and  amplification
specificity was investigated using. We did not observe more than one main melting peak per
primer pair (Fig. 3-02B), suggesting the presence of a unique amplicon.
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Figure 3-02: Transgenes zygosity
A) Zygosity of  the animals was determined using SYBR Green based relative quantitative PCR of  20 μg of
genomic  DNA;  data  presented  as  the  mean  of  relative  transgene  copy  number  calculated  via  the  ΔΔCp
method ± SEM; number of technical replicates=3. B) Specificity of the amplification was analyzed using melting
peak method.
|92|
| Results
2)  Neuropathology in mice overexpressing A30P alpha-synuclein
2.1  Alpha-synuclein expression throughout brain of A30P mice
In order to investigate the potential effect(s) of sph1 on synucleinopathy developed in A30P
mice, we first confirmed the expression of the transgenic human A30P mutated a-syn protein
under  the  Thy-1  promoter  in  12 month-old  mice.  Immunohistochemical  analysis  of  the
transgenic a-syn expression in A30P mouse brain was performed using an antibody specific
for the human a-syn and providing no signal in nTg mice (Fig. 3-03A). Expression was found
throughout the brain and spinal cord of transgenic mice (Fig. 3-03A). Intracellular distribution
of a-syn was investigated at higher magnification and the location of a-syn was found to be in
cell soma and neurites (Fig. 3-03B), reflecting a synaptic staining as suggested previously
(Kahle et al. 2000).
Figure 3-03: Expression of the human A30P alpha-synuclein in different brain 
regions of A30P mice
A) Expression  of  the  transgenic  human  A30P mutated  a-syn  on  7 μm thick  sagittal  mouse  brain  sections
embedded in paraffin. Sections were immunostained using a human specific a-syn antibody and counterstained
using hematoxylin. The transgene expression was detected throughout the brain of transgenic mice, including
the spinal cord, brainstem, cerebellum, cortex, midbrain and olfactory bulb, but no signal was detected in nTg
mice. B) Using higher magnification, presence of staining in cell soma (black arrow), neurites (black arrowhead)
or generally neuropils (thick black arrow) were observed in the brainstem. Expression pattern was confirmed in
at least two different animals; scale bar = 20 μm.
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2.2  Progressive accumulation of proteinase K resistant a-syn in the 
brainstem of A30P mice
Presence and accumulation of a-syn aggregation was investigated in A30P mice using an
assay based on protease digestion  resistance.  We used proteinase K,  a  serine  protease
digesting  native  proteins,  to  investigate  compactness and  insolubility  of  a-syn,  classically
used to highlight presence of fibrillar structures  (Miake et al.  2002).  For this purpose, we
digested paraffin sections bound to nitrocellulose membranes with proteinase K. As expected,
the signal for a-syn was drastically decreased after digestion (Fig. 3-04A–C). Proteinase K
resistant a-syn was detectable in 16 month-old mice (Fig. 3-04B) but almost undetectable in
A30P mice at 12 months of age (Fig. 3-04C).
Figure 3-04: Distribution of proteinase K resistant alpha-synuclein in brainstem 
of 16 month-old A30P mice
IHC detection of  transgene using  the human a-syn specific  antibody 15G7.  7 μm thick  paraffin  embedded
sections were blotted on nitrocellulose membranes and digested using 50 μg/ml of proteinase K for 12 hours.
A) Strong staining throughout the brain was observed in non-digested sections of A30P mice. B) Proteinase K
resistant a-syn was observed in 16 month-old A30P mice, mainly located in brainstem and in midbrain. C) No
resistant a-syn specific staining was observed in 12 month-old A30P mice.  D) Densitometric quantifications of
a-syn signal in brainstem of A30P mice and nTg control; data presented as the mean ± SEM; n=3; * P<0.05 one-
way ANOVA post-hoc LSD. HB: hindbrain; FB: forebrain; MB: midbrain; BS: brainstem.
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Proteinase K resistant a-syn was located mainly in the brainstem of A30P mice. The increase
of indigestible a-syn in the brainstem of aging A30P mice (nTg: 204.6 ± 76.46, 10 M A30P:
620.9 ± 169.6,  14 M A30P: 699.2 ± 243.5,  16 M A30P: 2301 ± 169.8,  one way ANOVA,
p<0.001, Fig. 3-04D) has already been reported previously (Kahle et al. 2000; Neumann et al.
2002; Freichel et al. 2007).
2.3  Accumulation of SDS-insoluble a-syn in A30P mice hindbrain with
aging 
To confirm the increase of insoluble a-syn levels observed in hindbrain of A30P mice with
aging using proteinase K digestion protocol, we extracted proteins based on their solubility in
increasing amount of detergents and measured a-syn protein levels using sequential protein
extraction.
High concentrations of detergents are of high interest to study protein aggregation as they
break non-covalent protein bonds, in contrast to proteinase which cuts proteins into smaller
units without cleaving peptide bonds, providing information regarding the stability of different
protein filaments. Increase of RIPA insoluble a-syn was previously reported in brains of PD
patients (Tofaris et al. 2003), in brain of a patient carrying the a-syn A30P mutation leading to
familial form of PD (Seidel et al. 2010), and also in brains of mice overexpressing A30P a-syn
(Kahle et al. 2001).
As the protein extraction protocol is based on several centrifugation and suspension steps,
pellets that need to be suspended become smaller and more difficult to handle. Therefore,
despite  the  fact  that  brainstem  was  the  region  most  strongly  stained  in  proteinase K
resistance analysis, we choose to work with the complete hindbrain of 18 month-old mice
which also contain the brainstem and which provide two to three time more material that the
brainstem region alone. 
We studied the RIPA insoluble fraction using western blot and detected immunoblot using the
human specific a-syn antibody 15G7 which provided a specific signal at around 17 kDa (nTg:
0.165 ± 0.144, A30P 12 M: 15.03 ± 7.02, A30P 14 M: 16.98 ± 5.14, A30P 16 M: 100 ± 21.99).
These  results  support  the  hypothesis  that  insoluble  a-syn  species  are  also  present  in
12 month-old A30P mice (1way ANOVA, p<0.05).
As suggested by the proteinase K digestion results, insoluble a-syn signal increase drastically
at  16 months  (1way  ANOVA,  p<0.001,  Fig. 3-05A and  B).  This  is  also  reflected  by  the
presence  of  smaller  and  higher  molecular  weight  species  of  a-syn.  When  detecting
immunoblot using mc42 antibody, specific for human and mouse a-syn, we did not observe
RIPA insoluble signal in nTg mice (nTg: 0.57 ± 0.180, A30P 12 M: 10.65 ± 6.92, A30P 14 M:
15.37 ± 6.90, A30P 16 M: 100 ± 21.73), but we confirmed the presence of insoluble a-syn in
12 month-old A30P (1way ANOVA, p<0.05) and an increase of insoluble a-syn in A30P mice
with aging (1way ANOVA, p<0.001, Fig. 3-05B and C).
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Figure 3-05: Presence of RIPA insoluble alpha-synuclein species in hindbrain of
A30P mice
Insoluble proteins were extracted from mouse hindbrain using a protocol based on detergent solubility. Levels of
RIPA insoluble a-syn solubilized in 2 M urea were analyzed using western blot of 30 μg protein.  A) Using an
antibody specific for human and mouse a-syn, we observed a-syn bands at around 15 and 17 kDa in 12 and
14 month-old A30P transgenic mice. In 16 month-old A30P mice, an increasing intensity of the main bands was
detected as well as the appearance of other a-syn species. B) No major differences could be seen when using
an antibody specific for human a-syn.  C and D) Densitometric quantification of a-syn signal using mc42 and
15G7 antibodies respectively; data presented as the mean ± SEM; n=3; * P<0.05, *** P<0.001 one-way ANOVA
post-hoc LSD.
|96|
| Results
3)  Reduction of alpha-synuclein aggregation in A30P mice by the 
coexpression of synphilin-1 in hindbrain of double transgenic mice
As described in the introduction, sph1 was frequently reported to increase a-syn aggregation
in vitro  (Engelender et al. 1999; O’Farrell  et al. 2001) but also  in vivo  (Krenz et al. 2009;
Smith et al. 2010). 
Recently, Wong et al. demonstrated  in vitro that sph1 could act as a tag targeting different
protein aggregates (including a-syn) to degradation via macroautophagy (Wong et al. 2012).
In this section, we analyzed long term effects of sph1 expression on a-syn aggregation by
using several methods specific for different forms of a-syn aggregates.
3.1  Synphilin-1 expression in sph1 mice
Similarly to  the  previous investigation of  a-syn,  we  analyzed brains  of  sph1 mice to  find
regions expressing high levels of sph1 and susceptible to impact the pathology induced by
a-syn overexpression.
Brains  of  transgenic  mice  overexpressing  human  sph1  under  the  PrP  promoter  were
embedded in paraffin and immunostained using an antibody specific for the myc-tag, a flag
inserted  at  the  N-terminus  of  transgenic  human  sph1  (Fig. 3-06A).  We  observed  a
homogeneous staining over the whole brain, with the most predominant expression in the
cerebellum, the cortex and the brainstem.
By using higher magnification, we also noticed the presence of transgenic sph1 in cell soma
and  in  dendrites,  suggesting  its  presence  in  the  neuropil  (Fig. 3-06B).  In general,  the
expression pattern of sph1 in sph1 mice was very similar to expression of a-syn found in the
A30P mice.
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Figure 3-06: Expression of the transgenic human synphilin-1 in different brain 
regions of synphilin-1 mice
A) Expression  of  the  transgenic  human  sph1  was  analyzed  on  7 μm thick  sagittal  mouse  brain  sections
embedded in paraffin. Sections were immunostained using an antibody specific for myc-tag conjugated to the
sph1  transgenic  protein,  and  counterstained  using  hematoxylin.  The  transgene  expression  was  detected
throughout the brain of transgenic mice, including the spinal cord, brainstem, cerebellum, cortex, midbrain and
olfactory  bulb.  B) Using  higher  magnification  of  selected  brain  regions  (highlighted  by  black  rectangles),
presence of staining in cell soma (black arrow), neurites (black arrowhead) or generally neuropils (thick black
arrow) were observed. Expression pattern was confirmed at least in two different animals; scale bar = 20 μm.
3.2  Coexpression of alpha-synuclein and synphilin-1 in several brain 
regions and including brainstem in double transgenic mice
To confirm that brainstem, cerebellum and cortex coexpress a-syn and sph1 in the same
subset of neurons, we performed double immunofluorescence staining of human a-syn and of
human myc-tagged sph1. In brain of double transgenic mice, we detected neurons containing
both sph1 and a-syn transgenic proteins (Fig. 3-07), presenting 1–5 μm round structures in
the perinuclear soma both stained with human specific a-syn and myc-tagged sph1 (Fig. 3-07,
white arrowheads).
|98|
| Results
Figure 3-07: Coexpression of alpha-synuclein and synphilin-1 in double 
transgenic mice
A) Coexpression of the transgenic A30P mutated human a-syn and of the transgenic human sph1 was analyzed
on 7 μm thick sagittal mouse brain sections. Sections were immunostained using fluorescent antibodies specific
for the human a-syn protein and for myc-tag conjugated to the sph1 transgenic protein. Nuclei were stained with
DAPI.  Coexpression  of  both  transgenic  proteins  was  confirmed  in  some  cells  of  double  transgenic  mice.
B) Using higher magnification, presence of perinuclear located 1–5 μm round structures positive for both a-syn
and sph1 transgenes was observed (white arrows). Expression pattern was confirmed in 4 different animals; red:
a-syn, green: sph1, blue: DAPI; scale-bar=20 μm.
These data confirm the expression of both proteins within some cells, but also suggest a
possible interaction of both transgenic proteins in our model. We did not observe any staining
in non-transgenic mice using the human a-syn antibody, and only low level of background
using myc antibody (Fig. 3-07).
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3.3  Decreased levels of soluble alpha-synuclein in brainstem of A30P 
mice coexpressing synphilin-1
Before investigating any potential effect(s) of sph1 on a-syn aggregation, we first analyzed the
effect of sph1 on soluble levels of transgenic a-syn protein. We used western blot analysis of
hindbrain lysed in TBS extraction buffer and ultracentrifuged at 120.000 g to extract most
soluble  proteins  of  the  cytoplasm  (Fig. 3-08).  Consistent  with  previous  observations,  we
detected  an  age-dependent  increase  of  soluble  monomeric  human  (A30P  4 M:
62.72 ± 5.31%; A30P 18 M: 100.00 ± 7.85%) and total a-syn (A30P 4 M: 64.48 ± 9.41%; A30P
18 M: 100.00 ± 12.98%) signals at 17 kDa in brainstem of A30P animals (P<0.05, one way
ANOVA, post-hoc LSD). In contrast, we did not observe a significant accumulation of human
mutant  (double 4 M: 80.69 ± 3.22%; double 18 M: 83.70 ± 8.28%) and total  a-syn (double
4 M:  77.16 ± 3.01%;  double  18 M:  87.23 ± 12.36%)  in  age-matched  double-transgenic
animals (P>0.05, one way ANOVA, post-hoc LSD). Investigation of soluble sph1 in western
blot  using this extraction method provided signal  of  poor quality at  120 kDa, allowing the
confirmation of animal genotype but making a quantitative analysis of sph1 levels impossible
(representative picture in (Fig. 3-08)). These results suggest that another extraction method is
necessary to extract sph1 from brain tissue, probably due of a poor solubility of transgenic
sph1 in sph1 and in double transgenic mice.
Figure 3-08: Synphilin-1 decreased levels of soluble alpha-synuclein protein in 
double transgenic mice
Levels of soluble a-syn were investigated using western blotting. 30 μg of 4 and 18 month-old mouse brain
lysed  in  TBS  and  ultracentrifuged  30 min  at  120 000 g  to  extract  soluble  proteins  were  loaded  per  lane.
A) Immunodetection of a-syn showed increasing levels of soluble a-syn in A30P transgenic animals with aging,
but not in double transgenic animals.  B) Densitometric quantifications of a-syn signal using mc42 and 15G7
antibodies,  respectively,  showed  a  significant  difference  between  4  and  18 month-old  A30P  mice;  data
presented as the mean ± SEM; n=3; * P<0.05 one-way ANOVA post-hoc LSD.
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3.4  Strong reduction of proteinase K resistant alpha-synuclein levels 
in brainstem of A30P mice coexpressing synphilin-1
To  explore  levels  of  a-syn  aggregation  in  mice  coexpressing  sph1,  we  performed
immunohistological staining of human a-syn using 15G7 antibody on 7 μm thin mouse brain
section embedded in  paraffin  and digested with  50 μg/ml  of  proteinase K for  30 min.  For
convenience,  proteinase K  protocol  was  established  a  second  time  on  glass  slides  as
described  in  (Tanji  et  al.  2010) (faster  protocol,  no  need  to  prepare  special  sections  on
nitrocellulose). A strong reduction of a-syn staining was observed after digestion in both A30P
and double transgenic mice (Fig. 3-09). Antibody specific for the human a-syn did not provide
any signal in nTg and sph1 animals. In A30P brain sections digested with the proteinase K we
observed the presence of  cell  soma and neurites completely stained with a-syn antibody
(Fig. 3-09). But surprisingly, the frequency of these observations as well as intensity of the
staining was lower in double transgenic animals when compared to A30P mice (A30P: 3.917
± 0.45, double: 0.617 ± 0.331 stained neurons per field, unpaired t test, p<0.01). These data
indicate that a-syn aggregation observed in A30P mice can be decreased or slowed down by
sph1 coexpression in vivo.
Figure 3-09: Synphilin-1 coexpression decreased proteinase K resistant 
alpha-synuclein levels in brainstem of A30P mice
Levels of proteinase K resistant a-syn were investigated by IHC using a specific antibody against the human
a-syn  15G7  on  7 μm  thick  paraffin  embedded  sections  digested  30 min  with  50 μg/ml  proteinase K.
A) Undigested  sections  of  A30P mice  displayed  a  dense  a-syn  positive  staining  in  larger  neurons  of  the
brainstem (black arrows). Interestingly, this dense staining pattern was almost absent in double transgenic mice.
In digested sections, a relatively strong a-syn staining was present in cell soma (black arrows) and neurites
(black arrowheads) of A30P mice. Less intense and frequent staining was observed in double transgenic mice.
B) Quantifications of a-syn positive cells number using 8 fields of 3 sections per animal; data presented as the
mean ± SEM; n=3; *** P<0.001 when compared to nTg; §§ P<0.01 when compared to A30P; one-way ANOVA
post-hoc LSD.
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3.5  Levels of RIPA insoluble alpha-synuclein are reduced in hindbrain
of A30P mice coexpressing synphilin-1
Histological  investigation of proteinase K resistant  a-syn provided the first  insight that the
aggregation  of  a-syn  to  compact  structures  might  be  decreased  in  A30P  animals
coexpressing sph1. By using sequential protein extraction based on an increase amount of
detergents, we investigated if A30P hemizygous mice also present RIPA insoluble a-syn and if
coexpression  of  sph1  could  decrease  these  a-syn  species  in  double  transgenic  mice.
Therefore, we performed sequential protein extraction of mouse hindbrain and analyzed the
RIPA insoluble fraction resolved in 2 M urea using western blot (Fig. 3-10).
Figure 3-10: Levels of RIPA insoluble a-syn was decreased in A30P mice 
coexpressing synphilin-1
Levels  of  RIPA  insoluble  a-syn  species  were  investigated  in  hindbrain  of  mice.  RIPA  insoluble  proteins
solubilized in 2 M urea were analyzed using Western blot. A) Immunoblot detections using an antibody specific
for the human and mouse a-syn (mc42) showed large increase of insoluble a-syn signals at 17 kDa in A30P and
double transgenic when compared to nTg mice. We observed the presence of a RIPA insoluble a -syn fragment
at around 12 kDa in A30P and double transgenic mice. We did not observe an accumulation of RIPA insoluble
a-syn with aging.  B) Densitometric quantifications of a-syn signals using mc42 antibody showed significantly
higher levels of RIPA insoluble a-syn in A30P and double transgenic mice at 18 months of age when compared
to nTg or sph1. No significant difference could be detected between 18 month-old A30P and double transgenic
mice; data presented as the mean ± SEM; n=3; * P<0.05 when compared to nTg; one-way ANOVA post-hoc
LSD.
Consistent  with  previous  observations,  we  detected  an  increase  of  insoluble  monomeric
human and mouse a-syn when using mc42 antibody (nTg: 4.29 ± 0.77%; sph1:4.28 ± 2.17%;
A30P: 100.0 ± 51.5%; double: 65.6 ± 22.13%) at 17 kDa in hindbrain of  A30P and double
transgenic  animals  when  compared  to  nTg  (P<0.05,  one  way  ANOVA,  post-hoc  LSD;
Fig. 3-10A). We observed a decrease of insoluble a-syn in age-matched double-transgenic
animals  when  compared  to  A30P  (Fig. 3-10A).  This  observation  was  not  statistically
significant,  which  could  be  the  consequence  of  variability  within  lines  (P>0.05,  one  way
ANOVA, post-hoc LSD).
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Moreover, we did not observe an accumulation of RIPA insoluble a-syn monomer or oligomers
with age in hemizygous a-syn mice (Fig. 3-10B) suggesting that at 18 months in hemizygous
A30P mice, expression level of a-syn is not sufficient to observe an accumulation of RIPA
insoluble a-syn. However,  we noticed the presence of an a-syn fragment in 18 month-old
A30P mice  at  around  12 kDa  which  was  absent  in  the  other  genotypes  (Fig. 3-10B).  In
contrast to the proteinase K digestion, these data suggest that proteinase K resistant a-syn
structures have a different nature than a-syn species isolated using the sequential protein
extraction.
3.6  Decreasing high molecular weight a-syn aggregates in A30P mice 
by synphilin-1 coexpression
To identify a-syn species decreased in the proteinase K resistant assay in double transgenic
animals, we performed AGERA of proteins isolated from hindbrain in a non-centrifuged RIPA
homogenate.
The  homogenates  were  analyzed  using  1.5% agarose  gel  to  separate  higher  molecular
structures. We first investigated homozygous mice and found, in a comparable manner to
western blot, a strong increase of the monomeric form of a-syn in oldest A30P animals when
immunoblots were stained with antibodies specific either for the human or for the mouse and
human a-syn (Fig. 3-11A).
When comparing hemizygous A30P with hemizygous double transgenic mice, we observed a
smear of a-syn proteins species both in A30P and in double transgenic mice. However, these
smears were more comparable in strength and in molecular weight to younger homozygous
A30P  mice  (Fig. 3-11B)  suggesting  a  mild  aggregation  in  hemizygous  A30P  mice.
Interestingly,  we  did  not  observe pattern  or  intensity changes between A30P and double
transgenic a-syn smear in AGERA.
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Figure 3-11: Increase in a-syn high molecular weight species in homozygous 
A30P mice was not detectable in hemizygous mice
AGERA analysis of RIPA hindbrain homogenates. 50 μg of protein were loaded on an agarose gel and blotted
on a PVDF membrane.  A) A smear of a-syn high molecular weight species could be observed either using a
human or using a human and mouse specific antibodies in aging homozygous A30P mice. B) No specific high
molecular smear of a-syn was observed in both hemizygous A30P and double transgenic animals
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3.7  Homozygous A30P mice present an age-dependent increasing 
load of alpha-synuclein oligomeric species
In the aggregation process of a-syn, oligomers are considered to represent the first seeds
which result in a cascade of protein accumulation [reviewed in  (Lashuel et al.  2012)]. We
investigated  oligomeric  forms  levels  of  a-syn  using  dot  blot  and  antibodies  specific  for
oligomer structures (Fig. 3-12). To establish this method, we investigated the specificity of
different  oligomer  antibodies  using  as  negative  control  human  a-syn  protein  artificially
fibrillized and not presenting the epitope used to raise the antibodies, and as positive control
the same a-syn fibrils but sonicated at 40% power for 30 pulses of 0.5 second (Fig. 3-12) and
forming seeds with properties close to oligomers.
Figure 3-12: Specific detection of alpha-synuclein seeds using dot blot 
A) Different dilutions of recombinant a-syn were spotted on a nitrocellulose membrane and detected using the
A11 anti-oligomer antibody. No specific signal was observed when using fibrillized a-syn but a specific signal
was detected in sonicated a-syn fibrils. B) Densitometric quantifications of oligomeric a-syn using A11 antibody
showed a positive correlation between the amounts of material spotted and the signal intensity.
In order to solubilize oligomers without breaking their structures, several lysis buffers and
antibodies  were  tested.  We  found  an  age-dependent  increase  of  oligomer  in  A30P
homozygous animals using mouse hindbrain lysed in RIPA buffer without centrifugation and
using  the  Fila1  antibody (Fig. 3-13A–C).  A supportive  tendency was  observed  using  A11
antibody, but variability within samples did not provide significance. We then also measured
oligomer levels in A30P hemizygous mice coexpressing sph1, but did not observed a specific
staining (Fig. 3-11D) suggesting that in hemizygous animals the expression level of a-syn is
too low to form detectable levels of oligomers. These data are supported by the sequential
protein extraction results, where we found a very strong increase of insoluble a-syn species
larger  that  a-syn  monomer  in  A30P  homozygous  mice  (Fig. 3-05A,B) but  not  in  A30P
hemizygous mice (Fig. 3-10).
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Figure 3-13: Increase of oligomeric species in aging homozygous A30P mice 
was not detectable in hemizygous mice
A) Dot  blot  analysis  using  10 μg  of  mouse hindbrain  homogenate and  detected  using  A11 and Fila1,  both
anti-oligomer antibodies.  B) We observed a non-significant increase of oligomeric signal in A30P mice when
compared to nTg mice using A11 antibody. C) When using Fila1 antibody, we detected a progressive increase of
oligomeric  a-syn  with  mouse  aging;  data  presented  as  the  mean ± SEM;  n=3;  * P<0.05;  one-way  ANOVA
post-hoc LSD. D) No specific oligomeric a-syn was detected with both A11 and with Fila1 antibodies in hindbrain
of 18 month-old hemizygous A30P and double transgenic mice.
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3.8  Synphilin-1 decreased alpha-synuclein fibril levels in A30P mice
To investigate if the fibrillar structure of a-syn species decreased by sph1 coexpression, we
generated a group of  12 month-old  animals which  was shipped to  our  collaborator  (Prof.
Lucas, Madrid, Spain) to perform immunogold electron microscopy. Therefore fractionation of
brain lysate was performed to enrichment a-syn fibrils. Fibrils were then immunostained using
an antibody specific for  human and mouse a-syn and conjugated to gold particles. Weak
background staining was found in SNCA KO animals and in nTg mice  (SNCA KO: 0.75 ±
0.41, nTg: 2.32 ± 0.70 stained fibrils per field, one-way ANOVA, p>0.05, data not represented)
but an important increase was found in A30P mice when compared to nTg mice (nTg: 2.32 ±
0.70, A30P: 8.14 ± 0.55 stained fibrils per field, one-way ANOVA, post hoc Tukey, p<0.001,
Fig. 3-14), this increase was totally reversed in A30P mice coexpressing sph1 (A30P: 8.14 ±
0.55, double: 0.80 ± 0.24 stained fibrils per field, one-way ANOVA, post hoc Tukey, p<0.001,
Fig. 3-14).
Figure 3-14: Synphilin-1 coexpression decreased a-syn fibrils levels present in 
A30P mice
Figure provided by Prof. J. Lucas, Madrid, Spain
Immunoelectron microscopy of  a-syn filament-enriched fractions obtained from whole  brain  homogenate of
12 month-old  animals.  A) Filaments  of  a-syn  were  decorated  with  10 nm  gold  particles  as  indicated  by
arrowheads. B) An increased density of a-syn filaments was found in A30P animals when compared to nTg. In
contrast, density of a-syn filaments in sph1 and double-transgenic animals was decreased when compared to
nTg; data presented as the mean ± SEM; n=3; ** P<0.01, *** P<0.001 when compared to nTg, §§§ P<0.001
when compared to A30P, one-way ANOVA, post-hoc LSD; scale bar: 50 nm.
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3.9  Alpha-synuclein soluble fragments levels present in hindbrain of 
A30P mice were decreased by synphilin-1 coexpression
In addition to oligomers, truncated a-syn species have also been reported to be prone to
aggregation  (Crowther et al. 1998; Kim et al. 2002; I. V. J. Murray et al. 2003). In order to
investigate whether sph1 expression can change patterns or levels of a-syn fragments, we
extracted  proteins  of  18 month-old  mouse  hindbrain  using  TBS  extraction  buffer
ultracentrifuged at 120.000 g to extract the most soluble proteins of the cytoplasm (Fig. 3-15).
Western blot analysis using a-syn antibody specific for the C-terminal part of the human a-syn
shows  the  presence  of  two  a-syn  fragments  at  around  13  and  12 kDa  in  A30P  mice
(Fig. 3-15). Interestingly, intensity of a-syn fragment species was higher in A30P mice when
compared  to  double  transgenic  mice  (A30P:  100.0  ±  7.70;  double:  30.32  ±  5.04;  t  test;
p<0.001). When using an antibody specific for the central NAC domain and detecting both,
human and mouse a-syn, two specific fragments were observed in A30P mice and both were
reduced when sph1 was coexpressed; fragment f1 at 10 kDa (A30P: 100.0 ± 10.36; double:
8.23 ± 1.53; t test; p<0.01) and fragment f2 at 12 kDa (A30P: 100.0 ± 9.94; double: 23.96 ±
3.84; t test; p<0.01).
Epitope specificity  of  the human C-terminus antibody suggests  that  two N-terminal  a-syn
truncations of human a-syn were reduced by sph1 coexpression. However, since the mc42
antibody is detecting both, human and mouse a-syn, and because its epitope is targeted
against  the  central  part  of  the  protein,  we  cannot  conclude  if  fragments  seen are  C- or
N-terminal truncation of the human or of the mouse a-syn.
Figure 3-15: Soluble alpha-synuclein fragments in A30P mice were decreased in
mice coexpressing synphilin-1
A) Western blot analysis of 10 µg soluble proteins extracted from hindbrain of 18 month-old mice. Detection of
a-syn was performed using antibodies specific for the C-terminal or NAC domain.  B) We observed with both
antibodies  a  reduction  of  monomer  and  a  strong  reduction  of  fragments  in  double  transgenic  mice  when
compared to A30P; data presented as the mean ± SEM; n=3; § P<0.05, §§ P<0.01 and §§§ P<0.001 when
compared to A30P, one-way ANOVA, post hoc LSD.
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4)  Partial restoration of protein degradation impairments 
observed in A30P mice by synphilin-1 coexpression
Protein levels are a complex equilibrium between expression, degradation and aggregation.
As the a-syn protein levels expressed in young A30P and double transgenic mice was similar,
and as aggregation was decreased in double transgenic animals, we suggest that protein
degradation levels may be influenced by sph1. We analyzed the influence of sph1 on two
majors  protein  degradation  system:  the  ubiquitin-proteasome  system  (UPS)  and  the
autophagy-lysosomal pathway (ALP).
4.1  No modulation of ubiquitin-proteasome system activity by 
alpha-synuclein or by synphilin-1 expression
Activity  of  the  proteasome  was  first  investigated  using  bioluminescent  assays  based  on
labeled nucleotides and measuring the three proteolytic activities of the proteasome which are
chymotrypsin-like, trypsin-like, and caspase-like.
For this purpose we used brainstem of 18 month-old mice lysed in TBS buffer supplemented
with 5 mM MgCl2 and 5 mM ATP. To establish the time that the mixture of lysate, nucleotide
and  inhibitor  need  to  get  in  equilibrium,  we  first  investigated  the  effect  of  time  on  the
luminosity  measurement  (Fig. 3-16A).  We  observed  that  in  absence  of  an  inhibitor,
luminescence signal representing proteasome activity is stable from the first measurement.
Furthermore,  kinetic  analysis  of  the  proteasome inhibitor  lactacystin  showed a  latency of
around 50 min to reach its maximal effect.
For  this  reason,  all  further  measurements  were  performed  60 min  after  loading  the
experiment. We furthermore observed that the maximal effect of lactacystin occurred already
at 10µM  (Fig. 3-16A–B) and this concentration will be used for all further experiments. We
also analyzed the linearity of the response signal by increasing the concentration of protein in
the measured lysate  (Fig. 3-16C).  We found a relative linear response between 0.20 and
0.34 μg/µl of lysate (R=0.92) and used 0.30 µg/µl of proteins in the further experiments. We
then measured activity of several proteasome catalytic domains. The normalized and specific
signal  for  proteasomal  activity  was  calculated  by  subtracting  the  non-inhibited  lysate
luminescence  signal  by  the  inhibited  one  and  did  not  found  an  effect  of  transgene  on
chrymotrypsin-like activity (nTg: 2867 ± 172; sph1: 2729 ± 325; A30P: 2603 ± 179; double:
2663 ± 247, one-way ANOVA, p>0.05,Fig. 3-14D).
Despite a limited inhibition or a strong background signal in trypsin-like activity leading to a
measurement of  only 15% of specific signal,  we did not  find an effect on the trypsin-like
activity (nTg: 397 ± 15; sph1: 398 ± 60; A30P: 453 ± 29; double: 353 ± 89, one-way ANOVA,
p>0.05, not shown. For the caspase-like activity, the low inhibition of activity or the strong
background leads to the measure of 30% of specific signal and normalized signal suggests a
similar activity of this catalytic activity in all mouse lines (nTg: 479 ± 33; sph1: 502 ± 26; A30P:
492 ± 29; double: 484 ± 9, one-way ANOVA, p>0.05, not shown.
We can notice the higher caspase-like activity in A30P mice which did not reach significance
and could be the consequence of another protease with a caspase-like activity. Thus, these
data suggest that neither a-syn nor sph1 is modulating the proteasome activity.
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Figure 3-16: Activity of the proteasome was not modulated in A30P and in 
synphilin-1 mice
Proteasome activity  assay  in  18 month-old  mouse  hindbrain.  Tissues  were  lysed  in  hypotonic  TBS buffer
containing  5 mM  ATP  and  5 mM  MgCl2  and  analyzed  using  a  luciferase-based  Proteasome-Glo  assay.
A) Inhibition of  the proteasome was investigated  for  70 min  using  0,28 µg/µl  of  proteins and  an increasing
amount of the proteasome inhibitor lactacystin. In presence of inhibitor, B) maximal inhibition was reached after
50 minutes. Inhibitor effect was not measurable for less than 6 µM and a maximal inhibition effect was observed
at 10 µM. C) Linearity of the response curve was confirmed using an increasing concentration of protein in the
measured lysate. Saturation was not observed until 0.34 µg/µl of protein.  D) Chymotrypsin- like activity of the
proteasome was investigated in absence and in presence of 10 µM of lactacystin. Despite relatively effective
inhibition of the chymotrypsin- like activity, no differences were observed between mouse lines; data presented
as the mean ± SEM; n=4, one-way ANOVA, post hoc LSD.
4.2  No modulation of ubiquitin-proteasome system subunit levels by 
alpha-synuclein or synphilin-1 expression
Proteosomal activity measured previously reflects a complex equilibrium between the amount
of  catalytic  complex and abundance of  regulatory subunits  [reviewed in  (Kish-Trier  & Hill
2013)]. To assess any potential change of specific proteasomal components we investigated
levels  of  the  main  catalytic  and regulatory subunits  of  the  UPS.  Therefore,  we  analyzed
homogenates  of  mouse  hindbrain  lysed  in  RIPA  buffer  using  western  blot  to  quantify
proteasome component proteins.
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Functional catalytic 20S core levels were estimated in our samples by using alpha subunits
detection, subunits playing a major structural function in the proteasome [reviewed in (Jung &
Grune 2012)]. When using an antibody specific for the alpha 5 subunit, we did not find an
alteration  of  the  protein  levels  at  around 28 kDa  (Fig. 3-17A).  This  was  validated by the
utilization of a second antibody detecting an epitope shared by all alpha subunits of the 20S
(Fig. 3-17A) providing  no  general  trend  which  could  be  distinguished.  In  cells,  the  20S
proteasomal core requires assistance of regulatory units to become activated. We first studied
the  19S  regulatory  subunits,  which  associated  with  the  20S  particle  are  forming  the
structurally functional 26S proteasome.
More precisely, we investigated ATPase subunit Rpt2 levels which is required for the 20S gate
opening  (Köhler et  al.  2001),  but we  did not observe modification of the protein levels at
around 55 kDa depending of the animal genotype  (Fig. 3-17B). We then analyzed the 11S
regulatory complex which facilitates the degradation of small peptides by the 20S (Hill et al.
2002; Whitby et al. 2000). We did not find any potential regulation of 11S beta subunit levels
at around 30 kDa (Fig. 3-17C). Despite that we did not investigate all potential regulators of
UPS activity (such as levels of proteasomal gate opener protein PA200), our data suggest
that UPS levels and activity are not directly related to a-syn or sph1 overexpression.
Figure 3-17: Levels of main proteasome subunits were not altered in transgenic
animals
Western blot analysis of soluble proteins extracted from hindbrain of 18 month-old mice.  A) Analysis of 20S
alpha proteasomal subunits shows a multiple band pattern between 20 and 30 kDa representing the different
20S alpha subunit proteins. B) Analysis of the 19S proteasomal subunit using an antibody specific for the Rpt2
subunit.  C) Detection of 11S beta subunit levels at 30 kDa. No obvious changes in proteasomal protein levels
were detected in all transgenic mouse lines; n=3 for nTg and sph1 and n=4 for A30P and double.
4.3  Ubiquitin-proteasome system subunits are mislocalized in A30P 
mice but are restored in mice coexpressing synphilin-1
To assess possible misslocalization of UPS subunits, we then analyzed their expression and
their subcellular distribution in 7 μm thin paraffin embedded mouse brain sections. By using
an antibody specific for  the 20S alpha 5 subunit,  we observed an intense staining in the
perinuclear region of the cell soma in all animal lines (Fig. 3-18A). Similarly, when using an
antibody specific for the Rpt2 subunit of the 19S, we observed staining in the perinuclear
region and a lighter and more diffuse staining in the cell soma (Fig. 3-18B). All transgenic
mice  also  presented  this  staining  pattern  except  A30P mice  which  presented  a  stronger
staining in cell soma when compared to the perinuclear region (Fig. 3-18B, black arrow).
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We confirmed these results by staining sections with an antibody specific for the beta subunit
of the 11S (Fig. 3-18C), showing an abnormal staining in neurites of A30P mice (Fig. 3-18B,
black arrowheads) and an abnormal dense staining in the cell soma (Fig. 3-18B, black arrow).
These data suggest a potential recruitment of proteasomal proteins to aggregates developed
in A30P mice which is prevented by the coexpression of sph1.
Figure 3-18: Proteasome subunits were abnormally distributed in brain of A30P 
mice
Subcellular  localization  of  several  proteasomal  components  of  the  proteasome  in  brainstem  using  IHC.
A) Analysis of the 20S alpha 5 subunit of the proteasome showed a strong perinuclear staining and a weaker
staining in the soma.  B) When using an antibody specific for the 19S subunit, a similar pattern with stronger
perinuclear staining and weaker staining in the soma could be observed, except for A30P mice in which a
stronger staining was also found in the soma (black arrows). C) These data were also endorsed when using an
antibody specific for the 11S subunit of the proteasome. Staining was observed in the perinuclear region, except
for A30P mice were a stronger staining was detected in the cell cytoplasm (black arrow) and in neurites (black
arrowheads); scale bar: 50 µm.
4.4  Partial restoration of autophagy-lysosomal pathway activity 
markers in A30P mice by synphilin-1 coexpression
In addition to the UPS, we also analyzed the autophagy-lysosomal system to identify any
potential effect of sph1. The autophagy pathway is a complex machinery involving more than
20 specific ATG (autophagy-related) proteins to induce the formation of autophagosomes and
their degradation into lysosomes. For this reason, we analyzed levels of only some markers of
this complex process. 
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Figure 3-19: Decrease of autophagic flux observed in A30P mice was restored 
by synphilin-1 coexpression
Autophagy marker levels were investigated in proteins extracted from hindbrain of 18 month-old mice using
western blotting. A and B) Genotypes of  animals  were confirmed using specific antibody against  sph1 and
|113|
Results |
a-syn. Autophagy markers beclin-1, p62 and LC3 were also detected. C) Densitometric quantifications showed
a  non-significant increase  of beclin-1  in A30P when compared to nTg mice, but a strong increase in double
transgenic mice when compared to nTg, sph1 or A30P mice.  D) Increased  levels of p62 in A30P mice were
detected when compared to nTg or double transgenic mice, but no differences were found between nTg and
double transgenic mice.  E) Analysis of  the autophagosomal  marker  LC3 revealed a strong reduction of  the
LC3-I  signal  in  both  A30P and  double  transgenic  mice.  F) In  contrary  to  the  LC3-I  results,  no  significant
differences  in  levels  of  LC3-II  were  observed;  mean  ±  SEM;  n=3,*  p<0.05,  **  p<0.01,  ***  p<0.001  when
compared to nTg and § p<0.05 when compared to A30P, one-way ANOVA, post hoc LSD.
We first investigated beclin-1 levels, a protein which is involved in autophagy by mediating the
initial nucleation of the isolation membrane (Bjørkøy et al. 2009) and is playing a role in the
initial nucleation of the autophagosome (Kabeya et al. 2000; Tanida et al. 2008). We observed
an increase of beclin-1 levels in A30P and double transgenic mice (nTg: 78.5 ± 16.9; sph1:
77.2 ± 16.7; A30P: 100 ± 10.6; double: 165.7 ± 23.9, one-way ANOVA post hoc LSD, p<0.05,
Fig. 3-19A) suggesting a higher induction of autophagosome formation in A30P and double
transgenic mice. Moreover, we observed increased levels of beclin-1 in double transgenic
when  compared  to  A30P mice  (one-way  ANOVA post  hoc  LSD,  p<0.05)  supporting  the
increased autophagic flux observed in double transgenic mice (Smith et al. 2010).
Then,  we used p62,  an  adapter  protein  target  of  the  autophagy and accumulating when
autophagy is impaired  (Wong et al. 2012). We observed an increase of p62 signal in A30P
mice that was partially restored in double transgenic mice (nTg: 70.7 ± 7.9; sph1: 78.7 ± 4.5;
A30P: 100 ± 11.0; double: 73.0 ± 4.7, one-way ANOVA post hoc LSD, p<0.05, Fig. 3-19B)
suggesting an impairment of the autophagic flux in A30P mice.
To confirm and to understand the origin of this autophagic flux decrease, we investigated
levels of LC3 in brainstem of 18 month-old mice. LC3-I is a cytosolic protein which conjugates
to phosphatidylethanolamine (PE) to form LC3-II. LC3-II is then recruited to autophagosomal
membranes,  facilitating  the  fusion  of  autophagosomes  with  lysosomes  and  inducing  the
degradation  of  autophagosomes  and  their  components  (including  LC3-II).  Therefore,
investigating turn-over of LC3-I and LC3-II provides important information on the formation,
accumulation and degradation of autophagosomes (Tanji et al. 2010). We found in A30P and
double transgenic animals decreased levels of the cytoplasmic LC-I form (nTg: 257.2 ± 19.1;
sph1: 197.3  ± 23.1; A30P: 100  ± 2.8; double: 105.4 ± 8.5, one-way ANOVA post hoc LSD,
p<0.001, Fig. 3-19B). Moreover, we also found a slight decrease of the LC3-II form that did
not reach significance in A30P and double transgenic (nTg: 127.7 ± 21.3; sph1: 104.4 ± 17.3;
A30P: 100 ± 6.4; double: 91.7 ± 15.8, one-way ANOVA post hoc LSD, not significant for A30P
and p<0.01 for double transgenic, Fig. 3-19B).
Together, these data suggest that despite a decrease of autophagic flux, a-syn expression is
increasing the turn-over of the LC3-I into LC-II without accumulation of LC-II.
4.5  Presence of alpha-synuclein into autophagosomes and 
lysosomes
To  underline  the  relevance  of  a-syn  degradation  by  the  autophagy  in  A30P  mice,  we
investigated the presence of a-syn into autophagosomes and lysosomes. Therefore, a group
of mice was prepared in our laboratory and brains cross-linked using paraformaldehyde were
shipped to the laboratory of Prof. Winkler (Erlangen, Germany).
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A diffuse pattern of the autophagy markers such as LAMP2a and LC3 in the cell soma was
observed in young animals (Fig. 3-20) whereas animals overexpressing a-syn exhibited more
structured  and  inclusion-associated  distribution  throughout  the  cells  (Fig. 3-20).
Immunostaining  for  a-syn  in  aged  A30P  and  double-transgenic  animals  revealed  both
1) somatic  expression  in  inclusion-like  structures,  and  2) a  presence  in  swollen  neuronal
processes. A30P mice revealed already a-syn pathology at 4 months of age in the brainstem
despite weak and diffuse signal pattern of both ALP marker Lamp2a and LC3.
Altogether these data are showing the processing of a-syn by lysosomes and therefore the
role of the ALP in a-syn degradation in A30P and double transgenic mice.
Figure 3-20: Colocalization of alpha-synuclein staining with autophagosomal 
and lysosomal markers in A30P and double transgenic mice
Figure provided by Prof. J. Winkler, Erlangen, Germany.
IF analysis  of  a-syn and either  the autophagosomal  marker  LC3 or  the lysosomal  marker  LAMP2A at  the
histological  level.  A) Specific  fluorescence  staining  for  a-syn  and  LC3  in  4 month-old  animals  providing  a
cytoplasmic LC3 staining with puncta (white arrow). B) Similar approach using antibodies specific for a-syn and
LAMP2A showed comparable results, LAMP2A and a-syn present a cytoplasmic diffuse staining with presence
of double stained puncta (white arrow). Scale bar: 50 µm.
4.6  Promotion of aggresome-like structures formation by 
coexpression of synphilin-1 in A30P mice
Sph1 was reported to promote degradation of aggregated proteins via its polyubiquitination
and  its  targeting  to  the  inducible  aggrephagy  (Liang  et  al.  1999).  Immunofluorescence
staining of  paraffin  sections of  mouse brain  using antibodies specific  for  a-syn and sph1
showed a dense staining in the perinuclear region of double transgenic mice  (Fig. 3-21A)
thereby supporting the potential presence of aggresome-like structures in double transgenic
mice. To confirm this finding, we used as aggresome marker gamma-tubulin  (Kihara et al.
2001),  a  protein  mainly  located  in  the  centrosome  (Wong et  al.  2012) playing  a  role  in
organizing microtubules at the centrosome (Kopito 2000).
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Using  antibodies  specific  for  gamma-tubulin  and  either  transgenic  myc- tagged  sph1
(Fig. 3-21B) or human a-syn (Fig. 3-21B) showed a colocalization of both, sph1 and a-syn,
with gamma-tubulin in the perinuclear region and supported the presence of aggresome-like
structures in double transgenic mice.
Figure 3-21: Formation of ubiquitinated aggresome-like structures in A30P mice
coexpressing synphilin-1
Investigation of aggresome-like structures in brainstem of 18 month-old double transgenic mice. A) Detection of
a-syn  using  a  human  specific  antibody  and  sph1  using  a  myc  antibody  showed  the  presence  of  dense
perinuclear staining.  B and C) Presence of gamma-tubulin in the perinuclear region showed a strong overlap
with sph1 and a-syn stainings, implicating the presence of both proteins in aggresome-like structures. Scale bar:
50 µm.
5)  Reduction of histological markers of neuropathology in 
brainstem of A30P mice coexpressing synphilin-1 
Since  the  discovery  of  a-syn,  multiple  models  were  proposed  to  explain  pathological
mechanisms involved in synucleinopathies. Whereas the relevance of abnormal accumulation
of a-syn levels in neurodegeneration is more and more evident  (Lashuel et al.  2012), the
toxicity of different a-syn species is still actively debated. In this chapter, we aim to correlate
the presence of several  a-syn species with the neuropathology usually observed in A30P
mice and double transgenic mice. 
To fulfill this purpose, classical methods used to investigate neuropathology (such as silver
and thioflavin S histochemistry staining as well as ubiquitin immunostaining) were applied.
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5.1  Attenuation of silver positive inclusions in brainstem of A30P 
mice when coexpressing synphilin-1
Silver  staining  is  a  method  routinely  used  to  investigate  protein  aggregation  in  several
neurodegenerative  diseases  (KING  1948).  This  method  has  been  used  for  decades  by
pathologists to confirm the diagnosis of Alzheimer's or Parkinson's disease in  post mortem
patient  brains.  To  generate  more  reproducible  results  we  used  the  FD  NeuroSilver  kit
(Fig. 3-22). A yellow-gold color was observed in all  mice and is reported to be the typical
background observed when staining with this kit (Martin et al. 2006; Smith et al. 2010). Strong
staining localized in cells swellings (black arrow) and surrounded by a light diffuse staining
halo was observed in A30P mice but less in double transgenic mice (Fig. 3-22).
These data support a potential exacerbated pathology in A30P mice when compared to nTg
or to double transgenic. Unfortunately, we also observed unspecific silver retentions in some
sections  (black  arrowhead).  These  retentions  were  forming  unshaped  structures  which
prevented a precise quantification.
Figure 3-22: Synphilin-1 coexpression decreased silver positive structures in 
A30P mice
Neurohistological analysis performed in brainstem of 18 month-old mice using the FD NeuroSilver kit. A yellow-
gold background was observed in all mice and is typical for this kit. Blurry aspecific retentions of silver were
observed in  some sections (black arrowheads).  No pathology was detected in  nTg or  in  sph1 mice.  Cells
accumulating silver and surrounded by a light halo (black arrow) were observed in A30P mice.
5.2  Reduced thioflavin S positive inclusions by synphilin-1 
coexpression in brainstem A30P mice
Another  alternative  to  silver  staining  is  the  thioflavin S  staining  (Dictenberg  et  al.  1998).
Thioflavin S is an amyloid-binding fluorescent dye which bind to beta-sheets fibrils (O’Toole et
al. 2012). Homogenous diffuse light background was observed accompanied by the presence
of punctuate background in all mice (punctum < 1 µm). Thioflavin S staining on A30P animals
showed a very strong and distinct signal in cell  bodies (white arrowhead) and in neurites
(white arrow) (nTg: 0.7 ± 0.16; sph1: 0.43 ± 0.04; A30P: 4.7 ± 1.1; double: 0.6 ± 0.3 positive
cells per field, one-way ANOVA post hoc LSD, p<0.001, Fig. 3-23).
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Surprisingly,  we  did  not  find  in  double  transgenic  cell  bodies  or  neurites  stained  with
thioflavin S, confirming the tendency observed in silver staining. These data suggest that the
accumulation of a-syn seen in double transgenic mice does not result in amyloid structures
formation.
Figure 3-23: Synphilin-1 coexpression in A30P mice decreased thioflavin S 
reactivity in brainstem of A30P mice
Neuropathology was analyzed using 1% thioflavin S staining in brainstem of 18 month-old mice. A) Thioflavin S
staining was observed in cell bodies (white arrowhead) and in neurites (white arrow) in A30P mice; scale bar:
50 µm. B) Thioflavin S positive cells were counted in 3 different animals, using 4 sections per animal and 8 fields
per sections; data presented as the mean ± SEM; *** p<0.001 when compared to nTg and §§§ p<0.001 when
compared to A30P, one-way ANOVA, post hoc LSD.
5.3  Modification of ubiquitin inclusion shapes in A30P mice 
overexpressing synphilin-1
Ubiquitin immunochemistry is another method used by pathologists to characterize several
neurodegenerative diseases [reviewed in  (Sun et al. 2002)]. We stained paraffin embedded
sections  of  mouse  brain  with  an  ubiquitin  antibody and  observed,  as  expected,  staining
throughout the whole cell in nTg animals. In contrast to A30P mice, double transgenic mice
displayed a stronger ubiquitin staining (Fig. 3-24) suggesting an accumulation of ubiquitinated
proteins. More interestingly,  A30P mice presented a staining pattern composed of several
small inclusion dots distributed in the whole cytoplasm, and double transgenic mice presented
a main inclusion in the perinuclear region. This staining supports the idea that the decrease of
a-syn inclusions observed in double transgenic mice is accompanied by a reorganization of
aggregates when compared to A30P mice (Fig. 3-24A). To confirm that the ubiquitin inclusions
observed  in  double  transgenic  mice  are  well  composed  of  sph1,  we  performed
immunofluorescent staining using antibodies specific for ubiquitin and sph1. We observed a
diffuse  ubiquitin  staining  overlapping  the  sph1  staining  and  suggesting  a  possible
colocalization (Fig. 3-24B). These results are consistent with previous studies showing the
ubiquitination of sph1 by parkin (Chung et al. 2001), SIAH (Liani et al. 2004; Avraham et al.
2005) or dorfin (Ito et al. 2003).
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A more  recent  study  even  suggests  a  role  for  sph1  in  autophagy-amenable  aggresome
formation via the K63 polyubiquitination of the ankyrin-like repeat domain 1 (ANK1) (Wong et
al. 2012). Therefore, we used an antibody specific for K63 polyubiquitination and observed a
diffuse staining of K63 polyubiquitin antibody with presence of more dense structures located
in  the  perinuclear  region.  These  dense  structures  were  also  stained  by  myc  antibody,
suggesting  sph1  polyubiquitination  in  these  perinuclear  inclusions  (Fig. 3-24C)  and
highlighting their aggresome-like properties.
Figure 3-24: Synphilin-1 coexpression in A30P mice modified the structure of 
ubiquitin positive inclusions
A) IHC analysis of ubiquitin positive inclusions in brainstem of 18 month-old mice. A ubiquitous staining was
observed throughout the brain of all animals. A stronger ubiquitin staining was observed in A30P and double
transgenic mice, and was accompanied in A30P mice by numerous small inclusions scattered over the whole
cytoplasm (black arrows). In contrary, double transgenic animals showed few large perinuclear inclusions (black
arrowhead); scale bar: 10 µm. B) Investigation of sph1 and ubiquitin localization by IF, ubiquitin staining resulted
in a general labeling of all cells, inappropriate for colocalization studies; scale bar: 50 µm. C) Stainings using an
antibody  specific  for  K63  polyubiquitin  chains  resulted  in  a  more  specific  labeling  of  dense  perinuclear
structures, corresponding to the sph1 staining pattern; scale bar: 50 µm.
5.4  Increased levels of high molecular weight ubiquitinated proteins 
in A30P mice coexpressing synphilin-1
To gain more insight into the accumulation of ubiquitinated proteins observed in histology, we
performed western  blot  analysis  of  soluble  proteins  extracted  in  TBS buffer  and  of  total
proteins homogenized in RIPA buffer.
|119|
Results |
Figure 3-25: Synphilin-1 coexpression increased levels of high molecular 
weight proteins
A) Soluble levels of ubiquitinated proteins were investigated in hindbrain of both 4 and 18 month-old mice using
western blot analysis. Immunoblots were detected with an antibody specific for ubiquitin. Staining provided two
bands in nTg at around 25 kDa, as well as presence of two other bands between 50 and 75 kDa in A30P and
double transgenic. B) Ubiquitinated proteins between 20 and 75 kDa were quantified by densitometry. A30P and
double transgenic mice showed an increased load of ubiquitinated proteins with aging. Ubiquitinated proteins
were increased in young and old double transgenic when compared to age-matched A30P mice; data presented
as the mean ± SEM; n=3, * p<0.05, ** p<0.01, one-way ANOVA, post hoc LSD. C) Immunoblots detected with a
second antibody specific for ubiquitin showed the ubiquitin monomer at around 8 kDa as well as short smear
above 250 kDa revealing a strong increase of high molecular weight signals in 18 month-old double transgenic
mice; data presented as the mean ± SEM; n=3, * p<0.05, ** p<0.01, one-way ANOVA, post hoc LSD. D) Levels
of  ubiquitinated high molecular species were investigated in hindbrain of  18 month-old mice using AGERA.
Immunoblots were detected with an antibody specific for ubiquitin showing a long smear of ubiquitinated proteins
in all mice. Interestingly, ubiquitin smears were stronger in sph1 and double transgenic mice.
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By using western blot, we analyzed levels of ubiquitinated proteins and found an increased
amount of ubiquitinated proteins with aging in both, A30P (A30P 4M: 159.5 ± 18.0; A30P 18M:
387.4 ± 59.5, one Way ANOVA, post hoc LSD, p<0.01, Fig. 3-25A,B) and double transgenic
mice (double 4M: 312.9 ± 29.9; A30P 18M: 516.1 ± 10.22, one Way ANOVA, post hoc LSD,
p<0.01, Fig. 3-25A,B). However, we also confirmed the accumulation of ubiquitinated proteins
in both A30P and double transgenic when compared to nTg (nTg 18M: 100 ± 9.1, one way
ANOVA, p<0.001, Fig. 3-25A,B). Finally, we detected an increase of ubiquitinated proteins in
double transgenic when compared to A30P mice at 4 months (one Way ANOVA, post hoc
LSD,  p<0.05,  Fig. 3-25A,B)  and at  18 months  (one Way ANOVA,  post  hoc LSD,  p<0.05,
Fig. 3-25A,B).
Similar  results  were  also  suggested  using  another  ubiquitin  antibody showing a  stronger
accumulation of high molecular weight ubiquitinated proteins in double transgenic mice that
when compared to A30P mice and resulting in a smear stacked in the top of the running gel
(Fig. 3-25C).
In order to better characterize these proteins, less soluble structures were investigated by
running brain homogenates without centrifugation in agarose gels (Fig. 3-25D). Immunoblots
stained with ubiquitin antibody showed a small increase of high molecular weight proteins
even stronger in double transgenic animals. We suggest that the formation of aggresome-like
structures previously observed may lead to an increase of ubiquitinated proteins in A30P mice
coexpressing sph1.
5.5  Reduced levels of activated astrocytes observed in A30P mice 
coexpressing synphilin-1
Synucleinopathy progression was shown to be accompanied by inflammatory responses and
immune abnormalities both in mice overexpressing a-syn (Chu et al. 2000) and in PD patients
[reviewed  in  (Lim  et  al.  2005)],  but  mechanisms  and  roles  of  this  activation  remain
controversial.  Therefore, we used inflammation markers to confirm the decrease levels of
neuropathology previously observed in double transgenic mice using aggregation markers.
We first investigated in paraffin embedded mouse brain sections levels of activated astrocytes
by using GFAP immunohistological staining. We observed a general increase of activated
astrocytes in A30P and in double transgenic mice (nTg: 1.25 ± 0.75; sph1: 1.67 ± 0.88, A30P:
16.33 ± 0.33; double: 10.0 ± 0.58; one Way ANOVA, post hoc LSD, p<0.01, Fig. 3-26A) and a
decreased levels of activated astrocytes in double transgenic mice when compared to A30P
mice (one Way ANOVA, post hoc LSD, p<0.01, Fig. 3-26A).
Investigation of activated microglia using Iba1 immunohistological staining shows a general
increase of these cells in A30P and double transgenic mice when compared to nTg mice
(nTg: 1.56 ± 0.28; sph1: 2.33 ± 1.11, A30P: 7.50 ± 2.53; double: 6.3 ± 1.04; one Way ANOVA,
post  hoc  LSD,  p<0.01,  Fig. 3-26B)  but  the  decrease  event  number  observed  in  double
transgenic when compare to A30P mice did not reach significance (one Way ANOVA, post
hoc LSD, p>0.05, Fig. 3-26B). These data suggest that coexpression of sph1 in A30P mice is
reducing the pathology observed in A30P mice not only at the inclusion level, but also in a
more systemic matter.
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Figure 3-26: Synphilin-1 coexpression reduced levels of inflammation markers 
in A30P mice
Inflammation in the brainstem of 18 month-old mice was investigated by counting the number of activated glial
cells  using  IHC.  A) GFAP staining  showed  a  specific  signal  of  branched  cells  characteristic  for  activated
astrocytes.  B) Immunohistological staining of Iba1 show two categories of signal 1) small cells stained in their
soma and 2) small cells stained in their soma and branched. Only microglial cells with more than two branches
were counted for the quantification. A30P and double transgenic mice presented increased levels of activated
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microglia  when  compared  to  nTg.  A decreased  intensity  of  microglial  cell  activation  was  found  in  double
transgenic mice when compared to A30P mice but did not reach significance. C) Only astrocytes with more than
three branches were integrated in the quantification. An increased number of activated astrocytes in A30P was
observed when compared to nTg, but the observed inflammation was reduced in double transgenic mice when
compared to A30P mice; scale bar: 50 µm; data presented as the mean ± SEM; n=3, *** p<0.001, ** p<0.01, *
p<0.05 when compared to nTg and §§ p<0.01 when compared to A30P, one-way ANOVA, post hoc LSD.
6)  Delay of behavioral symptoms observed in A30P mice 
coexpressing synphilin-1
To  investigate  the  relevance  of  the  decreased  neuropathology  observed  in  brainstem,
behavioral  analysis of  A30P mice coexpressing sph1 were performed at a more systemic
level. In this section, we explored new and already published phenotypic impairments in A30P
mice to study the impact of sph1 on synucleinopathy progression.
Therefore, we first evaluated the general health of the animals. As A30P mice were reported
to develop a motor phenotype (Neumann et al. 2002), we then focused on several motor skill
tests.  Finally,  we  tested  potential  sensory  and  memory  abilities  already  reported  to  be
impaired in A30P mice (Tufekci et al. 2012).
6.1  Normal health status in transgenic mice using SHIRPA
Health  status  of  mice,  including  potential  physical  or  neurological  abnormalities,  was
monitored using the primary screen of SHIRPA test battery (Neumann et al. 2002; Freichel et
al. 2007) in 3 month-old male mice.
Body condition was first assessed by looking at the skin, the coat, the whiskers and the eyes
of the animals. Mice did not present any abnormalities such as lesion of the skin, irregular
coat or whiskers, presence of biting or excessive lacrimation.
We then investigate sensory functions by looking at toe pinch, palebral closure, pinna and
retina reflex and startle response and found normal sensory functions in all  mouse lines.
Motor functions were assessed by observing the fluidity of gait, posture, muscle tone, and by
measuring time mice could stay hold on a reverse grid. We did not observe any abnormal gait
fluidity or posture, and we did not measure difference of time hold on the grid (nTg: 30.0 ±
0.00; sph1: 29.82 ± 0.18, A30P: 30.00 ± 0.00; double: 29.73 ± 0.27; one Way ANOVA; post
hoc Tukey, p>0.05, Fig. 3-27A).
Anxiety was investigated by evaluating the activity of mice placed into a new cage and by
recording both the presence of urine and the number of fecal stools at the end of the test in
the  novel  area.  We did not  observe obvious difference in  activity,  in  percentage of  mice
urinating (nTg: 12.5%; sph1: 18.2%, A30P: 7.7% double: 27.3% Fig. 3-27B) and in number of
stools (nTg: 4.5 ± 1.2; sph1: 5.4 ± 0.9, A30P: 5.7 ± 0.7 double: 6.0 ± 0.6; one Way ANOVA;
post  hoc  Tukey c,  p>0.05,  Fig. 3-27C).  Surprisingly,  weight  of  all  14 week-old  mice  was
slightly heavier that the physiological range of C57BL/6N mice (C57BL/6: 27 ± 2; nTg: 30.86 ±
1.08; sph1:32.95 ± 0.81, A30P: 33.77 ± 0.53 double: 35.18 ± 0.81; one way ANOVA, post hoc
Tukey, * p<0.05, Fig. 3-27D). This effect could reflect an animal housing which has tendency
to increase animal body weight.  Furthermore,  transgenic mice were heavier that nTg mice
already at 14 weeks (one Way ANOVA; post hoc Tukey, ** p<0.01, Fig. 3-27D).
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Figure 3-27: Transgenic mice displayed a normal health status
Health status investigation in 3 month-old mice using SHIRPA.  A) Grip strength was analyzed by reversing a
mouse  placed  on  a  metal  grid.  No  difference  between  nTg  and  other  transgenic  animals  was  observed.
B) Number of fecal stools and C) percentage of animals urinating were investigated when placing mice in a new
environment for 10 min. No modifications were observed along the different genotypes.  D) Increase of body
weight in transgenic mice was measured but only significant in double transgenic animals; data presented as the
mean ± SEM; ** p<0.01, n nTg=8, n sph1=11, n A30P=13, n double=11, one-way ANOVA, post hoc Tukey.
6.2  Mild increase of body weight in A30P mice
To get a better insight into the body weight difference observed during SHIRPA investigation,
weight of animals was monitored every 6 weeks for one year (Fig. 3-28). We found a strong
correlation between age and weight of mice (two-way ANOVA; post hoc Tukey, p<0.001). By
looking at individual time points, no weight difference was observed between lines, except for
46 and 50 weeks old double transgenic and 50 weeks old A30P mice (nTg 44 weeks: 38.55 ±
1.98, sph1 44 weeks: 42.38 ± 2.11, A30P 44 weeks: 43.81 ± 1.19, double 44 weeks: 44.22 ±
0.95, and nTg 50 weeks: 39.29 ± 2.18, sph1 50 weeks: 44.21 ± 2.67, A30P 50 weeks: 46.11 ±
1.39, double 50 weeks: 46.85 ± 1.12; repeated measurement one Way ANOVA; post hoc
Tukey; Fig. 3-28). But when analyzing the body weight over one year, we found a significant
increase of body weight in all transgenic lines (nTg: 36.93 ± 1.38, sph1: 40.0 ± 1.67, A30P:
40.70 ± 1.96, double: 41.47 ± 1.67; two-way ANOVA; post hoc Tukey; Fig. 3-28). 
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Additionally,  we also analyzed the body weight of  18 month-old animals,  representing the
latest time point used for the behavioral analysis. We validated found a general increase of
body weight in all transgenic lines, which was significant only in A30P mice (nTg: 38.80 ±
3.27, sph1: 43.18 ± 2.13, A30P: 47.88 ± 1.34, double: 46.40 ± 1.51; one Way ANOVA; post
hoc Tukey; Fig. 3-28). These data suggest a slight increase of body weight in all transgenic
lines which was more pronounced in A30P mice.
Figure 3-28: Increased body weight in A30P mice
Body weight was monitored between 12 and 56 weeks with an interval of 6 weeks.  A) An increase of body
weight with aging was observed in all mouse lines. Non-transgenic mice were displaying a lower body weight
when compared to transgenic animals;  data presented as the mean ± SEM; n nTg=8, n sph1=9, n A30P=9,
n double=11, two-way ANOVA, post hoc Tukey.  B) At 18 months, transgenic mice showed an increased body
weight when compared to the nTg; but a significant difference was observed only in A30P mice; data presented
as the mean ± SEM; n nTg=8, n sph1=9, n A30P=9, n double=11, two-way ANOVA, post hoc Tukey.
6.3  Different motor phonotypes observed in A30P and double 
transgenic mice
Transgenic  mice  overexpressing  a-syn  are  classical  models  to  study  the  molecular
mechanisms  of  synucleinopathy  and  their  influence  on  PD-relevant  locomotor  function
(Fleming et al.  2008; Freichel et al. 2007). Moreover, a progressive motor phenotype was
already observed in the human A30P mutated a-syn transgenic mouse used in this study
(Rogers et al.  1997).  To investigate the potential  effect of sph1 on the progressive motor
pathology observed in A30 mice, we used a combination of several motor skill tests that have
been already reported to detect motor pathology in the A30P mouse and including RotaRod
and  beam  walk.  Furthermore,  we  included  automatic  gait  analysis  (using  CatWalk)  and
investigation of  home-cage activity (using LabMaster)  to  detect any potential  decrease of
activity consequence of pathology.
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6.3.1  Delayed rotarod impairment in A30P mice coexpressing synphilin-1
Rotarod is a system composed of a rotating beam in which mice are running and the latency
to fall from the beam is measured and reflects motor coordination and fatigue (DUNHAM &
MIYA 1957). For the first experiment, ability of mice to learn this complex task at 14 weeks
was assessed (Masliah et al. 2000; Giasson et al. 2002; Gomez-Isla et al. 2003). Transgenic
mice did not present a decrease of motor ability when compare to nTg  (nTg: 151.0 ± 3.8,
sph1: 179.3 ± 2.7, A30P: 157.5 ± 7.2, double: 142.4 ± 3.9; one Way ANOVA; post hoc Tukey;
Fig. 3-29A) nor a difference in motor skill learning (two-way ANOVA; p>0.005; Fig. 3-29A).
These data suggest that mice did not present motor skilled impairment at 14 weeks. Evolution
of rotarod performances was investigated for 14 months and A30P and double transgenic
mice spent less time spend in the rod when compare to nTg mice (nTg: 146.2 ± 4.3, sph1:
163.6 ± 5.6, A30P: 112.0 ± 10.7, double: 130.2 ±10.28; two-way ANOVA; post hoc Tukey;
p<0.05; Fig. 3-29B).  More precisely,  we found a significant difference between A30P mice
already at 26 weeks (nTg: 160.3 ± 10.6, sph1: 175.6 ± 29.6, A30P: 131.7 ± 18.7, double:
170.1 ± 22.2; two-way ANOVA; post hoc Tukey; p<0.05; Fig. 3-29B gray arrow) and in double
transgenic only at 38 weeks (nTg: 142.5 ± 17.9, sph1: 165.8 ± 31.9, A30P: 84.0 ± 5.6, double:
104.6 ± 18.4; two-way ANOVA; post hoc Tukey; p<0.05; Fig. 3-29B black arrow). These data
suggest that pathology observed in A30P can be delayed by sph1 coexpression.
Figure 3-29: Synphilin-1 coexpression delayed rotarod impairment in A30P mice
Rotarod  performances  were  monitored  between 12  and  56 weeks  with  an  interval  of  6 weeks.  Mice  were
investigated 3 times a day for 5 consecutive days using an acceleration of 4 to 40 RPM in 7 min and the latency
to fall was recorded. A) Motor skill learning was analyzed in 12 month-old mice. No differences were observed
between  nTg and  transgenic  mice;  data  presented  as  the  mean  of  the  3 trials  per  day  ±  SEM;  n nTg=8,
n sph1=11, n A30P=13, n double=11, two-way ANOVA, post hoc Tukey.  B) A decrease of motor performance
with aging was observed in A30P and double transgenic mice. First motor symptoms in double transgenic (black
arrow) were delayed when compared to A30P mice (gray arrows); data presented as the mean of the 15 trials
per time point ± SEM; n nTg=8, n sph1=8, n A30P=9, n double=11, two-way ANOVA, post hoc Tukey.
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6.3.2  Reduced challenging beam walk performances in transgenic mice
In  a  next  step,  challenging beam walk  (Neumann et  al.  2002;  Freichel  et  al.  2007) was
performed to investigate coordination disorder in transgenic mice (Shiotsuki et al. 2010).
Challenging beam walk consists of  four transparent thermoplastic beams constituting four
sections of decreasing width and covered by a wire mesh  (Fig. 3-30A and B).  Mice  were
trained to transverse the beam without the wire mesh to their home-cages. On the testing day,
mice were placed on the beam with a wire grid. At 12 months, all transgenic mice need more
time to traverse the beam (nTg: 9.25 ± 1.05, sph1: 16.89 ± 2.24, A30P: 19.44 ± 5.92, double:
20.18 ± 4.71; two-way ANOVA; post hoc Tukey; p<0.05; Fig. 3-30C),  supporting that sph1,
A30P and double transgenic mice already developed pathology at 12 months.
Figure 3-30: Reduced challenging beam walk performances in transgenic mice 
Motor  disturbances  in  transgenic  animals  by  challenging  beam  walk  test.  A) Mice  were  trained  for  two
consecutive days to cross a one meter long plastic beam of decreasing width to get back to their home-cage.
B) The third day, a 1 cm² metal mesh grid was added to the plastic beam and the time to cross it was recorded.
C) An increase of the time required for crossing the beam was detected in all transgenic mice; data presented as
the mean ± SEM; n nTg=8, n sph1=8, n A30P=9, n double=11, one-way ANOVA, post hoc Tukey.
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6.4  Different origin of the motor impairments observed in A30P and 
sph1 mice
Characterization  of  motor  deficits  observed  in  double  transgenic  and  in  sph1  mice  was
performed using automatic gait analysis. This approach allows the measurement of classical
static  gait  parameters (distance between two consecutive steps or  between lateral  paws,
number of steps to cross the plate...) but also dynamic gait parameters (time needed to cross
the plate, step cycle, walking pattern...) which are impossible to measure by more classical
methods (such as paw labeling using ink).
Animals were recorded 20 times over 5 days and runs in which animals got a speed variation
within the walkway higher that 25% were not investigated. Moreover, runs on which mice
clearly stopped or climbed wall of the apparatus were also excluded to reduce the number of
run per animal to a maximum of 5. By using this general approach, all transgenic animals
presented a reduced walking speed which did not reach significance  (nTg: 17.00 ± 0.42,
sph1: 15.17 ± 0.83, A30P: 15.54 ± 0.75, double: 15.08 ± 0.55;one Way ANOVA; post hoc
Tukey; p>0.05; Fig. 3-31A). A30P mice also showed an increase number of steps necessary
to cross the walkway (nTg: 19.0 ± 1.5, sph1: 19.0 ± 0.60, A30P: 21.32 ± 1.4, double: 20.0 ±
1.8; one Way ANOVA; post hoc Tukey; p<0.05; Fig. 3-31B). These data were confirmed in
A30P mice by a decreased stride length,  representing distance between two consecutive
steps (nTg: 4.42 ± 0.11, sph1: 4.43 ± 0.06, A30P: 3.99 ± 0.08, double: 4.28 ± 0.13; one way
ANOVA; post hoc Tukey; p<0.05; Fig. 3-31C). These data suggest that A30P mice are using a
walking pattern requiring more steps to cross the walk way.
Using  the  same strategy,  analysis  of  step  cycle  (represented  in  Fig. 3-31D)  revealed  an
increase of stand in sph1 and double transgenic mice (nTg: 0.11 ± 0.004, sph1: 0.14 ± 0.009,
A30P:  0.12  ±  0.006,  double:  0.13  ±  0.003;  one  way  ANOVA;  post  hoc  Tukey;  p<0.05;
Fig. 3-31E). This increase of stand was accompanied by a non-significant increase of swing
(nTg: 0.13 ± 0.005, sph1: 0.14 ± 0.008, A30P: 0.12 ± 0.003, double: 0.13 ± 0.004; one way
ANOVA; post hoc Tukey; p<0.05; Fig. 3-31F) and of step cycle duration (nTg: 0.24 ± 0.006;
sph1: 0.28 ± 0.016, A30P: 0.25 ± 0.008, double: 0.27 ± 0.006; one way ANOVA; post hoc
Tukey; p>0.05; Fig. 3-31G). We suggest that sph1 and double transgenic animals are also
showing an abnormal gait pattern, but different from the one observed in A30P mice. This is
probably  reflecting  the  longer  stand  in  sph1  and  double  transgenic  mice  which  increase
slightly the step cycle pattern.
When using static gait analysis, no difference was observed in paw overlap (nTg: 0.92 ± 0.09,
sph1: 0.81 ± 0.05, A30P: 1.13 ± 0.05, double: 1.06 ± 0.09; one way ANOVA; post hoc Tukey;
p>0.05;  Fig. 3-31G),  neither  in  base  of  support  of  lateral,  frontal,  posterior  or  epsilateral
support  (one  way  ANOVA;  post  hoc  Tukey;  p>0.05;data  not  shown).  As  paw  overlap
represents mainly the posture of the animal, we suggest that the decrease in stand observed
in sph1 and double transgenic mice do not lead to a posture impairment.
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Figure 3-31: Motor deficits present in both A30P and sph1 transgenic mice 
resulted in gait impairments in CatWalk
Dynamic and static analysis of automatic gait analysis was performed in 18 month-old mice. A) No difference in
speed was observed in compliant runs between groups. B) An increased number of steps needed to cross the
beam was observed in A30P mice, C) resulting in a decreased stride length (distance between two consecutive
steps).  D) Step cycle representation.  E) Increased stand was measured in sph1 and double transgenic mice
F) which was not accompanied by an increase of swing G) or step cycle. H) No differences was found in print
positions (overlap between hind and front paw prints); data presented as the mean ± SEM; n nTg=8, n sph1=8,
n A30P=9, n double=11, one-way ANOVA, post hoc Tukey.
To understand the origin of the stand decrease in sph1 and double transgenic animals, we
also investigated in detail the walking patterns.
Analysis of step patterns, by displaying recorded print, showed an increase number of step for
A30P (Fig. 3-32A) and also showed clearly the presence of abnormal paw patterns in sph1
and double transgenic animals resulting to the addition of an extra hind paw step every 3 to 4
step cycles (Fig. 3-32A, white arrowheads).
Deep  modifications  of  the  epsilateral  walking  pattern  (usually  seen  in  nTg  mice  and
represented normally as parallel curves by the software) was observed in sph1 and double
transgenic (Fig. 3-32B). Analysis of step pattern using a time based axis clearly showed the
presence of extra  hind paw prints in sph1 and double transgenic mice  (Fig. 3-32C, black
stars).
To exclude any potential bias, runs with abnormal extra steps were re-visualized using slow
motion to exclude potential  presence of abnormal behavior (such as stop, sniffing or wall
climbing) in the analysis. These data suggest a motor deficit present in both 18 month-old
A30P and sph1 mice, leading to the development of different pathologies and resulting in
different abnormalities in CatWalk.
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Figure 3-32: Gait impairments in CatWalk suggest a coordination dysfunction in
synphilin-1 mice
Walking  pattern  analysis  from  the  automatic  gait  analysis  performed  in  18 month-old  mice.  A) Spatial
representation of prints suggests the presence of abnormal extra hind paw steps in sph1 and double transgenic
mice (white arrows). Note that slighter higher body weight in transgenic mice results to an increased paw signal.
B) Walking pattern representation provides a regular curve for nTg animals. Abnormalities in walking pattern
were detected in sph1 and double transgenic mice by the analysis software, such as 1) not taken into account or
2) not part of pattern. C) Time representation of prints are confirming the presence of extra hind paw stands in
sph1 and double transgenic mice (black stars).
6.5  Decreased home-cage activity during exploratory phase in 
transgenic mice in transgenic A30P mice
In several models of neurodegenerative diseases, motor impairments could be correlated to a
reduced  home-cage  activity  (Stanley  et  al.  2005).  Therefore,  motor  deficit  impacts  on
home-cage  activity  and  locomotion  were  studied  in  our  transgenic  mice  using
PhenoMaster/LabMaster. Activity was measured by infrared sensors surrounding a cage and
recording horizontal (locomotion) and vertical (rearing, cage lid climbing) activity Fig. 3-33A.
Water and food intake were additionally monitored.
Activity  of  mice  was  measured  every  minute  and  data  were  binned  per  30  minutes  to
normalize the dataset. Usual day/night activity shift was observed (Fig. 3-33B), highlighting
the need of performing analysis of the dark and the light phase separately. Moreover, mice
placed  in  a  new  cages  showed  an  increase  activity  (Freichel  et  al.  2007;  Nuber  et  al.
2013) which decreased over the time. Accordingly, an increased activity was observed the
first night when compare to the last night (nTg night1: 167.8 ± 11.96, nTg night3: 74.34 ± 3.5,
sph1 night1: 124.5 ± 9.24, sph1 night3: 67.4 ± 6.32, A30P night1: 102.2 ± 10.53, A30P night3:
41.31 ± 3.19, double night1: 85.24 ± 8.59, double night3: 57.8 ± 3.72; two-way ANOVA; post
hoc Tukey; Fig. 3-33C) indicating that data of different days should be analyzed separately.
For this reason, we considered activity of the last night, which better reflects physiological
conditions considering that mice were more acclimatized to the system.
All transgenic animals presented a decreased activity during the first night (two-way ANOVA;
post hoc Tukey; p<0.05; Fig. 3-33D). Remarkably, A30P mice presented a decreased activity
compared to the other mice the last night (two-way ANOVA; post hoc Tukey; Fig. 3-33E).
Contrarily to the night phase, motor activity during the light phase was not correlated to the
time spend in the system (nTg light1: 23.92 ± 3.44, nTg light3: 30.33 ± 3.392 sph1 light1:
25.57 ± 3.72, sph1 light3: 26.52 ± 4.57, A30P light1: 14.83 ± 2.26, A30P light3: 15.92 ± 3.67,
double light1: 16.71 ± 3.06, double light3: 20.76 ± 3.29; two-way ANOVA; post hoc Tukey;
p>0.05; Fig. 3-33F). Accordingly, A30P mice also presented a decreased activity during the
first and the last light phase (two-way ANOVA; post hoc Tukey; Fig. 3-33G). This effect was
also noticeable in double transgenic mice but only when we pooled data of the three light
phases (nTg: 27.28 ± 1.94, sph1: 27.15 ± 2.50, A30P: 15.20 ± 1.52, double: 20.00 ± 1.77; one
way ANOVA; post hoc Tukey; Fig. 3-33H).
These data imply a loss of home-cage activity over time in all mice, but most strongly in A30P
mice.
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Figure 3-33: Decreased home-cage activity during acclimatization period in all 
transgenic mice was more exacerbated in A30P mice
A) Home-cage  activity  was  investigated  in  18 month-old  animals  by  using  the  PhenoMaster/LabMaster
B) Activity was monitored over 70 h and a higher activity was observed during dark phases.  C) Decrease of
activity corresponding to acclimatization was observed allover the experiment.  D) The activity of all transgenic
mice was reduced during this acclimatization period,  E) but A30P mice stayed hypoactive when compared to
nTg at the end of the experiment. F) Acclimatization was not observed during light phase. G) A30P mice were
showing a lower activity during the last light phase;  data presented as the mean ± SEM; *p<0.05, **p<0.01,
***p<0.001,  n nTg=8,  n sph1=8,  n A30P=9,  n double=11,  two-way ANOVA,  post  hoc  Tukey.  H) Decrease  of
activity in A30P mice was confirmed when analyzing the complete light period, also showing a slight decrease of
activity in double transgenic mice; data presented as the mean ± SEM; *p<0.05, ***p<0.001, n nTg=8, n sph1=8,
n A30P=9, n double=11, one-way ANOVA, post hoc Tukey.
Reduced total distance traveled by A30P mice was also confirmed by the number of vertical
beam breaks. The number of breaks was higher during the dark phase (Fig. 3-34A). Vertical
beam breaks were more frequent during the first night than during the last night (nTg night1:
28.60 ± 2.15, nTg night3: 13.08 ± 1.14, sph1 night1: 17.25 ± 1.05, sph1 night3: 9.75 ± 1.13,
A30P night1: 17.70 ± 1.91, A30P night3: 8.44 ± 1.44, double night1: 15.85 ± 1.54, double
night3:  12.29 ± 1.05;  two-way ANOVA; post  hoc Tukey;  Fig. 3-34B).  Accordingly,  we also
observed a decrease of vertical activity in transgenic animals when compared to nTg during
the first night (two-way ANOVA; post hoc Tukey; p<0.05; Fig. 3-34C), and in the last night,
only  A30P mice  where  statistically  different  from nTg  (two-way ANOVA;  post  hoc Tukey;
Fig. 3-34D).
Finally,  we measured the amount of  food and water  consumed by the animals.  While no
differences in either food intake were observed (nTg: 12.01 ± 0.79, sph1: 12.89 ± 0.74, A30P:
10.81 ± 0.61, double: 11.33 ± 0.72; one way ANOVA; post hoc Tukey; p>0.05; Fig.  3-34E), a
decrease in water intake was measured (nTg: 16.40 ± 2.31, sph1: 10.99 ± 1.20, A30P: 10.15
± 0.54, double:  11.75 ± 0.93;  one way ANOVA; post  hoc Tukey;  Fig. 3-34F).  These data
suggest that despite locomotor deficit, mice can still eat properly, but that the loss of activity
may induce a reduction of water intake in transgenic mice.
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Figure 3-34: Validation of decreased home-cage activity in transgenic mice 
during acclimatization period using complementary parameters
A) Vertical activity in home-cage was monitored over 70 h in PhenoMaster/LabMaster. The activity pattern was
similar to the ambulation pattern observed previously, including the presence of a dark and light phase effect
B) as well  as an acclimatization effect  over  3 days.  C) Vertical  activity confirmed the decreased ambulatory
activity  in  all  transgenic  lines,  D) as  well  as  the  hypoactivity  in  A30P  mice  during  the  last  light  phase.
E) Decreased activity in transgenic mice during acclimatization could be already observed after 15 min of testing
using ambulation  F) and vertical activity;  data presented as the mean ± SEM; *p<0.05, **p<0.01, ***p<0.001,
n nTg=8,  n sph1=8,  n A30P=9,  n double=11,  two-way  ANOVA,  post  hoc  Tukey.  G) No  changes  in  food
consumption was observed between lines, H) but a reduction of water intake was measured in sph1 and A30P
mice,  not  significant  for  double  transgenic  mice;  data  presented  as  the  mean  ±  SEM;  *p<0.05,  **p<0.01,
n nTg=8, n sph1=8, n A30P=9, n double=11, two-way ANOVA, post hoc Tukey.
6.6  Decreased exploratory activity in transgenic mice lines
To analyze if differences observed in PhenoMaster/LabMaster were related to anxiety or to
depression, we analyzed mice in open field (Freichel et al. 2007; Nuber et al. 2013).
We observed a decrease of mice activity during the first 10 min of the test (nTg: 3646 ± 597,
sph1: 2462 ± 231, A30P: 23351 ± 170, double: 2336 ± 190; one way ANOVA; post hoc Tukey;
Fig. 3-35A)  and  these  data  support  the  decrease  of  activity  seen  the  first  30 min  in  the
PhenoMaster/LabMaster.
When decomposing the field in several central parts, we observed that mice spent most of the
time in the most peripheral part of the field, reflecting the decrease of activity observed when
analyzing the whole field (nTg: 3336 ± 577, sph1: 2085 ± 236, A30P: 2056 ± 135, double:
2070 ± 146; one way ANOVA; post hoc Tukey; p<0.05; Fig. 3-35B). Neither differences in the
distance in the different central regions (Fig. 3-35B) nor in time spend in the several parts of
the  open  field  (Fig. 3-35C),  nor  the  latency to  reach  the  central  parts  (Fig. 3-35D)  were
observed.
These data suggest that transgenic mice explored less in the open field but do not present
sign of excessive anxiety or depression.
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Figure 3-35: Decreased total activity in open field in all transgenic mouse lines
Activity and exploratory behaviors were investigated by exposing mice for 10 min in an open field. To analyze
exploratory behavior of mice, open field was virtually divided in four concentric squares of increasing area (I4 to
I1). A) Representative exploratory behaviors of animal tracked in open field. B) Total distance traveled by mice
in open field. C) Distance spent in the different areas of the open field. Distance traveled by transgenic mice was
decreased only in the most peripheral part of the open field.  D) Time spent in each part of the open field was
similar for every genotype.  E) Latency to reach the center of the open field did not differ between genotypes;
data presented as the mean ± SEM; ***p<0.001, n nTg=8, n sph1=8, n A30P=9, n double=11, one-way ANOVA,
post hoc Tukey.
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6.7  Reduced olfactory deficit in A30P mice coexpressing synphilin-1
Olfactory deficit has been reported as an early sign of the synucleinopathy both in PD patients
and in several mice overexpressing a-syn (Archer 1973; Walsh & Cummins 1976). To assess
in  our  mice  potential  olfactory  impairment,  we  used  a  setup  consisting  of  a  large  cage
separated in two compartments of equal size by an opened plastic wall and spread on both
side with new bedding material.  In a first time, we studied spatial  preference and did not
observe that mice preferred a specific compartment.
We then added into the cage bedding material of the mouse home-cage in a compartment.
Mice were put into the cage compartment containing the new bedding and the latency to
leave the compartment as well as the time spent in each compartment was recorded. We did
not observe any preference for any of the bedding (nTg familiar: 53.10 ± 3.67, nTg new: 46.90
± 3.67, sph1 familiar: 55.94 ± 3.09, sph1 new: 44.05 ± 3.09; A30P familiar: 55.97 ± 3.71, A30P
new: 44.03 ± 3.71, double familiar: 52.26 ± 2.63, double new: 47.03 ± 2.63; two-way ANOVA;
post  hoc  Tukey;  Fig. 3-36A).  These  data  suggest  that  all  mice  got  a  slight  smell  deficit
because of age. However we cannot exclude that the mice got used to be but put in new
bedding and do not prefer anymore the older bedding to the fresh one.
Therefore, we repeated the experiment by comparing bedding preference of mice between
their own bedding and rat bedding. We observed that mice prefer their own bedding except
A30P mice (nTg familiar: 63.55 ± 4.61, nTg rat: 36.45 ± 4.61, sph1 familiar: 75.60 ± 6.06,
sph1 rat: 24.41 ± 6.06; A30P familiar: 58.88 ± 4.34, A30P new: 41.12 ± 4.34, double familiar:
65.26 ± 2.30, double new: 34.74 ± 2.30; two-way ANOVA; post hoc Tukey; Fig. 3-36A). These
data confirm the observation that over-expression of a-syn lead to an olfactory deficit and that
this deficit was restored or delayed by sph1 coexpression.
Figure 3-36: Decreased olfaction in A30P mice
Smell perception was investigated in 18 month-old mice. A) Mice were placed in a new cage separated in two
equal parts by a plastic wall featuring an opening. One part of the cage contained the familiar bedding and the
second one fresh bedding. Time spent in each part of the box was investigated and no preference was found for
one  of  the  compartment.  B) The test  was repeated  by  using  rat  bedding.  Mice  spent  less  time in  the  rat
compartment, except for the A30P line;  data presented as the mean ± SEM; ***p<0.001, n nTg=8, n sph1=8,
n A30P=9, n double=11, one-way ANOVA, post hoc Tukey.
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6.8  Cognitive function investigation in A30P mice
Finally, we investigated cognitive functions (such as spatial learning and memory) which were
reported to be impaired in A30P mice (de Visser et al. 2006). For this purpose, we performed
water maze, a test on which mice are trained to memorize the location of an escape platform
placed in a tank filled with opaque water.
In a first step, spatial learning was investigated by adding a cue on the platform and exposing
the mice four times per day to the water maze during two subsequent days. We observed a
general learning effect in all genotypes which was not significant anymore after the third trial
(nTg trial1: 168.5 ± 81.4, nTg trial2: 172.2 ± 62.7, nTg trial3: 100.8 ± 12.8, nTg trial4: 86.7 ±
9.1, sph1 trial1: 183.1 ± 35.4, sph1 trial2: 145.1 ± 57.5, sph1 trial3: 94.0 ± 15.2, sph1 trial4:
67.1 ± 3.5, A30P trial1: 270.5 ± 113.5, A30P trial2: 160.8 ± 20.3, A30P trial3: 188.5 ± 40.8,
nTg trial4: 89.9 ± 11.3, double trial1: 147.6 ± 22.2, double trial2: 99.3 ± 12.6, double trial3:
128.5 ± 20.0, double trial4: 82.5 ± 6.6;two-way ANOVA; post hoc Tukey; Fig. 3-37A). These
data  suggest  that  mice  learned  the  position  of  the  target  already  after  the  third  trial.
Furthermore, we did not observe differences in the distance needed to find the platform either
between the fourth and the last trial of the first day or between the fifth and the first trial of the
second day (nTg trial5: 93.4 ± 15.7, sph1 trial5: 81.1 ± 18.0, A30P trial5: 81.1 ± 14.4, double
trial5: 105.4 ± 16.2; two-way ANOVA; post hoc Tukey; Fig. 3-37A). These data support that
mice remembered the position of the cue already at the end of the first day. No difference
between  the  genotypes  was  observed,  suggesting  that  spatial  vision  is  not  impaired  by
transgene expression.
We then tested the spatial memory by removing the cue. We observed an increased distance
needed to find the platform in all genotypes (nTg last cued: 88.1 ± 11.8, nTg first spatial task:
242.8 ± 55.7, sph1 last cued: 81.1 ± 18.0, sph1 first spatial task: 393.3 ± 89.7, A30P last
cued: 81.1 ± 14.3, A30P first spatial  task: 400.4 ± 124.6, double last cued 105.4 ± 16.2;
double first spatial task: 395.2 ± 116.9; two-way ANOVA; post hoc Tukey; Fig. 3-37A and B).
Moreover,  the  genotype  of  our  animal  did  not  have  an  influence  of  this  observation.
Surprisingly,  we found only a  non-significant  improvement of  the time needed to  find the
platform during the spatial  task (two-way ANOVA; p>0.075),  suggesting that  mice did not
learn where the platform was located without a clue (Fig. 3-37B). These data were confirmed
when we looked for spatial memory by removing the platform and analyzing time spent in
quadrant. We did not observe an increase of time spend in quadrant in which platform was
previously placed (nTg correct: 29.9 ± 4.5, nTg wrong: 23.4 ± 1.5, sph1 correct: 38.1 ± 7.9,
sph1 wrong: 20.3 ± 2.6, A30P correct: 27.6 ± 5.8, A30P wrong: 23.4 ± 1.5, double correct:
35.8 ± 3.8, nTg wrong: 21.4 ± 1.3, two-way ANOVA, p>0.05). These data confirm that mice
did  not  learn  the  task  and  the  position  of  the  platform,  making  the  interpretation  of  the
genotype effect on this test a complex task.
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Figure 3-37: Transgenic mice did not develop spatial learning deficits
Spatial learning and memory were analyzed in 18 month-old mice using the Morris water maze. A) Mice were
first trained for two days, four times per day, to reach a flag cued platform to escape the water tank. Distance
needed to reach the platform was decreasing until  the end of  the first  experimental  day.  B) To test  spatial
learning, the cue was removed and the distance needed to find the platform was monitored. Time to reach the
platform was increased when compared to the cued test. No difference was observed between groups;  data
presented as the mean ± SEM, n nTg=8, n sph1=8, n A30P=9, n double=11, two-way ANOVA, post hoc Tukey.
C, D) Representation of animal swimming pattern during the probe test, in which the platform was removed and
the time spent in each quadrant of the maze was recorded.  C) Swimming pattern of an animal which learned
where the platform was and D) an animal which did not learned it. E) No significant preference was observed for
the  target  quadrant  in  the  maze;  data  presented  as  the  mean  ±  SEM;  n nTg=8,  n sph1=8,  n A30P=9,
n double=11, one-way ANOVA, post hoc Tukey.
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Discussion
Parkinson's  disease  (PD)  is  characterized  anatomically  by  the  presence  of  intraneuronal
cytoplasmic inclusions, called Lewy bodies (LBs) and Lewy neurites (LNs) (Lewy 1913; Duffy
& Tennyson 1965), which are mainly composed of alpha-synuclein (a-syn)  (Spillantini et al.
1997). Despite that the localization of LBs in the brains of PD patients was shown to follow a
specific distribution in time and space (Braak et al. 2003; Jellinger 2004), the existence of a
direct link between LBs and the PD-associated neuropathology is controversial  (Kramer &
Schulz-Schaeffer  2007;  Burke  et  al.  2008).  However,  an  increasing  body  of  evidence  is
showing that the presence of insoluble a-syn species in neurites and in presynapses is linked
to  dendritic  spine  degeneration  and  to  pathology  [(Kramer  &  Schulz-Schaeffer  2007),
reviewed  in  (Yasuda  et  al.  2013)].  In  this  context,  studying  mechanisms inhibiting  a-syn
aggregation  may lead to  novel  strategies  to  target  the  development  of  synucleinopathies
[reviewed in (Blazer & Neubig 2009)].
Synphilin-1 (sph1) is a well-known interaction partner of a-syn (Engelender et al. 1999), also
present in LBs (Wakabayashi et al. 2000), and first reported to promote a-syn aggregation in
cell models (O’Farrell et al. 2001), protecting them against a-syn-mediated toxicity (Tanaka et
al. 2004) and neurotoxic agents  (X Li et al. 2010). Several mouse models overexpressing
sph1 were generated using virus-mediated gene transfer or transgenic animals in order to
better understand the role of sph1 in synucleinopathy  in vivo (Jin et al. 2008; Krenz et al.
2009; Nuber et al. 2010; Smith et al. 2010). But the consequences of sph1 overexpression on
a-syn  aggregation  and  neuroprotection  were  not  consistent,  as  described  in  more  detail
below.
In  this  study,  we  first  aimed  to  investigate  the  role  of  sph1  in  the  development  of
synucleinopathy in vivo and on a more general level, in order to investigate the importance of
a-syn  aggregation  on  the  development  of  synucleinopathies.  Therefore,  we  cross-bred  a
mouse  overexpressing  the  human  A30P  mutated  a-syn  under  the  control  of  the  Thy-1
promoter, which develops a progressive synucleinopathy [reported originally in  (Kahle et al.
2000; Kahle et al. 2001)] with a mouse overexpressing human wildtype sph1 under the PrP
promoter  (Nuber et al. 2010). We investigated in detail the impact of sph1 coexpression on
a-syn levels, as well as on a-syn aggregation. To confirm the relevance of protein aggregation
in the development of synucleinopathy, we investigated both at the histological and at the
behavioral levels the effect of sph1 in mice overexpressing the human A30P mutated a-syn
(termed A30P).
Importantly, the breeding strategy applied to generate the experimental group of animals is
critical in this project, which consists mainly of a cross study comparison [reviewed in (Yoshiki
& Moriwaki 2006)]. However, our approach was simplified by the maintenance of single A30P
and sph1 transgenic mice on the same C57BL/6NCrt background. To ensure that these mice
did not shift to a specific inbred substrain background (originating for example from numerous
inbreeding),  we  first  cross-bred  homozygous  A30P mice  with  homozygous  sph1  mice  to
generate a first generation of hemizygous double transgenic mice.
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To maintain  the  experimental  group inbred,  the  first  generation  of  hemizygous mice  was
crossed in to produce a second generation consisting of a mixed population of non-transgenic
animals (nTg; ~6%), transgenic A30P and sph1 mice hemi- and homozygous (respectively
~12%  and  ~6%),  double  transgenic  hemizygous  (~24%)  mixed  hemi-  and  homozygous
(~24%) and homozygous (~6%) [summarized in table 4-01]. 
By using this  strategy,  the direct  generation of  an experimental  group of  30 homozygous
animals (a  reasonable number of  animals for  behavioral  and neuropathological  analyses)
would have required the generation of at least 500 mice, which was not achievable within the
time-line of this project.
Therefore,  we  used  nTg  littermates  to  cross-breed  homozygous  mice  from  the  second
generation, resulting in a third generation of hemizygous mice with the same background. A
strategy including two successive cross-breedings would not  have been suitable to  get  a
complete and adequate inbred double transgenic line (statistical model described in  (Lynch
1988)). Moreover, as original homozygous lines were regularly back-crossed with commercial
C57BL/6NCrt mice every 5-10 generations, substrain divergence can be considered minimal
(Taft et al. 2006), and the generation of double transgenic mice may therefore be considered
as a cross-in.
Table 4-01: Mendelian distribution of double transgenic hemizygous 
cross-breeding
genotype nTg sph1 +/o sph1 +/+ A30P +/o A30P +/+ sph1 +/o
A30P +/o
sph1 +/+
A30P +/o
sph1 +/o
A30P +/+
sph1 +/+
A30P +/+
probability ~6% ~12% ~6% ~12% ~6% ~24% ~12% ~12% ~6%
1)  Synphilin-1 induced alpha-synuclein levels reduction
1.1  Levels of soluble alpha-synuclein
Despite that the function of sph1 is still poorly understood, early descriptive studies reported
the involvement  of  sph1 in  protein  aggregation  (Engelender  et  al.  1999).  Therefore,  it  is
surprising  that  previous  in  vivo studies  did  not  notice  any  effect  of  sph1  on  levels  of
endogenous a-syn (Jin et al. 2008; Nuber et al. 2010) or transgenic a-syn (Smith et al. 2010).
In our study, we focused mainly on the impact of sph1 on the evolution of soluble a-syn levels.
As  reported,  we  observed  an  accumulation  of  human  A30P  mutated  levels  in  single
transgenic  mice  with  age  (Kahle  et  al.  2001),  but  interestingly  we  did  not  detect  an
accumulation of soluble a-syn protein in A30P mice coexpressing sph1.
To better characterize which exact a-syn species are reduced in double transgenic mice, we
then  tested  their  solubility  using  different  lysis  buffers  containing  various  amount  of
detergents. When using strong detergents, we observed more pronounced reduction of a-syn
levels,  confirming that  sph1  is  reducing  abnormal  accumulation  of  soluble  a-syn  in  mice
overexpressing A30P a-syn. In contrast to previous studies (Jin et al. 2008; Nuber et al. 2010;
Smith et al. 2010), our findings suggest that sph1 decreases endogenous a-syn levels.
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As  investigation  of  protein  levels  using  western  blot  is  directly  dependent  of  the  protein
extraction used to solubilize proteins of interest, and as a-syn is reported to have a very rich
structural composition (Ullman et al. 2011), the protein extraction method may have a large
effect on the a-syn species solubilized and may lead to contradictory results.
In this context, we tested several protein extraction protocols to measure a-syn protein levels
and to limit extraction protocol artifacts related to low solubilization of lipophilic or aggregated
proteins. This extensive investigation pointed out a robust reduction of most soluble a-syn
forms during aging by sph1 and also demonstrated a pronounced reduction of a-syn species
requiring high levels of detergent for solubilization.
Our data stand in contrast with previous observations in mice overexpressing A53T mutated
a-syn,  reporting  that  sph1  coexpression  do  not  reduce  a-syn  levels  (Smith  et  al.  2010).
However  it  is  important  to  note that  A30P and A53T a-syn mutations have already been
reported to lead to different aggregation properties, illustrated for example by reduced binding
to  cellular  membranes  as  a  consequence  of  A30P  mutation,  or  by  faster  aggregation
dynamics due to A53T mutation  (M. K. Lee et al. 2002; Lim et al. 2011; Martin et al. 2006;
Fortin et al. 2004; Yang et al. 2010). We suggest that different a-syn mutations lead to the
formation of a different pool of a-syn conformers, which may present different susceptibility to
be  degraded  by  sph1.  For  the  first  time,  we  showed  that  sph1  reduces  age-dependent
accumulation of soluble a-syn, leading to a protective effect (Zaarur et al. 2008; Smith et al.
2010).
1.2  Levels of insoluble alpha-synuclein
The impact of sph1 on a-syn aggregation was extensively reported in vitro (Engelender et al.
1999; O’Farrell et al. 2001; Tanaka et al. 2004; Büttner et al. 2010)  but less well studied in
vivo (Krenz et  al.  2009; Smith et  al.  2010).  In  the  in  vitro studies,  sph1 was reported to
promote  a-syn  aggregation,  but  the  methods  used  to  investigate  aggregates  were  not
consistent.  In  the  first  study,  the  percentage  of  cells  containing  cytoplasmic  eosinophilic
inclusions was investigated (Engelender et al. 1999). Later, fluorescence intensity was used
to identify the percentage of cells containing sph1 or a-syn-positive inclusions, in mammalian
and yeast cells that overexpressed fluorescent tagged sph1 or a-syn  (O’Farrell et al. 2001;
Büttner  et  al.  2010).  Finally,  other  authors  counted  the  percentage  of  cells  presenting
perinuclear accumulation of sph1 and ubiquitinated proteins, resembling aggresomes (Tanaka
et al. 2004). However, the exact solubility state of a-syn was not investigated in these studies.
The  effect  of  sph1  on  a-syn  aggregation  in  vivo is still  controversial.  In  the  first  sph1
transgenic animal generated, the effect of sph1 overexpression on endogenous a-syn levels
was not reported (Jin et al. 2008). In a second transgenic mouse, absence of sph1's impact
on endogenous  a-syn  levels  was  observed  using  a  method based  on sequential  protein
extraction to enrich less soluble proteins  (Nuber et al.  2010). In contrast, increased a-syn
aggregation  was  shown  in  non-transgenic  mice  using  thioflavin  S  staining  when  a
virus-mediated approach was used to overexpress sph1 (Krenz et al. 2009). Finally, double
transgenic mice overexpressing sph1 and human A53T mutated a-syn did not provide a clear
readout, showing increased proteinase K resistant a-syn levels in tissue lysate, but not at the
histological level, and a decreased number of silver positive inclusions (Smith et al. 2010).
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To better characterize the effect of sph1 on a-syn solubility, we enriched less soluble proteins
from brain homogenate using a sequential protein extraction based on detergents (Culvenor
et  al.  1999;  Tofaris  et  al.  2003) and  another  method  based  on  the  separation  of  high
molecular weight proteins using AGERA (Weiss et al. 2008). In both methods, we did not
observe a drastic effect of sph1 on a-syn solubility. When investigating the presence of highly
folded aggregates at the histological level using proteinase K digestion (Schulz-Schaeffer et
al. 2000; Neumann et al. 2002; Tanji et al. 2010), we found a strong decrease of insoluble
a-syn in both cell bodies and their processes of double transgenic animals. These data were
confirmed by extracting less soluble a-syn species, then labeling them with gold-conjugated
anti-a-syn  antibody  and  finally  analyzing  these  structures  by  electron  microscopy  (Díaz-
Hernández et al. 2004; Tomás-Zapico et al. 2012). By using this method, we suggest that the
precise a-syn species decreased in double transgenic mice present a filamentous nature. At
the histological level, we observed a decrease of inclusion quantity when performing staining
of  paraffin  embedded sections with  an  anti-a-syn  antibody.  However,  this  method is  less
suitable for quantification and does not reflect the low protein solubility.
Reduction  of  a-syn  aggregation  by  sph1  overexpression  was  investigated  mainly  in  the
hindbrain of hemizygous A30P mice and more precisely in the brainstem. It is important to
point out that we did not observe obvious a-syn aggregation in other brain structures of these
mice. Thus, we were unable to confirm sph1's effect  on a-syn aggregation in other brain
regions. However, it is unlikely that sph1's effects are specific to only particular cells of the
brainstem due to its rich diversity of neuron types  (Smith & DeMyer 2003), but we cannot
exclude that the amount of a-syn may regulate the efficiency of sph1-mediated degradation,
and that an increased amount of a-syn would result in the inhibition of this pathway. This
hypothesis could be tested in homozygous animals which are overexpressing a-syn at higher
level than the hemizygous mice. It is also interesting to mention that despite the similar spatial
expression patterns of sph1 and a-syn, we detected only few specific cell  subpopulations
coexpressing  high  amounts  of  both  transgenes  in  double  transgenic  mice.  This  result  is
surprising  because  both  promoters  were  reported  to  drive  protein  expression  mainly  in
neurons  (Baybutt  & Manson 1997; Vidal et al.  1990). Therefore it  would be interesting to
identify these cells and molecular mechanisms driving this effect.
For the first time, we showed in vivo that sph1 does not increase a-syn aggregation, but even
decreases  the  levels  of  some  specific  a-syn  species  and  especially  a-syn  fibrils.  The
reduction of a-syn aggregation by sph1 was already suggested previously in cells (Wong et
al. 2012) but was never reported in vivo.
 Levels of oligomeric alpha-synuclein
Toxicity of a-syn is reported to be driven by the formation of oligomers, possibly representing
intermediate structures between soluble and fibrillar forms of a-syn [reviewed in (Lashuel et
al. 2012)]. Therefore, investigation of a-syn oligomers is necessary in order to understand the
potential protective effect of sph1 on a-syn-related toxicity. By using dot blot and FRET, we
detected a-syn oligomers in homozygous A30P mice but not in hemizygous mice, supporting
that a-syn levels play a critical role in the formation of oligomers. It is discussable whether
a-syn  oligomer  levels  were  too  low  to  be  detected  in  hemizygous  animals  or  whether
oligomers are not formed or degraded or transformed in other species with a higher kinetic. 
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Thus, it is unclear if sph1 in our study plays a role in the formation of a-syn oligomers. It is
interesting to note that the authors of a recent study (Wagner et al. 2013) also described the
presence of  oligomers in  the same A30P mice.  For  further  analysis,  we suggest  another
protocol described in a recent study (Fagerqvist et al. 2013), in which the authors were using
a reducible amino-reactive crosslinker (DSP) to protect protein-protein interactions. However,
despite the use of this method, authors noticed a large variation in oligomer levels among
transgenic animals, stressing the complexity of oligomer analysis.
1.3  Levels of soluble synphilin-1
To  assess  if  the  mechanism  leading  to  the  reduction  of  a-syn  levels  also  involves  the
degradation of sph1, we used western blot to measure sph1 levels. Reduction of sph1 in brain
lysates  of  mice  coexpressing  A30P a-syn  was  observed  when  using  a  stringent  protein
extraction buffer. However, data generated using human A53T mutated a-syn overexpression
did  not  suggest  any  influence  of  a-syn  expression  on  sph1  levels  (Smith  et  al.  2010).
However,  this  hypothesis  was  not  further  explored  in  this  study,  which  was  probably  a
consequence of the complexity of sph1 immunostaining, due to the existence of multiple sph1
isoforms (I. J. Murray et al. 2003; Humbert et al. 2007) and from the few antibodies available.
We noticed in our study that the absence of detergents in the lysis buffer (TBS fraction of the
sequential protein extraction) resulted in a poor electrophoresis separation, thereby making
protein quantification difficult. We were able to overcome this problem by using detergents
(0.5% SDS and 1% NP-40) suggesting a low solubility of sph1 as observed previously (Nuber
et al. 2010). In this context, the lower levels of sph1 observed in double transgenic mice may
either result from decreased levels of soluble sph1 or result from an increased aggregation.
Similarly  to  the  reduction  of  soluble  a-syn  levels,  we  cannot  conclude  if  the  difference
observed  between  our  study  and  the  study  using  A53T  a-syn  animals  (Smith  et  al.
2010) results from the different a-syn mutations or from the different experimental conditions.
Therefore, it is unclear if reduced sph1 levels in double transgenic mice are a consequence of
a-syn-induced  degradation  of  soluble  sph1  or  a-syn-mediated  coaggregation.  Protein
solubility gradient-based assays are an alternative that may help to define more precisely if
lower levels of sph1 result from a decreased levels of protein or from its reduced solubility,
which can be confirmed using sph1 tracking during protein degradation induction.
2)  Synphilin-1 coexpression induced an increase of soluble 
ubiquitinated proteins as well as autophagy activity in A30P mice
2.1  Synphilin-1 did not modulate alpha-synuclein expression
In the previous paragraph we reported that sph1 decreased the age-dependent accumulation
of a-syn in mice overexpressing the human A30P mutated a-syn. To understand the origin of
this  a-syn reduction,  it  is  important  to  consider  that  intracellular  protein  levels  undergo a
continuous synthesis/degradation cycle to keep a pool of functional  proteins and to avoid
accumulation  of  damaged  proteins  [schematized in  Fig. 4-01.  and  reviewed in  (Goldberg
2003)]. Therefore, it is possible that the reduction of a-syn in double transgenic mice results
from a higher synthesis, from a lower degradation of a-syn, or from both.
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To  investigate  the  a-syn  synthesis,  we  determined  a-syn  levels  in  young  animals  using
western blot and did not observe differences in levels of the monomeric a-syn form between
A30P and double transgenic  animals.  Moreover,  preliminary transcriptional  analysis  using
Affymetrix did not reveal dysregulation of endogenous snca, thy-1 or prp mRNA levels. These
results also suggest that sph1 is not modulating the expression of endogenous nor transgenic
a-syn.  However,  microarrays  are  a  method  originally  conceptualized  to  screen  whole
organisms' transcriptomes and screening technologies may present variability resulting from
normalization  issues.  In  the  specific  case  of  genechip  technologies,  noise  or  low affinity
originating from a non-optimal primer design, as well as low abundance of RNA of interest (Ji
& Davis 2006),  may induce false negative data  (Choe et al.  2005).  Confirmation of these
results  at  the  single  mRNA level  could  have  been  performed  by  qPCR.  However,  the
comparison of western blots from young animals and Affymetrix from old animals suggests
that levels of a-syn are probably not deregulated at the transcriptional level but may rather
originate from a dysregulation of protein degradation.
2.2  Synphilin-1 promoted autophagosomal degradation
We started protein degradation investigation with the autophagy-lysosome pathway (ALP), a
pathway which was reported to play a major role in the degradation of excess levels of a-syn
[reviewed  in  (Ebrahimi-Fakhari  et  al.  2012)].  For  this  purpose,  we  analyzed  levels  of
autophagy markers using western blot and observed in A30P mice an accumulation of p62,
which is a cargo receptor for ubiquitinated proteins targeted for degradation by the ALP and
which itself is a substrate for autophagy (Komatsu et al. 2007; Pankiv et al. 2007; Bjørkøy et
al. 2009). We suggest that p62 accumulation in A30P mice indicates a potential impairment of
autophagosomal  degradation  which  is  not  present  anymore  in  double  transgenic  mice.
Accordingly,  changes  in  p62  levels  between  A30P  and  double  transgenic  mice  were
confirmed by an increase of beclin-1 levels in double transgenic mice. Indeed, elevated levels
of beclin-1 are inducing autophagy [suggested by drastic autophagy attenuation in beclin-1
heterozygous knockout mice (Qu et al. 2003) and by the rescue of autophagy impairments in
several  animal  models overexpressing beclin-1  (Spencer et  al.  2009; Fields et al.  2013)].
Consistently,  an  increase  of  beclin-1  was  also  reported  in  other  double  transgenic  mice
overexpressing A53T a-syn and sph1 (Smith et al. 2010).
Two different hypotheses can emerge from these observations: either sph1 can interfere with
the inhibition of the ALP in A30P mice or sph1 promotes protein degradation via autophagy
during  abnormal  protein  accumulation.  An  increasing  body  of  evidence  is  supporting  an
elevated level of autophagy in models overexpressing sph1 (Zaarur et al. 2008; Wong et al.
2008; Wong et al. 2012). In these multiple cell models overexpressing various proteins prone
to aggregate, sph1 coexpression was reported to mediate a specific aggregate degradation
but the numerous steps involved in autophagic flux are making this molecular pathway highly
dynamic and complex to study [reviewed in  (Xilouri et al. 2013; Lamark & Johansen 2012;
Lynch-Day et al. 2012)]. This analysis is simplified by stopping cell machinery during tissue
lysis  and  quantification  of  autophagy-markers  using  western  blot  is  well  established  and
accepted [reviewed in  (Klionsky et al. 2012)]. To better understand autophagy activation by
sph1,  specific  enzymatic  kinetics  and  a  detailed  pathway analysis  should  be  performed.
Unfortunately these studies cannot be performed ideally in adult brain tissue lysate.
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Despite these limitations, the decrease of autophagic flux observed in A30P single transgenic
mice as well as the recovery of autophagy in double transgenic mice, were supported by
several  studies showing that  a-syn inhibits  autophagy [(Klucken et al.  2012),  reviewed in
(Winslow & Rubinsztein 2011)] and that sph1 promotes autophagy [(Wong et al. 2008; Smith
et al. 2010; Wong et al. 2012)].
In  addition  to  the  modulation  of  p62  and  beclin-1  levels  observed  in  A30P and  double
transgenic mice, the observation of similar numbers of autophagosomes and reduced LC3-I
levels (without changes in LC3-II levels) suggest that a-syn and sph1 do most likely not play a
role in the formation of autophagosomes. Therefore, it remains unclear whether a-syn and/or
sph1 modulate autophagic flux.
Figure 4-01: Proteostasis network
Picture copied from (Hartl et al. 2011)
The protein quality control network integrates chaperone pathways to facilitate the folding of newly synthesized
proteins into their native conformations. Chaperones also prevent and remodel misfolded proteins. Absence of
either refolding or degradation by UPS may lead to protein aggregation. Some molecular chaperones slow or
prevent protein misfolding and aggregation, but in case of overwhelmed chaperone network capacity, non-native
proteins may form large and amorphous aggregates. Degradation of these aggregates by chaperone extraction
or by autophagy could be considered as the ultimate mechanisms to rescue cells from wide aggregation spread.
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2.3  Synphilin-1 promoted the formation and the redistribution of high 
molecular weight polyubiquitinated structures
The role of sph1 in aggregate formation was found directly after sph1 discovery (Engelender
et al. 1999). But ten years later, a function of sph1 in aggregate removal by autophagy via
aggresome formation and K63 polyubiquitination was suggested (Wong et al. 2008; Wong et
al. 2012). To test if ubiquitin signaling played a role in the reduced a-syn aggregation and/or in
the increased autophagy observed in A30P mice coexpressing sph1, we first used western
blot  to  quantify  the  total  levels  of  ubiquitinated  proteins.  In  double  transgenic  mice,  we
observed a general  increase of  soluble ubiquitinated proteins which was confirmed when
using several protein extraction buffers and different types of electrophoresis. Despite that
sph1 was reported to induce the formation of aggresomes in a ubiquitin-dependent pathway
(Wong et al. 2012), effects of sph1 overexpression on levels of ubiquitinated proteins were not
reported previously.
As ubiquitination is an abundant and versatile post-translational protein modification which
may  originate  from  multiple  mechanisms  [reviewed  in  (Kulathu  &  Komander  2012)],  we
investigated patterns of ubiquitin staining at the histological level. We detected in A30P mice
the presence of multiple small somatic ubiquitinated structures which were contrasting with
the presence of  large and dense ubiquitin-positive  structures at  the perinuclear  region of
double transgenic mice. Additionally, ubiquitin-positive structures found in double transgenic
mice were also sharing main aggresome properties such as perinuclear location, presence of
microtubules and colocalization with K63 polyubiquitinated proteins.
These different ubiquitin-positive structures, which were present in both A30P and double
transgenic  mice,  indicate  different  inclusion-like  properties.  Effects  of  sph1  on  aggregate
removal were suggested in several cell models (Zaarur et al. 2008; Wong et al. 2008; Wong
et al. 2012) which additionally showed that sph1 properties are not only specific to a-syn but
also to other aggregation-prone proteins. We propose that coexpression of sph1 may induce
transport of a-syn (and other proteins) to the perinuclear region where these complexes could
be sequestered into aggresomes susceptible to autophagic degradation (Fig. 4-02).
We also investigated the UPS in our mice since an increasing body of evidence suggests its
critical role in a-syn turn-over [reviewed in  (Ebrahimi-Fakhari et al. 2012)]. When analyzing
proteasomal activity in brain lysates using specific catalytic substrates, we did not observe
genotype-related differences in proteasome activity between mice overexpressing the human
A30P mutated a-syn and mice overexpressing the human sph1 protein. These results were
already suggested in a previous study using mice overexpressing a-syn (Martìn-Clemente et
al. 2004), but face multiple in vitro studies in which fibrillar and oligomeric forms of a-syn (but
not the monomer) were shown to inhibit  the overall  proteasomal degradation based on a
recombinant UPS system (Lindersson et al. 2004). However, it is also interesting to note that
our data fit the previous report of (Alvarez-Castelao & Castaño 2011) in which the authors did
not observe an effect of sph1 on UPS activity but a decreased degradation of a-syn by the
UPS. This may reflect a potential of sph1 to shift a-syn degradation from the UPS to the ALP.
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Figure 4-02: Aggresome autophagy pathway
Picture modified from (Chin et al. 2010)
Proteins misfolded (1) may be either refolded by chaperones (2) or tagged with Lys48-linked polyubiquitin chains
(3) to  be  degraded  by  the  proteasome  (4).  Failure  of  chaperone  and  proteasome  systems  result  in  an
accumulation of misfolded proteins leading to the formation of oligomerized and aggregated species (5) which
were reported to cause cytotoxicity. Misfolded proteins can also be tagged with Lys63-linked polyubiquitin by
several E3 ligases (such as parkin cooperating with E2 enzyme Ubc13/ Uev1a) (6), we suggest that sph1 acts
on a-syn toxicity at this level. Lys63-linked polyubiquitin chains promote binding of misfolded proteins to HDAC6
(7) and thereby to the dynein motor complex for retrograde transport towards the MTOC to form aggresomes
(8).  Lys63-linked  polyubiquitination  promotes  the  binding  of  p62  and  facilitates  its  recruitment  to
autophagosomal membranes (9). Subsequent fusion of autophagosomes with lysosomes allows the degradation
of misfolded and aggregated proteins by lysosomal hydrolases (10).
However,  direct  comparison between our  ex vivo assay and other  in  vitro studies  is  not
relevant because absolute levels of a-syn fibrils and cell diversity in tissue lysate cannot be
reproduced in cell culture or recombinant models.  Furthermore, the concentration of a-syn
used in in vitro assays (Snyder et al. 2005) was 5000 times higher than in brain lysate from
the current  mouse model  (Kahle et  al.  2001),  making the  physiological  relevance of  this
observation questionable (a-syn was reported to inhibit the proteasome at 5 µM in vitro but
concentration of a-syn is less that 1 nM in mouse brain). Despite that reduced proteasome
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activity  was  repeatedly  reported  in  PD  patients  (McNaught  &  Jenner  2001;  McNaught,
Belizaire,  et  al.  2002;  McNaught  et  al.  2003),  the  relevance  of  a-syn  in  this  process  is
controversial (Tofaris et al. 2003) as this effect was only observed in the substantia nigra but
not in other brain regions featuring LBs and LNs. Still, we cannot exclude that subtle effects
on proteasomal activity by transgenic protein expression could be evened out due to the
conditions of our experiments (such as ATP addition or stress induced by tissue lysis to the
proteasomal  machinery).  But  these  conditions  seem  acceptable  when  compared  to  the
original report in which samples collected several days post mortem were processed similarly.
It is also important to note that the proteasomal activity is directly dependent on the subunit
composition of the 26S proteasome (such as 11S or 19S cap). To investigate this issue, we
measured protein levels of different UPS subunits and did not observe that a-syn or sph1
influenced  the  levels  of  catalytic  or  regulatory  subunits.  But  interestingly,  analysis  of
proteasome  at  the  histological  level  showed  an  abnormal  distribution  of  the  regulatory
subunits  of  the  proteasome  in  A30P  mice.  More  precisely,  proteasomal  subunits  are
classically reported to be located in the perinuclear region or in the nucleus. But in A30P
mice, this pattern was replaced by a more somatic staining, suggesting the recruitment of
proteasome  subunits  into  inclusions.  This  hypothesis  is  supported  by  previous  studies
showing the recruitment of proteasomal subunits in a-syn positive inclusions (Ii et al. 1997;
Snyder et al. 2003; Zhou et al. 2004). This observation, in addition to the increase of a-syn
fragments observed in A30P when compared to double transgenic mice, suggest that these
fragments might be a product of the UPS that may promote the formation of major a-syn fibrils
(C.-W. Liu et al. 2005).
Following this logic,  we suggest that the recruitment of  UPS regulatory subunits in these
inclusions does not inhibit the UPS function, but induces a vicious cycle of increased higher
a-syn truncation, leading to increased aggregation.
3)  Synphilin-1 reduced pathology in mice overexpressing the 
human A30P mutated alpha-synuclein
3.1  Reduced beta sheet structures in mice coexpressing synphilin-1
When sph1 was discovered during screening for a-syn interacting partners (Engelender et al.
1999), its abnormal presence in the brain of PD patients within LBs (Wakabayashi et al. 2000)
led to the hypothesis that sph1 may have a pathological function in synucleinopathy. This
hypothesis was opposed rapidly when it was observed that 1) parkin-ubiquitination of sph1 is
disrupted  by  familial-linked  PARK2 mutations  (Chung  et  al.  2001) and  that  2) the  sph1
mutation R621C was found to be associated with PD development (Marx et al. 2003).
Numerous cell culture models consistently showed that overexpression of sph1 promoted the
formation  of  inclusions  and  these  inclusions  were  characterized  later  in  more  detail  as
perinuclear ubiquitinated aggresomes  (Tanaka et al.  2004). The impact of aggresomes on
cells survival is contradictory. It was reported that aggresomes either increase cell toxicity (G.
Lee et al. 2002; Eyal et al. 2006; Alvarez-Castelao & Castaño 2011), do not modulate cell
toxicity (O’Farrell et al. 2001) or are even protective against a-syn induced toxicity (Tanaka et
al. 2004; Wong et al. 2008; X Li et al. 2010; Wong et al. 2012). Similarly, sph1 overexpression
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in mouse models provided inconsistent results. These animals were shown to develop either
no pathology (Smith et al. 2010), a mild pathology (Jin et al. 2008; Nuber et al. 2010) or a
strong pathology in a study based on intracranial injection of viral vectors (Krenz et al. 2009).
In this context, we investigated the impact of sph1 on the neuropathology developed in the
hindbrain of A30P transgenic mice. We focused particularly on the brainstem of these animals
as  this  brain  region  was  reported  to  demonstrate  the  highest  pathology when  using  PK
resistant a-syn staining (Schulz-Schaeffer et al. 2000; Neumann et al. 2002; Tanji et al. 2010).
In a first approach, we investigated neuropathology using silver staining (Braak & Braak 1999;
Uchihara 2007) and thioflavin S (Sun et al. 2002) in parallel because both dyes were reported
to lead to the same staining pattern (Vallet et al. 1992; Cullen et al. 1996; Sun et al. 2002).
These stainings, reflecting both degenerating axons (Gallyas et al. 1980) and the presence of
beta  sheet-structures  (Biancalana  &  Koide  2010),  were  showing  characteristic
synucleinopathy-related processes and cellular  inclusions in  the brainstem of  A30P mice.
Interestingly, these patterns were drastically reduced in double transgenic mice, supporting
results reported in A53T mutated a-syn transgenic mice (Smith et al. 2010). We would like to
mention that another study showed contrary observations when using a viral vector to induce
sph1 expression (Krenz et al. 2009). However, injection-related complications (killing almost
10% of dopaminergic cells in the SN) and high viral titer (resulting in a very strong expression
of  sph1  which  cannot  be  reached  using  a  transgenic  animal  model)  may  explain  the
differences observed in this study. It is also important to notice that animals used in this study
were relatively young (6 months) and did not present neuropathology (as demonstrated with
thioflavin S staining). We suggest that the protective effect of sph1 in A30P mice presented in
our  study  could  also  be  replicated  in  mice  injected  with  viral  vectors  inducing  sph1
expression. However, the age of the mice and the viral charge injected would have to be
optimized. Finally, the viral vector approach induces a strong expression of the transgene in a
short time, therefore we cannot exclude that this strong and very located expression may
result in an exacerbated pathology when compared to transgenic animal models.
Gallyas silver staining and thioflavin S are usually reported to identify inclusions, but as levels
of  aggregates are debated to  be a reliable  pathology marker  [reviewed in  (Bendor  et  al.
2013)] we cannot conclude using these stainings that sph1 had a neuroprotective function in
A30P mice. This was illustrated in a recent study showing that G51D mutated a-syn leads to
cell toxicity without promoting a-syn aggregation (Lesage et al. 2013). However, it is known
that  a  direct  increase  of  a-syn  degradation  results  in  an  improved  phenotype  in  mice
overexpressing a-syn  (Spencer et  al.  2009).  Despite that we  cannot conclude from these
stainings that  sph1 coexpression in  A30P mice was reducing their  neuropathology,  these
experiments support the decrease of aggregate load in double transgenic animals.
To endorse the neuroprotective effect of sph1, other neurodegeneration markers should be
investigated. Ideally, the impact of reduced a-syn aggregates on nigrostriatal degeneration
(and particularly loss of SN dopaminergic cells) should be investigated [reviewed in (Blandini
&  Armentero  2012)].  Unfortunately,  mice  overexpressing  the  human A30P mutated  a-syn
cannot be used for this purpose as they do not present nigrostriatal cell loss.
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3.2  Reduced neuroinflammation in mice coexpressing synphilin-1
It is intriguing that despite the similar origin of synucleinopathy in familial forms of PD, which
are consequence of SNCA duplication or triplication, and transgenic mice with a 2- to 5-fold
overexpression of human a-syn, transgenic mice do not present a loss of nigral cells (Kuo et
al.  2010).  It  would be a tentative interpretation  to suggest that the nigrostriatal  system of
rodents  may cope with  higher  levels  of  a-syn  than the  human brain,  especially  because
transgenic  mice  overexpressing  a-syn  are  also  known  to  reproduce  neuroinflammation,
oxidative  and  proteolytic  stress  [reviewed  in  (Blesa  et  al.  2012;  Bezard  et  al.  2013)],
neuropathology  at  the  histological  level  [oxidative  stress  reviewed in  (Bosco et  al.  2006;
Nakabeppu et al. 2007), proteolytic stress  (Ebrahimi-Fakhari et al. 2012; Cook et al. 2012;
Xilouri et al. 2013) and inflammation (Perry 2012)].
In  this  context,  we  also  used  inflammation  markers  (such  as  microglial  and  astroglial
activation),  to  confirm  that  the  aggregation  found  in  A30P  mice  is  accompanied  by
neuroinflammation  at  the  histological  level.  Accordingly,  we  observed  neuroinflammation
marks in A30P mice which were strongly reduced in double transgenic mice. However, the
origin of the inflammation observed in the brain of A30P transgenic mice is unknown and the
relevance  of  this  inflammation  as  a  causative  or  a  protective  mechanism is  discussable
[reviewed in  (Tufekci et al. 2012)]. Despite that neuroinflammation levels are usually poorly
reported when investigating potential effects of transgenes  (Fan et al. 2006; Spencer et al.
2009) or drugs (Wagner et al. 2013; Hebron et al. 2013), few other studies also showed that a
decreased synucleinopathy goes along with a decreased inflammation [reviewed in (Hirsch &
Hunot  2009;  Koppula et  al.  2012)].  However,  most  of  these studies were based on toxin
induced  animal  models,  which  are  themselves  inducing  the  production  of  ROS  and
inflammation.  For  example,  this  could  be  illustrated  by  the  injection  of  rotenone  in  mice
treated with the non-steroidal anti-inflammatory sodium salicylate (Thakur & Nehru 2013) or
MPTP intoxicated mice treated with the anti-inflammatory CNI-1493 (Noelker et al. 2013).
Finally, we also would like to point out that the observed neuroinflammation may result from
multiple  pathways  which  may lead to  abnormal  glial  activity.  But  most  studied  origins  of
neuroinflammation  in  synucleinopathy are  mitochondrial  dysfunction  [reviewed in  detail  in
(Hernández-Aguilera  et  al.  2013;  López-Armada  et  al.  2013)]  and  exocytosis  of  a-syn
[reviewed in (Marques & Outeiro 2012)].
Our results are supported by a previous study showing that sph1 is reducing a-syn-related
neuroinflammation  (Smith et al. 2010).  Therefore, it is interesting to note that the effect of
sph1 is  stronger  on  astroglial  cells  than  on  microglial  cells.  Accordingly,  astrocytic  a-syn
deposition was shown to initiate the recruitment of phagocytes and microglias that attack and
kill neurons (Halliday & Stevens 2011). As levels of microglial activity were suggested to be
correlated  with  neuronal  dysfunction  [reviewed  in  (Hirsch  &  Hunot  2009)],  low  levels  of
activated microglia may reflect a neuroprotective effect occurring in double transgenic mice.
To validate this hypothesis, inhibiting or activating microgliosis in A30P mice presenting would
be an interesting strategy to study a-syn aggregation and toxicity.
All  together,  we  suggest  that  the  reduced  a-syn  accumulation  and  neuroinflammation
observed in double transgenic mice speaks for a neuroprotective effect of sph1 coexpression.
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4)  Synphilin-1 reduced motor phenotype in mice overexpressing 
the human A30P mutated alpha-synuclein
4.1  Coexpression of synphilin-1 delayed motor phenotype onset 
observed in mice overexpressing alpha-synuclein
In the last chapter, we presented the impact of sph1 coexpression on soluble and insoluble
a-syn levels, as well as on the neuropathology observed in transgenic mice overexpressing
human A30P mutated a-syn.
To confirm the relevance of the neuroprotection suggested by histological observations, we
investigated a potential modification of the pathophysiology observed in A30P mice [reported
previously in (Freichel et al. 2007)]. We first focused on the progressive locomotor impairment
developed by A30P mice using an accelerating rotarod. We found that the first signs of motor
abnormalities were observed in A30P mice at 26 weeks and were delayed to 38 weeks in
double transgenic mice, suggesting that coexpression of sph1 may delay synucleinopathy.
Rotarod, and especially protocols using accelerating speed, are sensitive and reproducible
methods to detect motor impairment in transgenic animals [reviewed in (Karl et al. 2003)]. But
interestingly, in the first characterization of A30P mice (Freichel et al. 2007), a motor deficit on
the rotarod was found only in 51 week-old animals using rotarod, whereas it  appeared at
38 weeks of age in our study. It is important to note that the protocols used to investigate the
motor  phenotype  were  different  in  the  two  studies  (protocols  described  in  table 4-02).
Because motivation and motor learning may play an important role for rotarod performance,
we adapted the original protocol of (Freichel et al. 2007) following recommendations from
(Karl et al. 2003). In short, a training period was added and a larger number of trials were
given, leading to a longer testing period.
Table 4-02: Differences in rotarod protocol between Freichel et al. 2007 and 
Casadei et al. 2013
Study Freichel et al. 2007 Casadei et al. 2013
Number of animals used 6 males + 6 females 12 males
First locomotor investigation 8 month-old 4 month-old
Test frequency Every week Every 6 weeks
Training No Yes (1 day with 4 trials)
Testing day per investigation 1 4
Trial per testing day 3 4
Rotarod speed 0-32 rpm in 4 minutes 4-40 rpm in 7 minutes
In top of the impact of motivation and motor learning on rotarod performance, we also would
like  to  highlight  that  cardiopulmonary  endurance,  anxiety  or  body  weight  may  influence
rotarod outcome. Therefore, we confirmed that motor skill learning and body weight were not
different between A30P and double transgenic mice, but we could not directly investigate
cardiopulmonary performance of our animals.
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When using a challenging beam walk approach, an alternative test of motor performance, we
detected  deficits  in  both  A30P  and  double  transgenic  mice.  However,  it  is  important  to
mention that  this  test  was performed in  12 month-old  animals,  and differences in  rotarod
performance between A30P and double transgenic mice were no longer present at this age. A
surprising finding was that sph1 mice, which exhibited a motor phenotype at 12 months of age
in the challenging beam walk, did not present deficits in rotarod at any age.
To  better  understand  these  discrepancies,  we  performed  automated  gait  analysis  and
observed in A30P mice multiple gait abnormalities such as shorter steps and higher cadence,
which are possibly reflecting rigidity. We also observed in sph1 and in double transgenic mice
a conceptually different phenotype than A30P animals consisting of an increased stand and
abnormal  walking  pattern,  which  may  reflect  a  coordination  impairment  or  a  muscular
weakness.
It is unlikely that the gait abnormalities found in sph1 and double transgenic animals, using
challenging beam walk test or Catwalk, affected rotarod performance. Thus, it is unclear if the
late-onset  phenotype  found  on  the  rotarod  in  double  transgenic  mice  truly  reflects  a
synucleinopathy or a sph1-mediated pathology.
4.2  Mice overexpressing synphilin-1 or alpha-synuclein did not 
display abnormal anxiety behavior
The  investigation  of  motor  ability  in  rodents  is  a  sophisticated  task:  abnormal  motor
performance  may  arise  from  a  combination  of  complex  traits  (such  as  psychiatric
abnormalities or learning deficits), which may partially imitate the consequences of balancing
or coordination impairment resulting from neurodegeneration [reviewed in (Bailey et al. 2006;
Crawley 2008)].
Thus, to exclude possible artifacts in our study, a complete phenotyping was performed. In a
first  approach,  we  tested anxiety in  our  transgenic  animals  using  an open field  test  and
detected a decreased locomotor activity in all transgenic lines without observing an abnormal
number of visits or time spent to explore the center of the field. This suggests that the motor
deficits observed in transgenic mice in the aforementioned tests might have resulted in a
reduced exploratory activity which was not stress-related. This could have been confirmed
using multiple component analysis of motor deficits and anxiety index.
Literature reviewing open field tests in mice overexpressing a-syn identifies hyperactivity in
young transgenic animals as a common readout which contrasts extremely with a progressive
motor  phenotype  observed  at  older  ages.  Interpretation  of  open  field  behavior  becomes
therefore complex, as each model  is characterized by a specific age of motor phenotype
onset,  as  well  as  a  specific  character  of  early  hyperactivity,  and  a  specific  pathology
progression. Because of their strong influence on mice's behavior, all these parameters can
possibly lead to contradictory results. Accordingly, contradictory results were found for mice
overexpressing  a-syn.  For  example,  no  anxiety  impairment  was  reported  for  transgenic
mouse models overexpressing human Y39C mutated a-syn or murine a-syn under the Thy-1
promoter (Zhou et al. 2008; Rieker et al. 2011), but increased anxiety was described for mice
overexpressing human or human A53T mutated a-syn (Lam et al. 2011; Rothman et al. 2013).
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In this context, the presence of motor impairments in transgenic animals may also limit the
total distance traveled by animals, thus resulting in a reduction of time spent in the center of
the apparatus and imitating a possible anxiety-like behavior in old transgenic animals. Despite
this potential source of artifacts, we did not observe a reduced time spent in the center of the
open field, confirming that the reduced activity is not a consequence of increased anxiety
leading to a lower activity, but is more a direct consequence of a motor impairment. Therefore
open field data suggest that deficits observed in several tests of motor function (i.e. rotarod,
challenging beam walk and gait analysis) did not result from anxiety-like behavior. 
Obviously, the confirmation of these results using anxiety tests less dependent on motor skills
would  have  been  a  better  choice.  Many  solutions  using  stimulus  extinction  and  shock
sensitivity would have been possible [such as the Vogel  conflict  test  (Vogel et  al.  1971)].
Nowadays, less stressful  protocols based on animal behavior within automated cages and
stimulus extinction based on air-puff were shown to be more robust and less stressful for mice
(Marsicano et al. 2002).
4.3  Coexpression of synphilin-1 improved home-cage activity 
reduction observed in mice overexpressing alpha-synuclein
We  then  investigated  the  relevance  of  improved  motor  ability  observed  in  A30P  mice
overexpressing sph1 by tracking different activity patterns such as acclimatization or global
activity in a home-cage-like environment. Under these conditions, we observed in 18 month-
old A30P mice a reduced activity during both acclimatization and the dark phase on the third
day  of  observation  (period  in  which  mice  were  most  acclimatized  to  the  system  in  our
experiment).  Despite  similarly reduced activity observed during the acclimatization phase,
sph1 and double transgenic mice did not show reduced activity after acclimatization. These
data might suggest that the motor deficit observed earlier led to a reduced acute activity of all
transgenic mice. Moreover, the milder pathology in sph1 mice, as well as the delayed motor
deficit in double transgenic mice, did not reduce the baseline home-cage activity suggesting a
protective effect of sph1 on motor functions.
These conclusions are supported by several studies performed in our institute, in which mice
that  presented motor  phenotypes  in  rotarod and/or  in  beam walk  tests  also  presented a
reduced of home-cage activity (Portal et al. 2013; Hübener et al. 2012). It is interesting to note
that  in  the  original  description  of  the  A30P  mouse  pathology  (Freichel  et  al.  2007),  an
increased home-cage activity was measured in A30P mice when investigating 8 or 12 month-
old  mice  for  2 hours.  As described previously  for  the  anxiety  test,  these data  cannot  be
directly compared to our experiment in which older mice (18 month-old) were examined. It is
possible that hyperactivity in 8 or 12 month-old mice were masked by motor pathology.
When interpreting these results, it is also important to consider that automated behavioral
testing  systems  are  conceptualized  and  reported  to  be  similar  to  home-cages  (Tecott  &
Nestler  2004;  de  Visser  et  al.  2006).  However,  considerable  differences  between  these
systems and typical home-cage environments have been noted, and suggested to induce
stress in animals (Clemens et al. 2013).
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In this context, we suggest that the decreased activity observed during the acclimatization
period  is  a  consequence  of  an  advanced  motor  phenotype  and  does  not  result  from a
difference response to stress. To gain insight in the origin of the decreased activity observed
in light  phases, it  would have been interesting to  investigate circadian rhythm, and more
specifically  sleep/wake  cycle.  As  sleep  disturbances  are  frequent  nonmotor  symptoms
occurring in PD patients [reviewed in (Lyons & Pahwa 2011)], the potential impact of a-syn on
rest/sleep time periods could  have  been investigate  by measuring  inactivity  cycles  or  by
performing electroencephalography.
4.4  Coexpression of synphilin-1 improved olfactory deficits observed 
in mice overexpressing alpha-synuclein
Among non-motor symptoms, impaired olfaction is frequently observed in patients with PD
(Ward et al. 1983; Doty et al. 1989; Berendse et al. 2001; Parrao et al. 2012) . Accordingly,
olfactory deficits were also reported in mice overexpressing the human a-syn under the Thy-1
promoter (Fleming et al. 2008). We found in 18 month-old A30P mice a smell deficit illustrated
by an abnormal lack of rat smell avoidance which was not observed in double transgenic
mice. The presence of olfactory deficits in mice overexpressing the human A30P mutated
a-syn under the Thy-1 promoter is also confirmed by a recent article, in which the authors
describe an abnormal integration of adult born neurons in the olfactory bulb of transgenic
mice (Neuner et al. 2014).
It is important to note that abnormal anxiety or exploratory behavior may have a major impact
on  this  protocol.  However,  this  hypothesis  could  be  refuted  as  we  did  not  observe  an
anxiety-related phenotype of the transgenic lines in novel environment as suggested by the
open field test.
This experiment again is suggesting a general reduction of neuropathology in A30P mice
coexpressing sph1, even in regions with less remarkable aggregation such as olfactory bulb.
However, it would be important to confirm these results in other brain region less prone to
degeneration with aging.
4.5  Influence of synphilin-1 and alpha-synuclein on spatial memory
With this objective, we also checked for possible cognitive deficits in A30P mice, reported
originally in  (Freichel et al. 2007) using a Morris water maze to investigate spatial learning.
After training the mice for two consecutive days, we observed that they did not learn properly
the position of the platform. This was reflected by a low slope during the spatial  learning
(which consists of putting animals at a pseudo-random position into the water tank and letting
them find the platform) and suggesting that mice were not able to reach the platform in a
distance  as  small  as  during  the  training  using  cued  platform.  Furthermore,  mice  did  not
remember the position of the platform in the water maze, resulting in a random strategy to find
the escape.
In  this  context,  it  would be incorrect  to  compare spatial  learning between transgenic and
wildtype animals. We suggest that this behavior may result from a too short training, and/or
insufficient spatial cues in the room. Therefore, it would have helped to validate the absence
of spatial preferences in the room and increase the learning period.
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Perspective
1)  Confirmation of phenotype using synphilin-1 knock-out mice 
to confirm its function
To  confirm  the  potential  of  molecular  mechanisms  induced  by  human  synphilin-1
overexpression in transgenic mice overexpressing human A30P mutated a-syn protein, it is
mandatory to  show that  the  transgene  introduced  to  modulate  synucleinopathy was  fully
functional. This statement could be difficult, or even impossible, when studying proteins with
unknown role or function.
In this particular case, confirmation of the transgene activity/function could be avoided by
analyzing the effect of removing the gene from an animal (knock-out).
2)  Investigation of aggresome function and mechanisms in order 
to reduce synucleinopathy
To identify mechanisms leading to aggresome formation and degradation, we suggest to use
a  cell  model.  Using  proteasome inhibitor  to  induce  protein  aggregation  and  formation  of
aggresomes,  it  would  be  possible  to  study  proteins  reported  to  play  a  potential  role  in
aggresome formation such as hdac6 or gamma-tubulin. But also drugs which may increase
protein transport or inhibit K63 degradation to promote aggresome formation and degradation
of a-syn, could be studied.
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Conclusion
Altogether, this study shows that coexpression of sph1 in a mouse model overexpressing
a-syn  reduced  the  accumulation  of  soluble  forms  of  a-syn,  promoted  the  formation  of
aggresome-like  structures  without  reducing  detergent-insoluble  a-syn.  This  resulted  in  a
reduced  neuropathology  and  behavioral  improvements  in  mice  overexpressing  a-syn.
Therefore, we suggest that the recruitment of a-syn into aggresome-like structures may lead
to its degradation by inducing autophagy, slowing synucleinopathy development in the mouse.
Moreover, our data clearly demonstrate that aggregates observed in our double transgenic
model  do  not  share insolubility and content  in  a-filament,  suggesting that  sph1 does not
increase the load of a-syn aggregates, but changes a-syn inclusion structures. All in all, we
suggest that mechanisms induced by the overexpression of sph1  in vivo represent specific
and valuable strategies to treat synucleinopathy without disturbing normal cell function.
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Abbreviation
6-OHDA: 6-hydroxydopamine
aa: amino acid
a-syn: alpha-synuclein
ADP: adenosine diphosphate
AGERA: agarose gel electrophoresis for resolving aggregates
ALP: autophagy-lysosome pathway
ANK: ankyrin
atg: autophagy-related gene
ATP: adenosine triphosphate
BAC: bacterial artificial chromosome
CK: casein kinases 1 and 2
CMA: chaperone-mediated autophagy
Cp: crossing point
DAPI: 4',6-diamidino-2-phenylindole
DAT: dopamine active transporter (also termed SLC6A3)
Dpi: dot per inch
DNA: deoxyribonucleic acid
EDTA: ethylenediaminetetraacetic acid
ER: Endoplasmic reticulum
GABA: gamma-aminobutyric acid
GTP: guanosine triphosphate
HDAC6: histone deacetylase 6
HSP: heat shock protein
Hu: human
IHC: immunohistochemistry
IPD: idiopathic Parkinson's disease
IP: intraperitonial
KO: knock-out
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LB: Lewy body
LN: Lewy neurit
LAMP-2A: lysosome-associated membrane protein type 2A
LRRK2: leucine-rich repeat kinase 2
MMP: matrix metalloproteinases
MPP+: 1-methyl-4-phenylpyridinium
MPTP: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine
Ms: mouse
MTOC: microtubule organizing center
NAC: non-amyloid β component
NACP: non-amyloid β component precursor
PAGE: polyacrylamide gel electrophoresis
PBS: phosphate-buffered saline
PCR: polymerase chain reation
PD: Parkinson's disease
PDGFβ: platelet-derived growth factor β
PFA: paraformaldehyde
PINK1: PTEN-induced putative kinase 1
PK: proteinase K
PrP: prion protein
PTEN: phosphatase and tensin
PVDF: polyvinylidene fluoride
RIPA: radioimmunoprecipitation assay buffer
ROS: reactive oxygen species
RPM: revolutions per minute
RNA: ribonucleic acid
SDS: sodium dodecyl sulfate
SEM: standard error on the mean
SNCA: synuclein alpha gene
SNCAIP: synuclein alpha interactor partner gene
SNP: single-nucleotide polymorphism
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SNpc: substantia nigra pars compacta
Sph1: synphilin-1
Tg: transgenic
TH: tyrosine hydroxylase
UPS: ubiquitin-proteasome system
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Animal  activity  was  assessed  using  the  PhenoMaster/LabMaster,  a  system  consisting  of
infrared light-beam frames surrounding an animal cage. In the system, X represents the cage
length, Y the width and Z the height. Infrared beams are monitored by a control unit which
converts the electronic signal to a numeric output file recording beam breaks every 10 ms.
1)  Generation of PhenoMaster/LabMaster output files
Metadata  (including  individual  animal  number,  box,  weight,  line,  gender  and  age)  were
entered before the start of the experiment. An example of the input generated by the system
is represented in table 5-01. An example of extracted database is given in table 5-02.
Table 5-01: Information file input example
Nicolas_sph1-asyn-dtg_1;Exp021;Genotype;sex;
Box;Animal No.;Weight [g];Text1;Text2;Text3;
1;290;33,9;male;nTg;18m
2;291;34,0;male;nTg;18m
3;294;36,2;male;nTg;18m
4;284;38,7;male;nTg 18m
5;297;35,0;male;nTg;18m
Date; Time; Animal No.; Box; XT+YT; XT; XA; XF; YT; YA; YF; Z; CenT; CenA; CenF; PerT;
PerA; PerF; DistK; DistD; Speed; Drink; Feed;
;;;;[Cnts];[Cnts];[Cnts];[Cnts];[Cnts];[Cnts];[Cnts];[Cnts];[Cnts];[Cnts];[Cnts];[Cnts];
[Cnts];[Cnts];[cm];[cm];[cm/s];[ml];[g];
28-02-14;13:58;290;1;109;62;44;18;47;35;12;4;26;19;7;83;60;23;155;155;3;0.01;0.01;
28-02-14;13:59;290;1;130;70;43;27;60;40;20;5;59;38;21;71;45;26;333;178;3;0.02;0.01;
28-02-14;14:00;290;1;179;100;68;32;79;53;26;3;45;27;18;134;94;40;559;226;4;0.02;0.01;
To  perform  personalized  analysis,  some  basic  parameters  are  collected  in  temporary
variables (including time binning, experiment length and acclimatization time).
# define binning (for graphic plotting), experiment length and acclimatization time
merged.time <- 30 # define time use for the data binning
length.experiment <- 70 # define experiment length in hours
begin.time <- 30 # acclimatization time for the analysis
# define time when the dark phase start (in this example dark phase start at 15 h)
# time should be expressed in minutes (in this example 15 hours x 60 minutes = 900)
begin.dark <- 900
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# definition of variables (in this example two files generated by the system called
# analysis01 and analysis02
phenofiles <- c(analysis01, analysis02) # list of files to analyze
info <- NULL # variable recording metadata
info.tmp <- NULL # create a new temporary variable
file <- NULL # create a new temporary variable
cage.exper <- NULL # variable recording cages per experiment
# read each output file metadatas and save them into the variable “info”
for (file in phenofiles) { # loop over all file to analyze
# metadata incorporated at the beginning of the output file contain less field than
# the database. To record the number of animals per experiment, we used the line
# number when the large database start minus two unnecessary lines (containing the 
# file title and the header of the table)
number.cage <- count.fields(file, sep=";") # count fields per row
# find the last row with less fields that the maximal and remove the 2 lines
animal.per.run <- max(which(number.cage<max(number.cage))-2
# read the experiment output file skipping the two first rows which do not contain
# relevant information
info.tmp <- read.csv2(file, blank.lines.skip=TRUE, header=TRUE, 
nrows=animal.per.run, skip=2, dec=",", sep=";")
# add to the variable info the new rows
info <- rbind(info, info.tmp, deparse.level=1)
cage.exper.tmp <- c(which(phenofiles==file), animal.per.run)
cage.exper <- rbind(cage.exper, cage.exper.tmp)
}
# change column names
colnames(info) <- c("Box", "Animal.No.", "Weight", "Gender", "Genotype", "Age")
# create a backup file called "genotype.txt" that user can open at the end of the
# calculation to plot data or do more statistic in another software
write.table(info, file="genotype.txt", append=FALSE, quote=FALSE,
sep=";", dec=".", row.namesFALSE)
Table 5-02: Information file output example
Box Animal No. Weight Gender Genotype Age
1 290 33.9 male nTg 18m
2 291 34.0 male nTg 18m
3 292 36.2 male nTg 18m
4 293 38.7 male nTg 18m
5 294 35.0 male nTg 18m
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The PhenoMaster/LabMaster software creates a database for each experiment performed.
These databases contain X, Y or Z beams break, distance traveled, speed and amount of
food or water consumed. The parameters are saved by default every minute.  Furthermore,
the  system  separates  fine  movements  (animal  breaking  twice  the  same  beam)  from
ambulation (animal breaking two different beams) and movements in the center (breaks in the
most central beam of the X and Y axis) from movements in the periphery of the cage.
An  example  of  a  simplified  output  file  (one  animal,  5  minutes  and  for  the  ambulation
movement) is represented in table 5-03.
Table 5-03: PhenoMaster/LabMaster output file example
Date Time Animal No. Box XA YA Z CenA PerA DistD Speed Drink Feed
28-02-2014 13:45 290 1 44 35 4 19 60 155 3 0.01 0.01
28-02-2014 13:46 290 1 43 40 5 38 45 178 3 0.02 0.01
28-02-2014 13:47 290 1 68 53 3 27 94 226 4 0.02 0.01
28-02-2014 13:48 290 1 102 59 4 72 89 276 5 0.02 0.01
28-02-2014 13:49 290 1 51 42 6 23 70 178 3 0.03 0.01
LabMaster/PhenoMaster software converts a list of beam breaks to a number representing
the sum of breaks (or the distance) per minute. But the output files generated neither allow an
easy  comparison  between  genotypes,  nor  for  selecting  specific  time  periods  (such  as
acclimatization time or last active phase), and they also do not contain genotype of animals.
# correction of files by deleting unit raws
m.table.tmp <- NULL # create a temporary variable
for (file in phenofiles) { # for each file to analyze
m.table.2 <- NULL # create a new temporary variable
# extract the header of the database which contain animal metadata
m.table <- read.csv2(file, skip=(cage.exper[which(phenofiles==file), 2]+5))
# rename column
colnames(m.table) <- colnames(read.csv2(file, skip=
(cage.exper[which(phenofiles==file), 2]+3))
# save mouse age (represents different experiments/time points)
age <- head(read.csv2(file, skip=2, sep=";"), n=cage.exper[n, 2])
# create the column “Age”
for (tmp in unique(m.table$Animal.No.)){ # search age of each mouse
age.t <- age[age$Animal.No.==tmp, "Text3"] # read animal age
col.l <- length(m.table[m.table$Animal.No.==tmp, ]) # number of row
m.table[m.table$Animal.No.==tmp, "Age"]<- rep(age.tmp, rep=length.col) 
}
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# create a backup file for each output
write.table(m.table.2, file=paste("LabMaster", which(phenofiles==file), ".csv", 
sep=""), append=FALSE, quote=FALSE, sep=";", dec=".", row.names=FALSE)
}
Modified output files are extracted and merged into a single large database and results are
binned to allow the user to plot the evolution through the time easily.
# define files to analyze
phenofiles <- list.files(path=getwd(), pattern=".csv", all.files=TRUE,
full.names=FALSE, recursive=FALSE, ignore.case=FALSE)
# import tables and read data
res <- NULL # large merged database
res.tmp <- NULL # temporary variable
res.g <- NULL # merged and binned database
res.g.tmp <- NULL # temporary variable
file <- NULL # output files modified
for (file in phenofiles) {
# read modified outputs and pick most interesting columns
res.tmp <- data.frame(read.csv2(file, header=TRUE, dec="."))
res.tmp <- res.tmp[, c("Age", "Date", "Time", "Animal.No.", "Box", "XT", 
"XA", "XF", "YT", "YA", "YF", "DistD", "Z", "CenT", 
"CenA", "CenF", "PerT", "PerA", "PerF", "Drink", 
"Feed")]
# change date by a list of number (allow to compare experimental days)
date <- unique(res.tmp$Date)
res.tmp$Date <- match(res.tmp$Date, date)
# aggregate values by mean, if text increment it
res.g.tmp <- aggregate(res.tmp, 
by=list((0:(nrow(res.tmp)-1))%/% merged.time),
function(x) ifelse(is.numeric(x), mean(x), x[1]))
# correct time which cannot be binned
res.g.tmp$Time <- res.tmp[head((c(1:nrow(res.tmp))* merged.time),
n=nrow(res.g.tmp)), "Time"]
# correct date by displaying an integrate number (no fractionated date)
res.g.tmp$Date <- as.integer(res.g.tmp$Date)
# bind tables together
res <- rbind(res, res.tmp, deparse.level=0)
res.g <- rbind(res.g, res.g.tmp, deparse.level=0)
}
# modify line of animal (which cannot be aggregated)
mergi.e.line <- merge(res.g, info, all.x=TRUE, sort=FALSE)
res.g$Line <- mergi.e.line$Genotype
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# create backup files
write.table(res, file=paste("res-before-exclusion.txt", sep=""), append=FALSE, 
quote=FALSE, sep=";", dec=".", row.names=FALSE)
write.table(res.g, file=paste("resg-before-exclusion.txt", sep=""), append=FALSE, 
quote=FALSE, sep=";", dec=".", row.names=FALSE)
2) Calculation of new parameters and separation of day phases
The activity of an animal  was analyzed using the sum of X and Y activity,  providing less
variability than the analysis of X and Y activity separately. Similarly, activity in the center of the
cage was analyzed using the ratio of  the activity in the center and the total  activity.  The
following code will be applied to the database providing results per minute only, but can also
be applied to the binned database. An output example is provided in table 5-04.
To facilitate the analysis, the complete database is divided in several phases (such as first
dark  phase,  first  light  phase,  first  day...)  and  exported  in  separated  files  (example  in
table 5-04).
# variables analyzed
variable.to.analyze <- c("Age", "Date", "Time", "Animal.No.", "Line", "XA.YA", 
"DistD", "Z", "AnxA", "CenA", "Drink", "Feed")
# calculation of new variables
res$XA.YA <- res$XA + res$YA # sum of the X and Y axis
res$ActT <- res$CenT + res$PerT
res$AnxT <- res$CenT / res$ActT # ratio center by total activity
res$XF.YF <- res$XF + res$YF # sum of the X and Y axis
res$ActA <- res$CenA + res$PerA
res$AnxA <- res$CenA / res$ActA # ratio center by total activity
res$XT.YT <- res$XT + res$YT # sum of the X and Y axis
# keep only interesting rows (decrease database size and algorithm speed)
res.tmp <- NULL
for (n in variable.to.analyze){
res.tmp <- cbind(res.tmp, as.numeric(res[, colnames(res)==n]))
}
Table 5-04: Database output example
Age Date Time Animal. No Line XA.YA DistD Z AnxA CenA Drink Feed
06m 1 825 290 nTg 79 155 4 0.24 19 0.01 0.01
06m 1 826 290 nTg 83 178 5 0.46 38 0.02 0.01
06m 1 827 290 nTg 121 226 3 0.22 27 0.02 0.01
06m 1 828 290 nTg 161 276 4 0.45 72 0.02 0.01
06m 1 829 290 nTg 93 178 6 0.25 23 0.03 0.01
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# store date, time, animals and line in an extra variable to run selection loops
date <- sort(res[duplicated(res$Date)==F, ]$Date)
time <- sort(res[duplicated(res$Time)==F, ]$Time)
line <- sort(res[duplicated(res$Line)==F, ]$Line)
# creation of a table containing only the adaptation time
res.b <- NULL # temporary variable
animal.tmp <- NULL # temporary variable
# loop over ages and animal numbers
for (age.tmp in unique(res$Age)){
res.tmp <- res[res$Age==age.tmp, ]
for (animal.tmp in unique(res.tmp$Animal.No.)){
res.b.tmp <- res.tmp[res.tmp$Animal.No.==animal.tmp, ]
# select only the number of rows according to the acclimatization time
res.b.tmp <- res.b.tmp[1:begin.time, ]
res.b <- rbind(res.b, res.b.tmp, deparse.level=0)
}}
# save light phases data over the experiment, for complete or binned dataset
light <- NULL # temporary variable
for (age.tmp in unique(res$Age)){
res.tmp <- res[res$Age==age.tmp, ]
# Select light phase: light phase > begin.dark+12h and light phase < begin.dark
light.tmp <- res.tmp[(strptime(res.tmp$Time, format="%R") >
(strptime(begin.dark, format="%R")-(12*3600)-60)) &
(strptime(res.tmp$Time, format="%R")) <
(strptime(begin.dark, format="%R"))), ]
light <- rbind(light, light.tmp)
}
# Select dark phases: light phase < begin.dark+12h or light phase > begin.dark
dark <- NULL # temporary variable
for (age.tmp in unique(res$Age)){
res.tmp <- res[res$Age==age.tmp, ]
dark.tmp <- res.tmp[(strptime(res.tmp$Time, format="%R") < 
(strptime(begin.dark, format="%R")-(12*3600)) |
(strptime(res.tmp$Time, format="%R") > 
(strptime(begin.dark, format="%R")-60))), ]
dark <- rbind(dark, dark.tmp)
}
# saving tables
write.table( res, file="allexperiment_table.txt", append=FALSE, quote=FALSE, 
sep=";", dec=".", row.names=FALSE)
write.table( res.b, file="begginexperiment_table.txt", append=FALSE,
quote=FALSE, sep=";", dec=".", row.names=FALSE)
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Table 5-05: Result table example
Animal. No variable value Line Age
290 XA.YA 138.1 nTg 18m
290 DistD 239.8 nTg 18m
290 Z 8.2 nTg 18m
290 AnxA 0.374 nTg 18m
290 CenA 54.2 nTg 18m
290 Drink 0.05 nTg 18m
290 Feed 0.01 nTg 18m
3) Statistical analysis and generation of graphics
A function was created to plot data, to perform one-way ANOVA and to show possible outliers
within the same figure, allowing a fast investigation of the main activity readout.
MyBarplot <- function(mean) { # start a function
y1 <- mean$value # select a variable
x1 <- mean$group # select a group
z1 <- mean$animal # select an animal
mean1 <- tapply(y1, x1, mean, na.rm=TRUE) # calculate the mean
# function to define the standard error on the mean
sem <- tapply(y1, x1, function(x) sd(x, na.rm=TRUE)/sqrt(length(x)))
# highlight outliers based on 95% confidence interval using 
# first (or last) interquartile + (or -) 1.5*interquartile range (McGill 1978)
out <- boxplot.stats(y1)$out # outliers calculation
gen.out <- mean[names(out), "group"] # allow to insertion in graph
# draw barplot with standard error of the mean, and add one way ANOVA in the title 
# and one-way ANOVA with post hoc Tukey correction in top of each column
barx <- barplot(mean1, ylim=c(0, max(y1, na.rm=TRUE)*1.2), main=variable,
sub=paste("p=", format(anova(lm(y1~x1))[1, 5], digit=2)))
segments(barx, mean1-sem, barx, mean1+sem)
segments(barx-0.1, mean1+sem, barx+0.1, mean1+sem)
segments(barx-0.1, mean1-sem, barx+0.1, mean1-sem)
pval <- TukeyHSD(aov(y1~x1))$x1[, 4]
text(y=0.92*max(y1, na.rm=TRUE)*1.2, x=c(0.1:((length(pval))))/1.3,
labels=paste("p=", format(pval, digits=2)), cex=0.7, pos=4)
text(y=0.98*max(y1, na.rm=TRUE)*1.2, x=c(0.1:((length(pval))))/1.3,
labels=(format(names(pval))), cex=0.7, pos=4)
if (length(out)>0) text(y=out, x=gen.out, labels=paste("x", names(out)))
}
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To investigate if animal genotype has an influence on a variable for a specific time period, the
mean per genotype over the complete time period was displayed using a barplot.
# define a list containing the tables to analyze
stat.tables <- "allexperiment_table.txt"
# open a new pdf file
graphics.off()
pdf("04_boxplot-one-variable2.pdf", onefile=TRUE)
# open tables
for (file.tmp in stat.tables) {
res.animal <- read.csv2(file.tmp, header=TRUE, dec= ".")
# for each variable run the graphic
for (variable.tmp in unique(res.animal$variable)){
for (age.tmp in unique(res$Age)){
table.tmp <- res.animal[res.animal$Age==age.tmp, ]
table.tmp <- table.tmp[table.tmp$variable==variable.tmp, ]
# remove NA (Not Applicable)which appear when dividing by 0
mean <- na.exclude(table.tmp)
colnames(mean) <- c("animal", "variable", "value", "group", "age")
variable <- variable.tmp
myBarplot(mean)
}}}
# close the pdf
dev.off()
graphics.off()
Figure 5-01: Plot example
The barplot shows the mean and the standard 
error of each group. A cross indicates potential 
outliers  and  is  followed  by  the  respective  
animal  name.  The  barplot  title  contains  the  
name of the parameter investigated, the time  
point when the experiment was performed and 
the time phase considered.  Subtitle contains  
results of  one-way ANOVA for  the complete  
dataset to facilitate data exploration. Below the 
title,  the  results  of  one-way  ANOVA  using
post  hoc  Tukey  comparison  for  all  animal  
groups are indicated.
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Appendix B: Image analysis
Immunohistochemistry staining, classically evaluated qualitatively, needs to be quantified to
determine  the  relevance  of  potential  changes  observed  (Taylor  &  Levenson  2006).  The
extraction of information via image analysis represents a critical step in the quantification and
interpretation of stainings (Walker 2006). This is illustrated by the estimation of positive cells
analyzed by manual counting, which on top of being time consuming and laborious, is also
biased by inter-observer variations  (Prasad et al. 2011; Orlowski & Bjarkam 2012). In this
context,  image  analysis  using  an  algorithm,  presents  not  only  a  method  with  higher
reproducibility giving a faster readout, but also provides the opportunity to quantify areas or
intensities of stainings. The following macros were designed using ImageJ, an open source
software based on Java, allowing image processing (noise reduction, signal transformation),
signal  detection (refine detection,  selection of  a  particular  signal)  and the use of  multiple
analysis tools (measure area, particle analysis).
1)  Image capture
The first macro aims at making the counting of activated astrocytes easier, faster and more
reproducible  (staining  protocol  described  in  the  Materials  and  Methods  section  1.13  and
1.14). Pictures to analyze were taken using a 3×  12-bit channel color Zeiss Axio-cam MRc
camera mounted on an AxioPlan 2 microscope with a picture size of 1388×1040 pixels and
captured using AxioVision. A 20× objective was used to provide a good definition of single
astrocytes, resulting in an image of approximately 688×515 µm.
The second macro aims to fully automatize counting of cells positive for proteinase K resistant
alpha-synuclein staining (staining protocol described in Materials and Methods section 1.16).
A 4× objective was used to  provide a large investigation  field  and resulting in  an  image
representing approximately 3500×2630 µm.
2)  Astrocytes counting
To  help  performing  manual  counting,  ImageJ  was  used  to  highlight  staining  patterns
(procedure  illustrated  in  Fig. 5-02).  First,  original  uncompressed TIFF files  were  exported
using AxioVision and opened in ImageJ (Fig. 5-02A). Then, a color threshold using complex
restrictive threshold (based on multilevel thresholding scheme via class entropy  (Yen et al.
1995) was applied. Threshold output is shown in Fig. 5-02B and final output of the macro is
shown in Fig. 5-02C. Finally, cell counter function of ImageJ was used to estimate the number
of cells containing more than three stained branches.
// need to open pictures to analyze in ImageJ prior running the macro
// opening two copies with a specified name (trial1.TIF and trial2.TIF)
run("Duplicate...", "title=trial1.TIF");
run("Duplicate...", "title=trial2.TIF");
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// trial2.TIF converted in 16-bit then a threshold is applied to delimit staining
run("16-bit");
setAutoThreshold("Yen");
run("Convert to Mask");
// trial1.TIF and trial2.TIF added to facilitate counting
imageCalculator("AND create", "trial1.TIF","trial2.TIF");
selectWindow("Result of trial1.TIF");
Figure 5-02: Astrocytes counting example
A) Representative example of astrocytes staining using GFAP antibody. B) Threshold output used to highlight
the most significant staining (in black). Output will be used to define more clearly and in a more reproductive
manner single positive events.  C) Macro output  highlighting most relevant staining.  Output  files simplify the
determination of positive cells, improving the reproducibility of immunopositive event counting. Output files also
allow for the measurement of staining area and staining intensity.
In  this  example,  the  major  methodological  weakness  is  the  reproducibility  of  the  manual
determination of astrocytes. A more reproducible procedure based on the amount and area
stained per slide is proposed in the following macro. To automatize this analysis, a repertory
containing pictures to investigate is defined, pictures are then converted in gray scales and
mean of gray scale is measured. Background is reduced using a restrictive threshold (Yen
method) and the area stained is measured for each image.
// macro to quantify staining intensity and area stained
// save the working directory, select pictures and variable to measure
requires("1.38o");
dir = getDirectory("Choose directory");
list = getFileList(dir);
setBatchMode(true);
run("Set Measurements...", "area area_fraction mean standard min max limit 
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display redirect=None");
 run("Clear Results")
for (i=0; i<list.length; i++) { // open picture per picture
showProgress(i, list.length);
open(dir+list[i]);
// ImageJ consider signal as white, therefore pictures need to be inverted
rename("all_"+list[i]);
run("16-bit");
run("Invert");
// staining intensity determined by mean of scale of gray within the picture
run("Measure");
// staining area represented by the variable area
rename("threshold_"+list[i]);
setAutoThreshold("Yen dark");
run("Measure");
close();
}
selectWindow("Results");
saveAs("Results", dir+"summary.txt");
3)  Proteinase K resistant alpha-synuclein automatized
In the previous example, the estimation of astrocyte number via an algorithm is a complex
task, because of the specific shape of astrocytes. However, other events (such as estimation
of total cell number, aggregate number or positive cell body number) are easier to detect and
therefore to automatize. In this example, we will use a macro for counting the number of cells
positive for proteinase K resistant alpha-synuclein staining. Similar to the previous example, a
macro will be applied on all pictures present in a specified repertory. The macro first imports
pictures (Fig. 5-03A), converts them into gray scale and measures the mean of the staining
intensity. Then, a restrictive threshold is applied on the pictures (output shown in Fig. 5-03B)
to measure the stained area and to perform particle analysis using particle shape and size to
estimate the number of stained cells.
To determine the relevant size of particles, a representative picture was opened and the size
of  the  smallest  and  largest  event  was  measured  in  pixels  using  area  measurement
(represented as circles in Fig. 5-03B).
// macro to quantify staining intensity and to quantify area stained
// save working directory, select pictures and variable to measure
requires("1.38o");
dir = getDirectory("Choose directory");
list = getFileList(dir);
setBatchMode(true);
run("Set Measurements...", "area area_fraction mean standard min max limit 
display redirect=None");
 run("Clear Results")
for (i=0; i<list.length; i++) { // open picture per picture
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showProgress(i, list.length);
open(dir+list[i]);
rename("all-"+list[i]);
run("16-bit");
run("Invert");
run("Measure");
rename("threshold-"+list[i]);
setAutoThreshold("Yen dark");
run("Convert to Mask");
run("Measure");
run("Fill Holes"); // filling holes (make particle detection sensitive)
// generation of particles
run("Analyze Particles...", "size=250-5000 circularity=0.20-1.00 summarize");
close();
}
// save staining mean ans particle analysis in two different text files
selectWindow("Summary");
saveAs("Text", dir+"summary.txt"); // mean staining intensity
selectWindow("Results");
saveAs("Results", dir+"results.txt"); // particle analysis
Figure 5-03: Proteinase K resistant alpha-synuclein example
A) Representative example of cells presenting proteinase K resistant a-syn staining.  B) Output of restrictive
thresholding (in black).  The small  and the large circles represent 250 and 5000 square pixels  respectively.
C) Validation of the particle counting, particles were counted (represented in black) and further characterized by
the macro (area, number).
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